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Abstract 
 
Dystroglycan is central to the dystrophin-associated glycoprotein complex (DGC), 
which helps provide stability to muscle fibres. The absence of dystrophin in Duchenne 
muscular dystrophy results in the loss of this complex. The phosphorylation of β-
dystroglycan is thought to play an important role in controlling the integrity of the 
DGC.  This phosphorylation event has been shown to promote β-dystroglycan 
internalisation, possibly as a prerequisite to degradation. The work presented in this 
thesis aimed to use the zebrafish to investigate new therapeutic approaches to restore 
dystroglycan to the membrane and assess the extent to which muscle attachments can 
be strengthened in the dystrophin mutant zebrafish (sapje).  As in mammals, the 
stability of the zebrafish DGC is dependent on dystrophin expression. As such, β-
dystroglycan levels in sapje decreased in an age-dependent manner. Loss of dystrophin 
led to an initial elevation in phosphorylated β-dystroglycan levels. Treatment of sapje 
fish with proteasome and kinase inhibitors was able to prevent or slow the progression 
of dystrophy, in a dose-dependent manner. This was associated with a concomitant 
increase in dystroglycan and decrease in phosphorylated dystroglycan. This work 
provides insight into the molecular mechanisms that lead to the loss of dystroglycan 
from the membrane in dystrophic muscles, and may have therapeutic implications in 
the future. 
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Chapter 1: Introduction 
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1.1 Skeletal Muscle 
Skeletal muscle represents a significant component of vertebrate anatomy and has 
important roles in locomotion and energy metabolism. It is highly specialised to 
withstand the mechanical stresses caused by contraction, in order to maintain muscle 
cell integrity and force transmission. 
 
Skeletal muscle is made up of long, multinucleated myofibres, which are formed by the 
fusion of myoblasts. Each myofibre is surrounded by the sarcolemma (plasma 
membrane) and an overlying basal lamina. Myofibres contain an ordered array of 
sarcomeres, the contractile units of striated muscle, which comprise myosin-
containing thick filaments and actin-containing thin filaments. These myofilaments, 
together with additional structural and regulatory proteins, are arranged longitudinally 
as myofibrils. The contractile apparatus is linked to the sarcolemma by interactions 
with costameres, subsarcolemmal protein complexes (figure 1.1). These connections 
allow the transmission of contractile forces from sarcomeres across the sarcolemma to 
the extracellular matrix (ECM) and adjacent myofibres, allowing the synchronisation of 
muscle contraction and preventing sarcolemmal rupture. In addition to costameres, 
there are other sites of sarcolemmal attachment to the ECM including neuromuscular 
junctions (NMJs) and myotendinous junctions (MTJs). 
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The contractile apparatus is linked to the sarcolemma by interactions with costameres. 
Costameres are subsarcolemmal protein complexes that circumferentially align with the z-
discs and physically couple sarcomeres with the sarcolemma. The costameric network 
comprises many proteins including DGC components, integrins, a-actinin, vinculin and talin.
Figure 1.1: Skeletal myofibre structure
 
 
The importance of the basement membrane (BM), sarcolemma and cytoskeleton in 
skeletal muscle structure and function is highlighted by the vast number of muscle 
diseases caused by mutations in BM and cytoskeletal components, or the protein 
complexes linking them together. The two major protein complexes linking the 
cytoskeleton and basement membrane in adult skeletal muscle are the integrins and 
the dystrophin-associated glycoprotein complex (DGC), and these complexes are 
concentrated at costameres, NMJs and MTJs. A significant number of muscular 
dystrophies arise from mutations that affect the assembly of these complexes. 
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1.2 Muscular dystrophy 
Muscular dystrophies are a heterogeneous group of genetic disorders characterised by 
progressive weakness and degeneration of skeletal muscle. Damage to muscle fibres 
activates satellite cells, located between the sarcolemma and basal lamina, to initiate 
muscle fibre regeneration. Myofibres of healthy muscle are roughly equal in diameter, 
with nuclei at the periphery. However, dystrophic muscle consists of fibres of varying 
sizes with centrally located nuclei, indicative of degeneration and regeneration. 
Continued muscle damage leads to the loss of regenerative capacity. Muscle is 
gradually replaced by fatty and fibrous tissue, leading to muscle wasting and weakness. 
 
1.3 Duchenne muscular dystrophy 
The most common form of muscular dystrophy is Duchenne muscular dystrophy 
(DMD), an X-linked disorder affecting 1 in 3500 boys (Emery, 1993). DMD was first 
described in the 19th century by Meryon (1852) and Duchenne (1868). Affected 
individuals show a progressive loss of muscle strength starting in early childhood, 
initially affecting proximal muscles, rapidly extending to distal muscles and eventually 
to most voluntary muscle groups (Emery, 1993). Continuous muscle wasting results in 
the loss of ambulation before the age of 12 and culminates in premature death in the 
20s, usually due to respiratory or cardiac failure (Emery, 1993). 
 
DMD results from mutations in the DMD gene (Koenig et al., 1987), which encodes the 
protein dystrophin (Hoffman et al., 1987). The DMD gene, localised to chromosome 
Xp21(Davies et al., 1983), is the largest described in the human genome, spanning over 
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2.5Mb and comprising 79 exons (Coffey et al., 1992, Monaco et al., 1992, Roberts et 
al., 1993). The full length mRNA transcript is 14kb long and is predominantly expressed 
in muscle tissue, with lower levels in the brain (Chamberlain et al., 1988, Nudel et al., 
1988). The protein product of the DMD gene was named dystrophin, since muscular 
dystrophy results from its absence (Hoffman et al., 1987). 
 
Becker muscular dystrophy (BMD), a milder form of DMD, is also caused by mutations 
in the gene encoding dystrophin. In BMD, low levels of a truncated protein can be 
found, whereas DMD mutations result in the complete absence of functional 
dystrophin (Monaco et al., 1988, Koenig et al., 1989). 
 
1.4 Dystrophin 
Dystrophin is a 427kDa cytoskeletal linker protein found at the intracellular face of the 
sarcolemmal membrane. Dystrophin comprises 4 domains (Koenig et al., 1988): an N-
terminal actin-binding domain, a long central rod domain consisting of 24 spectrin-like 
repeats interspersed with 4 hinge regions (Koenig and Kunkel, 1990), a cysteine rich 
domain and a C-terminal domain (figure 1.2). The cysteine rich domain consists of a 
WW domain (Bork and Sudol, 1994), 2 EF hands (Koenig et al., 1988) and a ZZ domain 
(Ponting et al., 1996). WW domains are protein interaction modules that are 30 amino 
acids in length. They contain 2 conserved tryptophan residues, which are involved in 
interactions with proline-rich binding motifs. EF hands are highly conserved motifs 
involved in the binding of Ca2+ and Mg2+ ions. ZZ domains, cysteine-rich zinc-finger 
domains, are modules thought to mediate protein-protein interactions. 
Chapter 1 
6 
  
 
Several promoters regulate the expression of full length and truncated isoforms of 
dystrophin (figure 1.3). The expression of 3 full length (427kDa) dystrophin isoforms, 
primarily found in brain, muscle and Purkinje neurons, is regulated by 3 independent 
promoters (Nudel et al., 1989, Klamut et al., 1990, Gorecki et al., 1992). These isoforms 
differ only by the 1st exon. In addition, the DMD gene also contains at least 4 internal 
promoters. These give rise to truncated protein products of 260, 140, 116, 71 and 
40kDa, which are expressed in non-muscle tissues (Bar et al., 1990, Byers et al., 1993, 
Tinsley et al., 1993, D'Souza et al., 1995, Lidov et al., 1995). Defects in muscle 
dystrophin result in the most obvious phenotype (muscular dystrophy), although some 
DMD patients show other defects, such as cognitive impairment (Emery, 1993), which 
may be caused by deficiencies in other dystrophin isoforms. 
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Dystrophin is organised into 4 major domains: an N-terminal actin-binding domain, (ABD), a 
central rod domain consisting of 24 spectrin-like repeats (green) interspersed with 4 hinge 
regions (red), a cysteine rich domain (CR) and a C-terminal domain (CT).
Figure 1.2 Modular representation of dystrophin protein
Figure 1.3 Schematic showing the organisation of DMD gene
Dp427 (B)
Dp427 (M)
Dp427 (P)
2exon 30
Dp260 (R)
Dp140 (B3)
44 56
Dp116 (S)
Dp71 / Dp40 (G)
63
Promoters (depicted by arrows) in the 5’ end of the gene drive the expression of 3 full 
length (427kDa) dystrophin isoforms in brain (B), muscle (M) and Purkinje neurons (P). Each 
transcript consists of unique first exons spliced to a common set of 78 exons. The 3 protein 
products are termed Dp427(B), Dp427(M) and Dp427(P), reflecting their primary location. 
The smaller isoforms are produced from 4 internal promoters (R: retina, B3: brain, S: 
Schwann cells, G: general). These promoters are located in the introns upstream of exons 
30, 44, 56 and 63 as indicated above. These are expressed in the retina (R: Dp260), brain 
(B3: Dp140), Schwann cells (S:Dp116) or ubiquitously expressed (G:Dp71). Dp40 is 
produced by the alternative splicing of Dp71. 
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1.5 The dystrophin-associated glycoprotein complex (DGC) 
 
1.5.1 The protective role of the DGC 
In muscle, dystrophin plays an important structural role, forming part of a large 
complex at the sarcolemma termed the dystrophin-associated glycoprotein complex 
(DGC) (Ervasti et al., 1990). The DGC provides a stabilising mechanical link between the 
cytoskeleton of the myofibre and the surrounding ECM (Ervasti and Campbell, 1991, 
Ervasti and Campbell, 1993). This link is thought to protect the muscle from damage 
during repeated cycles of contraction and relaxation.  
 
In the absence of dystrophin, there is a significant reduction in the entire DGC 
(Ohlendieck and Campbell, 1991, Ohlendieck et al., 1993). Therefore, the link between 
the cytoskeleton and ECM is compromised, making the sarcolemma more fragile and 
susceptible to mechanical injury, which results in muscle damage. 
 
In addition to this mechanical role, the DGC may also act as a scaffold for signalling 
complexes. This is illustrated by its interactions with various signalling molecules, 
which are discussed further in subsequent sections. Thus, loss of complex components 
in muscular dystrophy may disrupt the signalling functions of the DGC as well as its 
protective role. 
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1.5.2 DGC components 
In addition to dystrophin, the DGC consists of cytoplasmic (α1- and β1-syntrophin, α-
dystrobrevin and nNOS), transmembrane (β-dystroglycan, α-, β-, γ- and δ-sarocglycan 
and sarcospan) and extracellular (α-dystroglycan and laminin-2) proteins (figure 1.4). 
Many of these components have been implicated in various muscular dystrophies, 
highlighting the importance of the DGC in maintaining muscle integrity. 
 
Dystrophin interacts with the DGC via its cysteine rich and C-terminal domains. α-
dystrobrevin and the syntrophins bind directly to each other and to the C-terminal 
region of dystrophin (Albrecht and Froehner, 2002). β-dystroglycan binds to the WW 
domain of dystrophin. This interaction is stabilised by one of two EF-hands located 
adjacent to the WW domain (Rentschler et al., 1999), and the ZZ domain (Ishikawa-
Sakurai et al., 2004). 
 
The cell adhesion protein dystroglycan is central to the DGC, interacting with the ECM 
via its α-subunit and dystrophin via its β-subunit. Dystrophin completes the link 
between the cytoskeleton and ECM, by binding to actin, via its actin-binding sites in 
the N-terminal and rod domains (Rybakova et al., 1996, Rybakova and Ervasti, 1997, 
Amann et al., 1998). 
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Figure 1.4: The dystrophin-associated glycoprotein complex (DGC)
Representation of the key proteins in the DGC, which forms a link between the 
cytoskeleton and ECM. Dystroglycan (shown in red) is central to this complex. The 
PPPY motif in the C-terminal tail of β-dystroglycan binds to the WW domain within 
the cysteine rich domain of dystrophin. Phosphorylation of the tyrosine residue 
within this motif disrupts dystrophin binding. 
(ABD – actin-binding domain; CR – cysteine rich domain; CT – C-terminal domain; 
SSPN – sarcospan; α-DB – α-dystrobrevin)
α
β
αβ γδ
Sarcoglycans
SSPN
Dystroglycan
Laminin
Extracellular matrix
α
Syntrophins
α-DB
Dystrophin
Actin cytoskeleton
Sarcolemma
nNOS
β1 nNOS
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1.6 Dystroglycan 
Dystroglycan expression is not muscle-specific and it has a variety of roles in other cell 
types. Given the important role of the DGC in preventing muscle damage, dystroglycan 
has been predominantly studied in the context of muscle and muscular dystrophies.  
 
Until recently, no mutations in the dystroglycan gene had been identified in a human 
disease. This is thought to be due to the fundamental role of dystroglycan in 
mammalian development. Mouse dystroglycan knockouts are embryonic lethal due to 
the failure of the extra-embryonic Reichert’s membrane to form (Williamson et al., 
1997). Although mutations in dystroglycan itself are rare, mutations in enzymes 
involved in the post-translational modification of dystroglycan result in muscular 
dystrophy (see section 1.6.2). 
 
1.6.1 Dystroglycan gene 
Dystroglycan was the first component of the DGC to be cloned (Ibraghimov-
Beskrovnaya et al., 1992). The dystroglycan gene, DAG1, is located on human 
chromosome 3p21 and comprises 2 exons, separated by a large intron. 
 
The dystroglycan gene encodes a propeptide that is post-translationally cleaved into α- 
and β-subunits (Ibraghimov-Beskrovnaya et al., 1992, Holt et al., 2000) (figure 1.5). 
These interact with each other non-covalently, forming a heterodimer within the DGC.  
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Figure 1.5: Processing of the dystroglycan propetide
(A) The dystroglycan gene, DAG1, encodes a single 895 amino acid propeptide with a signal 
sequence (SS), a mucin-like region, and a transmembrane (TM) region. This propeptide is 
post-translationally cleaved (P) at residue 653, to yield α- and β-dystroglycan shown in (B). 
The N-terminal domain of α-dystroglycan is cleaved at residue 312 (Kanagawa et al 2004) to 
form the mature protein shown in (C). Carbohydrate side chains are shown schematically as 
circles for O-linked glycosylation and branches for N-linked glycosylation. β-dystroglycan is 
shown inserted in a lipid bilayer with its C-terminus on the intracellular side (C).
P
Mucin-likeN-terminal C-terminal N C
TM
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1.6.2 α-dystroglycan 
The extracellular α-dystroglycan comprises globular N- and C-terminal domains, 
connected by a central, heavily O-glycosylated, mucin-like domain (Ibraghimov-
Beskrovnaya et al., 1992, Brancaccio et al., 1995) (figure 1.5). In addition to undergoing 
O-linked glycosylation, α-dystroglycan contains 3 N-linked glycosylation sites. The 
sugar modifications are important for the interactions between dystroglycan and its 
various ECM ligands; although treatment with N-glycanases has no effect on the 
binding ability of dystroglycan, complete deglycosylation of α-dystroglycan results in 
the loss of ligand binding (Ervasti and Campbell, 1993). This suggests that ligand 
interactions are mediated by the O-linked modifications of the mucin domain.  
 
The extent of α-dystroglycan glycosylation is dependent on tissue type, and is also 
developmentally regulated. α-dystroglycan is predicted to be approximately 70kDa, 
but on an SDS-PAGE gel, mammalian skeletal muscle α-dystroglycan has an apparent 
mass of approximately 156kDa (Ervasti and Campbell, 1991). 
 
Reduced glycosylation of α-dystroglycan, caused by mutations in genes encoding 
known or putative glycosyltransferases, is associated with a group of muscular 
dystrophies, known as the dystroglycanopathies (Muntoni et al., 2004, Godfrey et al., 
2007a, Moore and Hewitt, 2009, Muntoni et al., 2011). These include Fukuyama 
congenital muscular dystrophy (FCMD) and muscle-eye-brain disease (MEB). α-
dystroglycan is present in these patients, but has a lower molecular mass, consistent 
with reduced glycosylation (Michele et al., 2002b). This hypoglycosylation of α-
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dystroglycan results in decreased binding to ECM ligands such as laminin (Michele et 
al., 2002b), thus disrupting the link between the DGC and the ECM. 
 
Laminin binding is also affected by the only primary dystroglycan mutation that has 
been described so far in a human disease. A missense mutation within the N-terminal 
region of α-dystroglycan was identified in this patient, who was diagnosed with limb 
girdle muscular dystrophy (LGMD) with severe cognitive impairment (Hara et al., 
2011). This resulted in hypoglycosylation and reduced laminin binding activity of α-
dystroglycan in a mouse model harbouring the equivalent mutation. This further 
highlights the importance of a continuous link between the cytoskeleton and ECM. 
 
1.6.3 β-dystroglycan 
β-dystroglycan is also subject to N-linked glycosylation, producing a mature protein of 
approximately 43kDa. Glycosylation is necessary for the correct localisation of α- and 
β-dystroglycan, but not for the proteolytic cleavage of the propeptide (Holt et al., 
2000). 
 
β-dystroglycan consists of an extracellular domain, which interacts with the C-terminal 
of α-dystroglycan independently of glycosylation (Di Stasio et al., 1999), a 
transmembrane domain, and a proline-rich cytoplasmic domain (figure 1.5). The 
cytoplasmic domain contains a PPxY motif, which binds to dystrophin through an 
interaction with its WW domain. 
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1.6.3.1 β-dystroglycan interactions 
In addition to dystrophin, the cytoplasmic tail of β-dystroglycan interacts with other 
cytoplasmic proteins. One such protein is utrophin, the autosomal homologue of 
dystrophin (Love et al., 1989). Utrophin binds dystroglycan via WW, EF and ZZ domains 
(Chung and Campanelli, 1999, Ishikawa-Sakurai et al., 2004), forming complexes 
analogous to the DGC (James et al., 1996). In adult muscle, these complexes are 
normally restricted to MTJs and NMJs (Khurana et al., 1991, Nguyen et al., 1991). β-
dystroglycan also binds another cytolinker protein, plectin (Rezniczek et al., 2007). 
Both plectin (Rezniczek et al., 2007) and utrophin (Helliwell et al., 1992, Matsumura et 
al., 1992, Karpati et al., 1993b) are upregulated in dystrophin-deficient muscle, 
possibly as part of a compensatory mechanism. 
 
Caveolin-3 has a WW-like domain, which is able to bind to the PPxY motif in β-
dystroglycan (Sotgia et al., 2000). This interaction is able to disrupt the interaction 
between dystroglycan and dystrophin, thus may play a role in regulating dystrophin 
recruitment to the sarcolemma. 
 
SH2 domain containing proteins, including c-Src, can bind to the PPxY motif in β-
dystroglycan (Sotgia et al., 2001). Signalling molecules, including Grb2 (Yang et al., 
1995) and components of the ERK/MAP kinase pathway (Spence et al., 2004), have 
also been shown to bind to the cytoplasmic tail of β-dystroglycan. This suggests that 
dystroglycan has a role in cell signalling, in addition to its function in maintaining a 
structural link between the cytoskeleton and ECM.  
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1.6.3.2 Phosphorylation of β-dystroglycan 
Phosphorylation of the tyrosine residue within the PPxY motif of β-dystroglycan (Y892 
in humans, Y890 in mice) disrupts its interaction with dystrophin and utrophin (James 
et al., 2000, Ilsley et al., 2001). In the crystal structure of this interaction, Y892 is 
demonstrated to sit in a hydrophobic pocket of the WW domain, forming a hydrogen 
bond with a histidine residue from the WW domain (Huang et al., 2000). Addition of a 
phosphate group on the tyrosine would likely break this bond and make it too large to 
fit in the hydrophobic pocket. 
 
Unlike dystrophin and utrophin interactions, phosphorylation of β-dystroglycan at the 
tyrosine residue of the PPxY motif does not affect the binding of β-dystroglycan and 
caveolin-3 (Sotgia et al., 2000). In addition, SH2 domain proteins are recruited in a 
phosphorylation-dependent manner (Sotgia et al., 2001). Therefore, tyrosine 
phosphorylation of β-dystroglycan may act as a regulatory switch, inhibiting the 
binding of dystrophin, whilst promoting the binding of caveolin-3 and SH2 domain 
proteins. 
 
It is thought that phosphorylation of β-dystroglycan at the tyrosine residue in its PPxY 
motif is mediated by Src family kinases and that this modification plays a role in β-
dystroglycan internalisation to an intracellular compartment (Sotgia et al., 2003, Miller 
et al., 2012). Consequently, this phosphorylation event may play an important role in 
controlling the localisation of dystroglycan and thus the integrity of the DGC.  
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1.7 Sarcoglycan complex and sarcospan 
Sarcoglycans are N-glycosylated, transmembrane proteins that form a tetrametic 
complex as part of the DGC. 6 sarcoglycans (α-, β-, γ-, δ-, ε- and ζ-sarcoglycan) exist, 
but the predominant sarcoglycan complex in skeletal and cardiac muscle comprises α-, 
β-, γ- and δ-sarcoglycans (Chan et al., 1998, Holt and Campbell, 1998, Ozawa et al., 
2005).  
 
In addition to dystrophin deficiency causing sarcoglycan complex destabilisation, 
mutations in sarcoglycans themselves also cause muscular dystrophy. Limb-girdle 
muscular dystrophy (LGMD) types 2D, 2E, 2C and 2F arise from mutations in α-, β-, γ- 
and δ-sarcoglycans respectively (Laval and Bushby, 2004). Typicallly, mutations in one 
sarcoglycan result in the loss or reduction of the whole tetrameric complex (Vainzof et 
al., 1996).  
 
The role of the sarcoglycan complex within the DGC has not been well defined, but it is 
thought to have both signalling and mechanical roles, providing additional support to 
the DGC and sarcolemma (Ozawa et al., 2005, Barton, 2006) 
 
The sarcoglycan complex closely associates with the 4 transmembrane domain 
containing protein sarcospan, which is structurally related to the tetraspanin family 
(Crosbie et al., 1997, Crosbie et al., 1999, Crosbie et al., 2000). Tetraspanins play 
important roles in a wide range of cellular functions, such as adhesion and signalling, 
by clustering proteins at the membrane (Hemler, 2001). Thus, sarcospan may facilitate 
protein interactions at the DGC. 
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Complete or partial loss of the sarcoglycan complex results in the loss of sarcospan 
from the membrane, suggesting the stability of sarcopsan is mediated by this complex 
(Crosbie et al., 1999, Crosbie et al., 2000). However, sarcospan-deficient mice do not 
show a dystrophic phenotype (Lebakken et al., 2000), suggesting muscle may be able 
to compensate for the absence of sarcospan. Indeed, loss of sarcospan results in an 
increase in α7β1 integrin expression (Marshall et al., 2012).  α7β1 integrin is the main 
integrin complex found in muscle, and is also able to form connections between the 
cytoskeleton and ECM. 
 
1.8 α-dystrobrevin, syntrophins and nNOS 
α-dystrobrevin is a cytoplasmic protein thought to play a signalling role within the 
DGC. α-dystrobrevin deficient mice display a mild muscle disease phenotype, even 
though the assembly of the remaining DGC components at the sarcolemma is not 
affected (Grady et al., 1999). Neuronal nitric oxide synthase (nNOS), however, is 
displaced from the sarcolemma.   
 
The sarcolemmal localisation of nNOS is essential for its function in regulating blood 
flow to meet the metabolic demands of contracting skeletal muscle. nNOS produces 
nitric oxide (NO) in response to muscle contractions. NO induces guanylyl cyclase to 
synthesise cyclic GMP (cGMP), which functions as a vasodilator, increasing the local 
blood flow to meet the increased energy demands. 
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nNOS is also displaced from the sarcolemma in the absence of dystrophin (Brenman et 
al., 1995) and this is thought to contribute to the dystrophic process (Thomas et al., 
1998, Sander et al., 2000). Genetically increasing levels of nNOS is able to ameliorate 
the muscular dystrophy phenotype in dystrophin deficient mdx mice (Wehling et al., 
2001). In addition, use of PDE5 inhibitors, which increase levels of cGMP, is able to 
reduce cardiomyopathy and improve diaphragm muscle pathology in the mdx mouse 
(Adamo et al., 2010, Percival et al., 2012). 
 
Dystrophin and α-dystrobrevin interact with α1- and β1-syntrophin (Newey et al., 
2000), which bind nNOS through PDZ domains (Brenman et al., 1996). Dystrophin can 
also directly recruit nNOS via spectrin-like repeat 17 (Lai et al., 2013), and this 
interaction may be essential for nNOS recruitment to the sarcolemma. 
 
In addition to nNOS, the syntrophins are thought to be involved in localising several 
other proteins to the DGC, including signalling molecules, kinases and membrane 
channels (Gee et al., 1998, Schultz et al., 1998, Hasegawa et al., 1999, Neely et al., 
2001, Oak et al., 2001). This further highlights a signalling role for the DGC. 
 
 
1.9 Animal models of DMD 
Despite a wealth of research into DMD, no curative treatment exists. To further 
characterise the molecular mechanisms involved in the pathogenesis of DMD, and to 
develop treatments, several animal models have been utilised. 
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1.9.1 The mdx mouse 
The most characterised model of DMD is the mdx mouse (Bulfield et al., 1984, 
Hoffman et al., 1987), but it has a mild phenotype compared with the human condition 
and lifespan is only slightly shortened (Chamberlain et al., 2007). The mdx mouse has a 
premature stop codon in exon 23 of the DMD gene, resulting in a lack of full length 
dystrophin (Sicinski et al., 1989). mdx muscle undergoes an initial period of 
degeneration, followed by successful regeneration (Dangain and Vrbova, 1984, Tanabe 
et al., 1986). Muscles are differentially affected, with the diaphragm showing the most 
severe pathology (Stedman et al., 1991). However, other, less affected muscles are 
more susceptible to contraction-induced injury (Dellorusso et al., 2001), and exercise 
can be used to speed up the disease progression (De Luca et al., 2003). 
 
It is thought that the pathology in mdx mice may be moderated by a compensatory 
upregulation of utrophin. Double dystrophin and utrophin mutants (dKO mice) have a 
more severe phenotype which may be more comparable to DMD (Deconinck et al., 
1997). 
 
1.9.2 The GRMD dog 
The golden retriever muscular dystrophy (GRMD) dog (Cooper et al., 1988) has a 
phenotype more closely related to the human disease than the mdx mouse, although 
the severity is often quite variable (Kornegay et al., 1988, Valentine et al., 1988). 
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Although dogs are not ideal animal models, and are large and expensive, this model 
can be used to test potential treatments identified in murine studies. 
 
1.9.3 Zebrafish as a model for muscular dystrophy 
The zebrafish has emerged as a powerful tool for studying vertebrate development 
and disease due to its many advantages as a model organism. These include the rapid 
external development of optically transparent embryos, which are permeable to small 
molecules, and the ability to quickly generate large numbers of offspring. Zebrafish are 
genetically tractable, and many models of human diseases have been established, 
many of which closely resemble the condition (Lieschke and Currie, 2007). 
 
Zebrafish offer many specific attributes that are particularly suited for the study of 
muscle diseases. Genes important for muscle development and the maintenance of 
muscle integrity are highly conserved between zebrafish and mammals. Orthologues of 
most human muscular dystrophy genes can be found in the zebrafish genome (Steffen 
et al., 2007), and dystrophic phenotypes arise where these genes are disrupted. In 
particular, components of the DGC are present in zebrafish (Chambers et al., 2003, 
Guyon et al., 2003), and disruptions in these genes affect muscle integrity (Parsons et 
al., 2002, Bassett et al., 2003, Guyon et al., 2005, Nixon et al., 2005, Hall et al., 2007, 
Gupta et al., 2011).  
 
The zebrafish body is composed predominantly of skeletal muscle, which develops 
quickly and is fully differentiated by 48hpf (Kimmel et al., 1995). The somitic muscle 
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derives from segmented paraxial mesoderm. Slow-twitch muscle fibres differentiate 
first. These fibres originate from adaxial myoblasts, which migrate radially through the 
developing myotome to form a subcutaneous layer of mononucleated slow-twitch 
fibres (van Raamsdonk et al., 1978, Devoto et al., 1996). Fast-twitch muscle fibres, 
which make up most of the zebrafish trunk musculature, arise later from a separate 
pool of myoblasts, which fuse to form multinucleated fibres (Devoto et al., 1996, Henry 
and Amacher, 2004). 
 
Trunk skeletal muscle is simply organised in the zebrafish embryo, with myotubes 
spanning each somite along the anterior-posterior axis. At the somite boundaries, the 
muscle fibres attach to the vertical myosepta, sheets of matrix separating adjacent 
somites that are equivalent to mammalian MTJs (Charvet et al., 2011). The notochord 
and horizontal myoseptum, which separates dorsal and ventral halves of the 
myotome, also serve as attachment sites for the muscle fibres. DGC components are 
concentrated at these muscle attachment points (Guyon et al., 2003). 
 
In terms of evolution and anatomy, zebrafish are not as closely related to humans as 
mammalian models. Although zebrafish muscle shares many molecular and histological 
features with mammalian muscle, there are some obvious differences. For example, 
slow and fast muscle fibres are topographically separated in zebrafish, but are 
intermingled in mammals. In addition, unlike mammals, zebrafish musculature retains 
its somitic organisation throughout development. 
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Despite these limitations, the advantages of using zebrafish as a model system for 
muscular dystrophy outweigh the costs. For example, potential treatments can be 
analysed in fish on a much faster time scale than in mammals. Whilst it is not likely to 
replace other established models of muscular dystrophy such as the mdx mouse, the 
zebrafish can be an effective complement to mammalian models due to its useful 
attributes. 
 
Simultaneous use of both fish and mouse models would be more efficient and cost-
effective than using mammalian models alone. Although results from zebrafish studies 
cannot be directly translated into human therapy, they can be tested and refined in 
mammals. However, since zebrafish express many genes implicated in human 
muscular dystrophies, and mutations in these genes result in a dystrophic phenotype, 
this suggests that findings may be transferable to humans. 
 
Many zebrafish models of muscular dystrophy exist, reviewed in (Berger et al., 2012, 
Lin, 2012). These fish have robust and readily recognisable phenotypes, which are 
visible early in development. These models of muscular dystrophies have facilitated 
many valuable insights into dystrophic pathologies.  
 
The dystrophin-deficient zebrafish model of DMD, sapje, and a dystroglycan mutant 
have been utilised in this study, and are described in the relevant chapters. 
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1.10 Treatments for DMD 
 
 
1.10.1 Current treatment 
Currently, DMD patients are treated with the corticosteroids prednisone and 
deflazacort, although these drugs are associated with adverse side effects (Fenichel et 
al., 1991). These drugs improve muscle strength and slow the disease progression, 
though the mechanism of action is not entirely clear. It is thought these drugs may act 
to improve membrane stability (Jacobs et al., 1996), stimulate muscle repair (Anderson 
et al., 2000) and reduce inflammation (Kissel et al., 1991, Wehling-Henricks et al., 
2004, Rhen and Cidlowski, 2005). Dose optimisation studies and the development of 
modified steroids may help to improve the balance between the benefits and 
unwanted effects associated with corticosteroids (Hoffman et al., 2012). However, side 
effects still remain a major limitation, especially when the drugs are used for long 
periods of time. 
 
1.10.2 Potential treatments 
A number of different therapeutic approaches have been adopted with the aim of 
treating DMD, some of which are in clinical trials. 
 
1.10.2.1 Gene therapy  
Viral gene therapy can be used to directly replace the missing protein in a disease. 
However, in DMD, the large size of the dystrophin gene and the need to target all the 
affected muscles in the body represent limitations of this approach. Mini- and micro-
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dystrophin genes, which can be cloned into AAV (adeno-associated virus) vectors, have 
been designed based on mildly affected BMD patient mutations. These have been used 
successfully in mdx mice (Wang et al., 2000). 
 
A problem associated with introducing a previous absent protein is the risk of immune 
rejection. This is not seen in mdx mice, but gene therapy studies in dogs and humans 
have resulted in variable immunological responses (Wang et al., 2007, Mendell et al., 
2010). If immune responses can be minimised, the need to target all affected muscles 
still remains a challenge. In addition, the truncated protein expressed may not be able 
to fulfil all the functions of dystrophin, for example the localisation of nNOS to the 
sarcolemma. 
 
1.10.2.2 Cell therapy  
The delivery of muscle precursor cells or stem cells into dystrophic muscles has been 
explored as a potential therapy for DMD. Despite the promising results achieved when 
healthy donor myoblasts were transplanted into mdx mice (Partridge et al., 1989), 
subsequent human trials have yielded poor results (Karpati et al., 1993a, Mendell et 
al., 1995). These disappointing results have been attributed to immune rejection, along 
with insufficient numbers and migration of transplanted cells. 
 
More recently, transplantation of mesoangioblasts resulted in the expression of 
dystrophin and an improvement in muscle function in GRMD dogs (Sampaolesi et al., 
2006) and dKO mice (Berry et al., 2007). In contrast to myoblasts, mesoangioblasts are 
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able to migrate from the circulatory system, eliminating the need for intramuscular 
injections. Therefore, these cells may be able to migrate into inaccessible muscles such 
as the heart. However, the immune rejection of these cells may still be a problem. The 
potential of mesoangioblast therapy in humans is currently being explored in clinical 
trials (EudraCT no. 2011-000176- 33). 
 
1.10.2.3 Premature stop codon read through 
Approximately 10-15% of DMD patients have nonsense mutations in dystrophin, which 
may be amenable to treatment with drugs that promote the read-through of 
premature stop codons, such as aminoglycosides. 
 
Aminoglycoside antibiotics affect translational fidelity, resulting in the ability of 
transfer RNAs (tRNAs) to recognise incorrect codons (Davies et al., 1964). This allows 
the insertion of an alternative amino acid at the site of the premature stop codon 
(figure 1.6). Aminoglycosides bind to the decoding centre of ribosomal RNA (rRNA). 
This site normally facilitates accurate codon-anticodon pairing, however the 
conformational change induced by aminoglycoside binding decreases the accuracy of 
this pairing. 
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(A) Wildtype dystrophin mRNA 
encodes the full-length dystrophin
protein. The binding of the tRNA
with the anticodon that matches the 
sense codon resuts in the 
incorporation of a specific amino 
acid into the polypeptide chain. 
(B) Mutant dystrophin mRNA with a 
premature stop codon produces 
truncated dystrophin protein. 
Release factor (RF) proteins promote 
the release of the polypeptide chain. 
(C) In the presence of 
aminoglycoside antibiotics the 
truncated protein is still produced. 
However, some translation events 
result in the synthesis of a full-
length protein with an amino acid 
substitution at the site 
corresponding to the premature 
stop codon. Aminoglycosides affect 
translational fidelity, allowing tRNAs
to recognise “incorrect” codons 
including stop codons, allowing the 
incorporation of an amino acid. 
Figure 1.6: Suppression of stop codons by aminoglycosides
 
 
Chapter 1 
28 
  
Aminoglycosides were able to restore protein translation in cell-based assays and in 
the mdx mouse (Barton-Davis et al., 1999), but the toxic effects and the need for 
regular intramuscular or intravenous administration limit the clinical use of these 
drugs.  
 
PTC124 was developed as part of a cell-based screen for compounds that promote 
premature stop codon read through and can be delivered orally (Welch et al., 2007). 
Restoration of dystrophin expression and an improvement in muscle force was 
observed in mdx mice treated with PTC124 (Welch et al., 2007), but subsequent 
patient trials yielded disappointing results; although there was increase in dystrophin 
expression and an improvement in the six minute walk test (6MWT, a standardised 
measure of ambulation) in most patients treated with the drug, the results were not 
statistically significant (Finkel, 2010). Although the efficacy of PTC124 needs to be 
improved to achieve better clinical outcomes, this could be a promising therapy for a 
subset of DMD patients. 
 
1.10.2.4 Exon skipping  
As with premature stop codon read-through, exon skipping is also dependent on the 
individual mutation. However, it is estimated that 83% of mutations may be amenable 
to this type of gene correction (Aartsma-Rus et al., 2009).  
 
This approach involves the design of anti-sense oligonucleotides (AONs), which 
hybridise with target mRNA sequences to alter RNA processing. Exclusion of mutation 
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containing exons restores the reading frame, resulting in the production of a 
truncated, partially functional dystrophin protein. 
 
Exon skipping has been successful in mdx (Alter et al., 2006) and dKO mice (Goyenvalle 
et al., 2010), and has been taken into clinical trials. AONs targeting exon 51, which 
would be applicable to the largest proportion of DMD patients (approximately 13%), 
have been tested in clinical trials. Using intramuscular and systemic delivery routes, 
these AONs were able to restore dystrophin expression to varying degrees (van 
Deutekom et al., 2007, Kinali et al., 2009). Efficacy was limited by rapid clearance from 
the circulation and poor cellular uptake, but different chemical backbones could be 
used to enhance delivery to muscles (Betts et al., 2012). 
 
Although progress in exon skipping is promising, several caveats remain. Since this 
therapy is mutation-specific, multiple AONs will need to be developed in order to treat 
different mutations. These may be regarded as different drugs by regulatory bodies, 
and each AON would have to progress through clinical trials separately. This would be 
expensive, time consuming and low frequency mutations may remain untreated. 
However, these problems could be overcome by the advent of multi-exon skipping 
(Yokota et al., 2012). 
 
1.10.2.5 Upregulation therapy 
Instead of replacing or repairing dystrophin expression, the expression of alternative 
proteins could be upregulated to compensate for dystrophin loss. This approach 
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circumvents any immunological problems associated with the introduction of 
dystrophin, and is not mutation-specific. 
 
Overexpression of several genes has been successful in ameliorating the dystrophic 
phenotype in mdx mice. These include α7β1-integrin (Burkin et al., 2001), nNOS 
(Wehling et al., 2001), cytotoxic T cell (CT) GalNAc transferase (Nguyen et al., 2002) 
and utrophin (Tinsley et al., 1996). 
 
Studies using utrophin and CT GalNAc transferase resulted in an increase in 
dystroglycan expression at the sarcolemma of mdx mice. By forming complexes 
analogous to the DGC, utrophin is able to stabilise dystroglycan and other complex 
components to the sarcolemma, thus maintaining sarcolemmal integrity. CT GalNAc 
transferase is involved in the synthesis of the CT antigen, which was shown to 
glycosylate α-dystroglycan in mdx mice overexpressing this enzyme. These transgenic 
mdx mice express increased levels of utrophin and complex components along the 
muscle fibre compared with their non-transgenic counterparts. Glycosylation of α-
dystroglycan with the CT antigen may promote the binding of extracellular ligands and 
stabilise its expression at the sarcolemma, where it can form complexes with utrophin. 
Therefore an increase in utrophin-associated glycoprotein complexes may be able to 
compensate for the loss of dystrophin. 
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1.10.2.6 Utrophin upregulation as a therapy 
It may be possible to increase levels of utrophin pharmacologically using small, orally-
bioavailable compounds. SMT C1100 was derived from a screen for transcriptional 
activators of utrophin. Despite promising results in the mdx mouse, plasma levels were 
not high enough in patient trials (Tinsley et al., 2011). New formulations may serve to 
improve the bioavailability of SMT C1100.  
 
SMT C1100 or similar compounds could also be combined with other approaches that 
increase the levels of utrophin, dystroglycan and associated complex components, to 
further stabilise sarcolemmal integrity. 
 
1.10.2.7 Protease inhibitors 
Loss of dystrophin results in an intracellular environment that supports the activation 
of a variety of proteolytic systems. As such, the activities of several proteolytic 
pathways have been shown to be increased in dystrophic muscle (Kominami et al., 
1987, Alderton and Steinhardt, 2000, Kumamoto et al., 2000, Nadarajah et al., 2011). 
The therapeutic potential of inhibiting pathways involving the proteasome, calpains, 
matrix metalloproteinases (MMPs) and lysosomal proteases have been investigated. 
Of these pathways, the proteasome system has probably received most attention in 
the literature.  
 
Inhibition of the proteasome has been shown to improve the dystrophic pathology in 
dystrophin-deficient muscle (Bonuccelli et al., 2003, Assereto et al., 2006, Bonuccelli et 
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al., 2007, Gazzerro et al., 2010). Treatment of mdx mice and muscle explants from 
DMD patients with proteasome inhibitors is able to restore expression of dystroglycan 
and other DGC components at the sarcolemma. It is proposed that stabilising this 
complex to the membrane is able to improve muscle pathophysiology. However, 
simply overexpressing dystroglycan in mdx mice was not able to rescue the dystrophic 
phenotype (Hoyte et al., 2004). This may be explained by the failure to prevent the 
degradation or recycling of dystroglycan. Further evidence to support this hypothesis 
comes from work using a targeted gene knock-in mouse model (Miller et al., 2012). 
Substitution of a phenylalanine at tyrosine residue 890 in the C-terminal tail of β-
dystroglycan prevented its phosphorylation and subsequent internalisation (see 
section 1.6.3.2). This resulted in the restoration of DGC components to the 
sarcolemma and an improvement in muscle function in mdx mice (Miller et al., 2012). 
 
Preventing dystroglycan phosphorylation provides another therapeutic target for 
DMD. Numerous inhibitors of both tyrosine phosphorylation and proteasomal 
degradation have been developed and are approved for treatment of other diseases 
such as cancer by regulatory bodies such as the FDA. Therefore side effects have 
already been explored. Some of these drugs also have the advantage of an oral 
delivery route. These could potentially be adopted as DMD therapeutics. 
 
1.11 Project aims 
This work aims to further investigate the potential of increasing dystroglycan function 
as a route for DMD therapy, using the zebrafish as a model. As discussed above, the 
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zebrafish provides a useful model for the evaluation of potential therapies, before 
translation to mammalian models and human trials.  
 
The regulation of dystroglycan function in muscle will be investigated using 
dystroglycan (dag1) and dystrophin (sapje) mutant fish models. Characterisation of the 
effects of the dag1 mutation on muscle structure and function will be carried out. 
Sapje fish will be used to investigate the protein expression levels and phosphorylation 
of dystroglycan in dystrophin-deficient muscle. Finally, the potential of chemically 
inhibiting dystroglycan degradation and phosphorylation as a therapy for DMD will be 
explored. 
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Chapter 2: Materials and Methods 
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2.1 Zebrafish Husbandry 
 
2.1.1 Home Office Regulation 
All studies were performed in accordance with Home Office requirements for the use 
of animals in scientific research and regulated procedures were carried out under the 
UK Home Office project licence number 40/3134. 
 
2.1.2 Maintenance of adult zebrafish 
Adult zebrafish are maintained in UK Home Office approved facilities in the Medical 
Research Council Centre for Developmental and Biomedical Genetics aquaria at the 
University of Sheffield. The aquaria follow a 14:10 hour light:dark cycle and are 
maintained according to standard protocols (Nüsslein-Volhard and Dahm, 2002).  
 
2.1.3 Zebrafish Strains 
 
2.1.3.1 Wildtype strains 
LWT (London Wildtype) embryos were used throughout for those experiments 
requiring wildtype embryos. 
 
2.1.3.2 Mutant strains 
Heterozgyous dystrophin mutant (sapjeta222a) and dystroglycan mutant (dag1hu3072) 
zebrafish are kept as breeding stocks in the aquaria on a LWT background. 
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2.1.4 Embryo Collection 
Embryos were obtained from the pair-wise mating of adult zebrafish (Nüsslein-Volhard 
and Dahm, 2002). Pairs of fish were placed into breeding trap tanks that prevent adult 
fish from ingesting embryos. These tanks consist of two plastic containers that fit 
tightly inside one another, the inner of which holds the fish and has a base that has 
been replaced by a grid. Embryos are able to pass through the grid and so are 
protected from the fish. The tanks also have a dividing wall to separate the male and 
female the night before embryo collection. The divider is removed the following 
morning and breeding is allowed to occur before collection of the resulting embryos. 
 
Embryos were staged according to standard criteria (Kimmel et al., 1995) sorted into 
groups of approximately 50 and placed in Petri dishes (Sterilin) containing fresh E3 
medium (see section 2.1.5.1). Embryos were incubated at 28.0°C up to a maximum of 
5.2dpf, at which point they were destroyed using bleach. 
 
2.1.5 Zebrafish media and solutions 
All chemicals are from Sigma unless otherwise stated.  
 
2.1.5.1 E3 embryo medium 
E3 medium was composed of 5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 0.33mM 
MgSO4 and 0.0001% methylene blue diluted in distilled water (dH2O).  
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2.1.5.2 Tricaine (MS222) 
A 0.4% (w/v) stock solution was made by diluting 400mg of powdered MS222 in 97.9ml 
dH2O and 2.1ml of 1M Tris pH9. The pH was adjusted to 7 (Westerfield, 2000). 
 
2.2 Detection of muscle phenotype by birefringence assay 
Larvae were anesthetized using a few drops of tricaine (MS222) and transferred to a 
glass dish. Larvae were viewed between two polarizing filters on a dissecting 
microscope (Leica MZ FLIII). The polarizing filters are rotated so that only light 
refracting through the striated muscle was visible. Images were acquired using a SPOT 
Idea™ USB camera (Diagnostic Instruments) and associated SPOT imaging software and 
exported in TIFF format. 
 
2.3 Zebrafish Motility Assays 
 
2.3.1 Hatching assay 
At 48, 50, 52 and 54hpf, embryos were divided into two groups depending on whether 
or not they had hatched from their chorions. At 3dpf, the muscle birefringence of the 
larvae was examined, and the percentage of sibling and mutant fish that had hatched 
at each time point was calculated. 
 
2.3.2 Swirl assay 
Larvae were divided into groups of approximately 20 for this assay. Petri dishes 
containing larvae in E3 media were swirled until larvae collected in the centre of the 
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dish (3cm diameter). When the swirling motion stopped, the number of larvae that 
swam out of the centre, and those left in the middle of the dish, were divided into 
separate dishes. The larvae were anaesthetised and muscle birefringence was 
examined. The percentage of sibling and mutant fish that had swam out of the centre 
was then calculated. 
 
2.3.3 Viewpoint Zebrabox System 
Larvae were placed into individual wells of 24-well plates. After transfer to the wells, 
larvae were allowed to acclimatise for 10 minutes in the Zebrabox apparatus. The 
locomotion of each larva was then recorded and analysed in the Zebrabox recording 
apparatus, equipped with Videotrack software (both from Viewpoint, France).  
 
The grid of the video-tracking software was aligned with the wells of the 24-well plate 
such that each fish was within one tracking area. The recording apparatus was used to 
capture movements within the predefined tracking areas. For tracking the larvae, the 
detection threshold was set at 15 (on a greyscale of 0–255), although this can be 
modified according to the contrast between the animal and the background. The 
length of the plate was used to set the scale in mm.  
 
The Videotrack software automatically calculated the distance travelled and duration 
of movements within 3 predefined speed categories.  The three speed categories 
were: Inactive movement (less than 2mm/s), slow movement (2- 10mm/s) and fast 
movement (more than 10mm/s).  
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A light cycle program of 30 seconds light, 2 minutes dark was used in order to induce 
movement of the larvae. This program was repeated 4 times for a total of 10 minutes 
recording time. Tracking data were exported into Excel. 
 
2.4 Preparation of embryos for microscopy 
 
2.4.1 Solutions used 
Name Components 
PBS 137mM NaCl, 2.7mM KCl,10mM 
Na2HPO4, 1.76mM KH2PO4 (pH 7.4) 
PBTX PBS with 0.1% (v/v)Triton X-100 
PBDT PBS with 1% (w/v) BSA, 1% (v/v) DMSO 
and 1% (v/v) Triton X-100 
 
2.4.2 Fixation 
Unless otherwise stated, all washing steps were 5-10 minutes with gentle rocking, with 
embryos in 1.5 ml tubes. 
 
Embryos were washed 2-3 times with PBS and then incubated with 4% 
paraformaldehyde in PBS for 2 hours at room temperature. Embryos were then 
washed 3 times with PBTX, once with 50% methanol in PBS and twice with methanol 
(Fisher), before being stored at -20⁰C in the final methanol wash.  
 
Those embryos being stained with rhodamine phalloidin (section 2.4.3) were not 
washed with methanol and were stored at 4⁰C in PBS. 
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2.4.3 Labelling F-actin 
Fixed embryos were incubated with PBTX for 1 ½ hours, followed by 1:20 rhodamine 
phalloidin (Molecular Probes, Invitrogen) in PBTX for 2 hours at room temperature. 
Stained embryos were then washed 3 times with PBTX and stored at 4⁰C in Vectashield 
mounting medium with DAPI (Vector Labs). 
 
2.4.4 Whole-mount immunofluorescence 
Fixed embryos were rehydrated through a methanol/PBTX series (75, 50 and 25% 
methanol in PBTX) and then washed twice with PBTX. Embryos were washed with 
water for 5 minutes, acetone for 7 minutes (at -20⁰C) and then water again for 5 
minutes. Embryos were then washed twice with PBDT for 30 minutes, before being 
incubated overnight at 4⁰C in PBDT containing the appropriate dilution of primary 
antibody (see table in section 2.10.1) Following primary antibody incubation, embryos 
were washed 3 times with PBDT for at least 30 minutes, before being incubated 
overnight with PBDT with the appropriate dilution of secondary antibody (see table in 
section 2.10.3). Following secondary antibody incubation, embryos were washed 3 
times in PBDT before being stored at 4⁰C in Vectashield mounting medium with DAPI. 
 
For those embryos co-stained with Alexa fluor 488 conjugated α-bungarotoxin (α-BTX) 
(Molecular Probes, Invitrogen), 1:20 α-BTX was added at the secondary antibody 
incubation stage. 
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2.4.5 Mounting of embryos onto microscope slides 
Glass microscopy slides (Fisher) were covered with 2 or 3 layers of insulating tape, and 
a chamber of approximately 5mm2 excised from the centre using a scalpel. The head of 
the embryo was removed and the trunk placed onto the microscope slide in 
Vectashield mounting medium with DAPI. A glass coverslip (Scientific Laboratory 
Supplies, No. 0) was placed over the top. Pressure was applied to the coverslip to 
ensure the desired orientation and positioning of the sample. Slides were stored in the 
dark at 4⁰C until use. 
 
2.5 Confocal microscopy 
Slides were examined using sequential scanning on an Olympus FV-1000 laser-scanning 
confocal system mounted on an Olympus BX61 upright microscope and driven by FV-
10 ASW software (version 1.4). The FV-1000 confocal microscope system is fitted with 
a 40mW Argon ion gas laser emitting lines at 457, 476, 488 and 515nm, a 1mW He-Ne 
gas laser emitting light at 543nm, a 10mW He-Ne gas laser emitting light at 633nm, 
and a 30mW solid state diode laser emitting light at 405nm. Embryos were viewed 
using a 20X/0.75NA UPlanSApo lens, a 40X/1.00NA UPlanApo oil immersion lens or a 
60X/1.42NA PlanApoN oil immersion lens. 40 or 60x objectives were used with 
Olympus immersion oil. Images were acquired using FV-10 ASW software (version 1.4) 
and exported in TIFF format. Images of each fluorescent channel and merged RGB 
images were exported. Images were processed using ImageJ crop and scale bar 
functions. 
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2.6 Chemical treatment of embryos  
 
 
2.6.1 Treatment with tricaine 
 
 
2.6.1.1 Effect of larval movement on muscle birefringence 
Dechorinated embryos were treated with 0.005% tricaine at 2.5dpf and incubated in 
the dark at 28⁰C. Images were acquired and processed as in section 2.2. 
 
2.6.1.2 Effect of larval sedation on Viewpoint tracking analysis 
LWT larvae were treated with various concentrations of tricaine at 2.5dpf and 
incubated for 30 minutes. Viewpoint tracking analysis was carried out as described in 
section 2.3.3. 
 
2.6.2 Drug treatment  
 
2.6.2.1 Compounds used 
Compound Source 
Aminophylline Sigma-Aldrich 
Dasatinib (BMS-354825) LC Laboratories 
MG132 Calbiochem 
PP2 Sigma-Aldrich 
PYR-41 Sigma-Aldrich 
Saracatinib (AZD0530) LC Laboratories 
Velcade (Bortezomib, PS-341) LC Laboratories 
Drugs were dissolved in DMSO and kept as stock solutions at -20⁰C. 
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2.6.2.2 Dechorionation of embryos 
Embryos were dechorionated manually with fine forceps (Dumont #5), or chemically 
with pronase (0.1mg/ml in E3 for 40 minutes at 28⁰C, followed by several washes in 
E3). 
 
2.6.2.3 Treatment of wildtype embryos 
Dechorionated LWT (London wildtype) embryos were transferred into 6 well plates at 
24hpf with the appropriate dilution of drug, or DMSO only, in E3 media. There were 50 
embryos per well in a total volume of 5ml. The final concentration of DMSO was 1%. 
Embryos were treated continually for 24 or 48 hours at 28⁰C. Embryo lysates were 
prepared as described in section 2.8.2.2. 
 
2.6.2.4 Treatment of sapjeta222a embryos 
Dechorionated embryos from a heterozygous sapje cross were transferred into 6 well 
plates at 24hpf with the appropriate dilution of drug, or DMSO only, in E3 media. 
There were 50 embryos per well in a total volume of 5ml. The final concentration of 
DMSO was 1%. Embryos were treated continually for 48 or 72 hours at 28⁰C, before a 
birefringence assay was carried out to determine the percentage of fish affected by 
the muscle pathology (see section 2.2). The assay was carried out blinded. Embryo 
lysates were prepared as described in section 2.8.2.2. 
 
For treatment after the onset of muscle damage, sapje larvae were identified at 3dpf. 
Larvae were treated in 6-well plates until 5dpf as above but with 10 fish per well. 
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2.7 Cell culture 
 
2.7.1 Growth of cell lines 
H-2Kb-tsA58 mouse myoblasts cells (Morgan et al., 1994) were cultured in T75 tissue 
culture flasks (75cm2) (Greiner Bio-One) and maintained in DMEM (Dulbecco’s 
modified Eagle medium) GlutaMAX™ with 4.5g/L glucose (Gibco). The medium was 
supplemented with 20% foetal calf serum, 2% chick embryo extract, 2% penicillin-
steptomycin and 20 units/ml of mouse recombinant interferon-γ (Peprotech). 
Myoblasts were incubated at 33⁰C in a 10% CO2 environment. Cells were passaged 
using 1% (v/v) trypsin-EDTA (Sigma), followed by centrifugation (11030 rotor, Sigma) at 
x80g for 3 minutes and resuspension in media. Myoblasts were kept at sub-confluent 
levels (≈50%) to prevent fusion into myotubes. 
 
2.7.2 Drug treatment of myoblasts 
Cells were plated into a 24-well plate and incubated overnight. The media were 
removed from the plates, and replaced with 500μl of media containing a specific 
concentration of drug diluted in DMSO, or DMSO only. The final concentration of 
DMSO was 0.1%. Cells were then incubated for 6 hours in the conditions described 
above. Drugs used are detailed in section 2.6.2.1. 
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2.8 Protein Biochemistry techniques 
 
2.8.1 Buffers and solutions 
Name Components 
RIPA buffer 50mM Tris.HCl (pH 7.5), 150mM NaCl, 1mM EGTA, 1mM 
EDTA, 1% (v/v) Triton-X, 0.5% (w/v) sodium deoxycholate, 
0.1% SDS (w/v), 1mM azide supplemented with protease and 
phosphatase inhibitors (1mM sodium orthovanadate, 1mM 
PMSF , 10µM TPCK, 10µM leupeptin, 1µM pepstatin, 
10µg/ml aprotinin, 10µg/ml benzamidine) 
2X SDS Loading Buffer 100mM Tris.HCl (pH6.8), 0.85M β-mercaptoethanol, 4% 
(w/v) SDS, 0.2% (w/v) Bromophenol blue, 20% (v/v) Glycerol 
SDS-PAGE Running 
Buffer 
200mM glycine, 25mM Tris, 0.1% (w/v) SDS 
Towbin Transfer Buffer 25mM Tris, 192mM glycine, 0.075% SDS, 20% Methanol 
Tris buffered saline 
with Tween-20 (TBST) 
50mM Tris. HCl (pH7.5), 150mM NaCl, 0.5% (v/v) Tween-20 
ECL I 100mM Tris. HCl (pH 8.5), 1.25mM luminol, 0.2mM p-
Coumaric acid, 
ECL II 100mM Tris. HCl (pH 8.5), 0.02% (v/v)H2O2 
Stripping Buffer 0.2M glycine, 0.1% (w/v) SDS, 1% (v/v) Tween-20. (pH 2.2) 
 
 
2.8.2 Preparation of lysates 
 
2.8.2.1 H2K myoblasts 
Cells were cultured in 24-well plates as described in section 2.7. The media were 
removed from the wells and the cells were washed in ice cold PBS (phosphate buffered 
saline) (see section 2.4.1). 20μl of ice-cold RIPA buffer containing phosphatase and 
protease inhibitors was added to each well, and the plate was incubated on ice for 15 
min. Cells were harvested by scraping the cells from the wells using a pipette tip, 
followed by pipetting into a 1.5ml microcentrifuge tube. A sonicator (Soniprep 150) 
was used for a period of 10 seconds 3 times in order to shear genomic DNA. Samples 
were centrifuged to remove insoluble debris and mixed with an equal volume of 2x 
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SDS loading buffer. Lysates were then boiled for 5 minutes to denature the protein and 
either run on a gel, or stored at -20⁰C. 
 
2.8.2.2 Zebrafish embryos 
Zebrafish embryos (individual or pooled) were placed into microcentrifuge tubes with 
20μl of ice-cold RIPA buffer per fish. Samples were homogenised by pipetting up and 
down or vortexing, and sonicating as described above. An equal volume of 2x SDS 
loading buffer was added, and lysates were boiled for 15 minutes. Samples were either 
stored at -20⁰C or centrifuged before running on a gel. 
 
2.8.3 SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Any kD™ Mini-PROTEAN® TGX™ Precast gels (Bio-Rad) with 10 or 12 wells were placed 
into a Mini-PROTEAN® Tetra Cell electrophoresis tank. SDS running buffer was added 
up to the fill line. Protein samples (see section 2.8.2) were loaded onto the gel 
alongside a molecular weight marker (Thermo Scientific PageRuler Plus Prestained 
Protein Ladder), and run for approximately 1 hour at 150V. The gel containing the 
proteins separated by SDS-PAGE was then used for western blotting (section 2.8.4). 
 
2.8.4 Western blotting 
The Bio-Rad Mini Trans-Blot™ Electrophoretic Transfer Cell system was used to 
transfer the proteins from the SDS-PAGE gel to PVDF (polyvinylidene difluoride) 
membrane (GE Healthcare). Transfers were performed using the manufacturer’s 
instructions. Towbin transfer buffer was used, and proteins were transferred at room 
temperature for 90 minutes at 400mA. 
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2.8.5 Antibody binding and detection 
Following protein transfer from the gel to the PDVF membrane, the membrane was 
placed in blocking solution for 1-2 hours on a rocker at room temperature. The 
blocking solution consisted of 5% (w/v) skimmed milk powder in TBST. The membrane 
was then incubated overnight at 4⁰C in the appropriate primary antibody at the 
recommended dilution (see table in section 2.10.1) in 5% skimmed milk powder in 
TBST. The membrane was washed 4 times with TBST at 15 minute intervals on a rocker 
at room temperature, before incubation with the appropriate HRP-conjugated 
secondary antibody (see table in section 2.10.2) for 1 hour at room temperature. The 
membrane was washed in TBST again at room temperature 3 times at 10 minute 
intervals. To obtain a signal, the membrane was developed by exposure to a mixture of 
ECL (enhanced chemiluminescence) reagents (1:1 ratio of each ECL reagent).  
Chemiluminescence signals were imaged on a Chemidoc™ XRS+ System (Biorad). 
 
2.9 Computer aided data analysis 
 
 
2.9.1 Quantification of western blot bands 
Quantification was carried out in Image Lab™ software version 3.0 (Bio-Rad) with a 
rolling disk background subtraction (diameter 10mm). Volume measurements for each 
band were taken and the values were normalized against α-tubulin signal and 
represented as a ratio of the average control signal for each antibody. 
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2.9.2 Quantification of birefringence image intensity 
Images were acquired and exported in TIFF format as described in section 2.2, and 
converted to 8-bit greyscale using ImageJ software (NIH). The ImageJ threshold and 
wand tools were used to select the somitic muscle area. The average grey value of the 
pixels in the selected area was then measured. The mean value of wildtype sibling 
images was used to normalize values obtained from mutant images. Intensity values 
from mutant fish images were expressed as a percentage of average sibling intensity.  
 
2.9.3 Line scanning and Fourier transform 
Images were acquired as described in section 2.2, and converted to 8-bit greyscale 
using ImageJ software (NIH). The ImageJ straight line tool was used to draw a line 
along the dorsal myotome of the fish, from the start of the 3nd somite to the end 22nd 
somite. The “Plot Profile” tool was used to plot a graph of image intensity along the 
length of the fish and these data were exported into Microsoft Excel. This process was 
repeated for the ventral somites. 
 
Excel files were imported into MATLAB (Mathworks) and processed using BIOSYST, 
program coding written by Mikko Juusola (Department of Biomedical Science, 
University of Sheffield). Line scans, L (i), in which i represents gray-scale intensities 
over the length of the sample, were subjected to Fourier analysis using this program. 
 
Sample interval was calculated by dividing the total distance of the line scan (in μm) by 
the number of data points (approximately 800-1000). The interval was used to 
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calculate the sampling frequency using the following equation: 
𝑆𝑎𝑚𝑝𝑙𝑖𝑛𝑔 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 =
1000𝜇𝑚
𝐼𝑛𝑡𝑒𝑟𝑣𝑎𝑙
  
The settings of the BIOSYST program were then changed to account for the sampling 
frequency. The “Analysis > Frequency Analysis > Set Parameters” command was used 
to set the window size to 200 data points. Line scans were divided into 50% 
overlapping stretches and windowed with a Blackman-Harris 4-term window, giving 5 
to 7 200-point-long spectral samples. The spectral samples were averaged to improve 
the estimates of their power spectra, < |𝐿(𝑓)|² > , where | | denotes the norm, f 
spatial frequency and <> the average over the different stretches. The “Analysis > 
Frequency Analysis > Power Spectra” command was used to transform the line scan 
data to their averaged power spectra. 
 
Power spectra files were exported from MATLAB into Origin 7 for the creation of 
graphs.  
 
2.9.4 Data analysis 
Data were processed using Microsoft Excel and then imported into GraphPad Prism 
software for the creation of graphs and statistical analysis.  
 
2.9.5 Statistical Analysis 
The D’Agostino-Pearson normality test was used to assess datasets for deviations from 
a normal Gaussian distribution, and Bartlett’s test was used to assess the equality of 
variances. If tests indicated that a dataset deviated from a Gaussian distribution, non-
parametric methods were applied (e.g. Mann Whitney U-test). If the datasets followed 
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a normal distribution and had similar variances, parametric methods were applied (t-
test or one-way ANOVA followed by multiple comparison post-tests). In all analyses, a 
threshold value of p<0.05 was considered statistically significant. 
 
2.10 Antibodies used 
 
2.10.1 Primary Antibodies 
Name of 
Antibody 
Epitope Species Dilution Source/ 
Reference Western 
Blotting 
Immuno-
fluorescence 
MANDAG2 C-terminus of 
β-dystroglycan 
(amino acids 
881-895) 
Mouse 1:100 1:100 (Pereboev 
et al., 
2001) 
1709 C-terminus of 
β-dystroglycan 
(amino acids 
881-895), with 
phosphorylated 
Y892 
Rabbit 1:500 1:200 (Ilsley et 
al., 2001, 
Miller et 
al., 2012) 
MANDRA1 C-terminus of 
dystrophin 
(amino acids 
3667-3671) 
Mouse - 1:50 (Nguyen et 
al., 1992, 
Morris et 
al., 1998) 
Anti- α-
tubulin 
α-tubulin Mouse 1:3500 - Sigma 
Aldrich 
 
 
 
2.10.2 HRP (horse radish peroxidase)-conjugated secondary antibodies used in 
western blotting 
 
Protein targeted against Species rasied in Dilution 
Anti-mouse IgG Goat 1:5000 
Anti-rabbit IgG Goat 1:5000 
All purchased from Sigma-Alrich 
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2.10.3 Fluorescently conjugated secondary antibodies used in immunofluorescence 
 
Protein targeted 
against 
Conjugate Species raised in Dilution 
Anti-mouse IgG Alexa Fluor 488 Donkey 1:200 
Anti-mouse IgG Alexa Fluor 594 Goat 1:200 
Anti-rabbit IgG Alexa Fluor 488 Donkey 1:200 
All purchased from Molecular Probes, Invitrogen 
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Chapter 3: A Dystroglycan nonsense mutation elicits a muscular 
dystrophy phenotype in zebrafish 
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3.1 Introduction 
 
3.1.1 Loss of dystroglycan function in muscular dystrophy 
 
3.1.1.1 Dystroglycan is a core component of the DGC 
Dystroglycan is central to the DGC, linking laminin in the ECM to actin in the 
cytoskeleton via the cytoskeletal linker dystrophin. The dystroglycan gene, DAG1, 
encodes a propeptide that is post-translationally cleaved into α- and β-subunits 
(Ibraghimov-Beskrovnaya et al., 1992, Holt et al., 2000), which interact with each other 
non-covalently (Yoshida et al., 1994). β-dystroglycan is a transmembrane protein that 
interacts with dystrophin via its intracellular C-terminal domain, and α-dystroglycan via 
its extracellular domain. The extracellular protein α-dystroglycan is heavily 
glycosylated, and these modifications are important for the interactions between 
dystroglycan and its ECM ligands.  
 
3.1.1.2 Aberrant glycosylation of α-dystroglycan results in muscular dystrophy 
 
Hypoglycosylation of α-dystroglycan results in decreased binding to laminin-2 (Michele 
et al., 2002a), disrupting the link between the DGC and the ECM. Reduced 
glycosylation of α-dystroglycan, caused by mutations in genes encoding known or 
putative glycosyltransferases,  is associated with a group of muscular dystrophies, 
known as the dystroglycanopthies (Godfrey et al., 2007b).  
 
Chapter 3 
54 
  
3.1.1.3 Mutations in dystroglycan are usually embryonic lethal in mammals 
Although aberrations in dystroglycan processing cause muscular dystrophy, mutations 
in dystroglycan itself are rare due to its involvement in early embryogenesis.  In fact, 
there has only been one dystroglycan mutation patient described to date (Hara et al., 
2011). This rarity is possibly due to embryonic lethality; mouse dystroglycan knockouts 
are embryonic lethal due to the failure of the extra-embryonic Reichert’s membrane to 
form (Williamson et al., 1997). The lethality of dystroglycan mutations in mammals has 
made the study of dystroglycan function in muscle somewhat challenging. Mice with a 
specific inactivation of the dystroglycan gene in skeletal muscle (MCK-DG null) were 
created, but these have a surprisingly mild phenotype (Cohn et al., 2002). Satellite cells 
in the MCK-DG null mice, which were not targeted by the muscle creatine kinase 
promoter used to create the conditional knockouts, were able to initiate expression of 
dystroglycan during muscle regeneration. The complete loss of dystroglycan in muscle 
was therefore not achieved. MORE-DG null mice, lacking dystroglycan in all embryonic 
tissues but not in extra-embryonic membranes, have a severe muscular dystrophy 
phenotype and eye and brain defects that resemble Walker-Warburg syndrome (Satz 
et al., 2008). However, these mice do not survive past the first month, with the 
majority dying within 48 hours of birth.  Mouse models deficient in fukutin or POMT1, 
enzymes thought to be involved in dystroglycan glycosylation, are also embryonic 
lethal (Takeda et al., 2003, Willer et al., 2004). 
 
Due to its rapid external development, the zebrafish circumvents the lethality of 
removing dystroglycan function that occurs in higher vertebrates. Therefore, the 
zebrafish represents an alternative model to study dystroglycanopthies, and the role of 
dystroglycan in muscle development and integrity. 
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3.1.2 Loss of dystroglycan in zebrafish causes a muscular dystrophy phenotype 
 
 
3.1.2.1 Dystroglycan morphant zebrafish 
Removing the function of dystroglycan in zebrafish using antisense morpholino 
oligonucleotides (MO) produces a dystrophic phenotype (Parsons et al., 2002). 
Injection of a dystroglycan MO results in the absence of dystrophin at the myosepta, 
loss of muscle integrity and cellular organisation, and necrosis of the muscle tissue. 
 
3.1.2.2 Dystroglycan mutant zebrafish 
There are 2 zebrafish dystroglycan mutants, patchytail (Gupta et al., 2011) and 
dag1hu3072 (Lin et al., 2011), both of which show a dystrophic phenotype.  
Due to the transparency of zebrafish embryos, muscle integrity can be examined using 
muscle birefringence (Granato et al., 1996). The ordered array of muscle fibres in 
wildtype skeletal muscle results in the diffraction of polarised light. Thus under 
polarised light, the somitic muscle can be detected as bright areas in a dark 
background. Reduction in birefringence is indicative of muscle damage or 
disorganisation, as seen in the zebrafish dystroglycan mutants. 
 
3.1.2.2.1 patchytail 
The patchytail mutant was identified from an ENU screen and is characterised by a 
dystrophic phenotype and impaired motility (Gupta et al., 2011). The mutation in 
patchytail is T1700A, which results in a missense change of valine to aspartic acid 
(V567>D) in the C-terminal domain of α-dystroglycan. This domain of α-dystroglycan is 
important for DGC assembly by interacting with the N-terminal domain of β-
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dystroglycan. The patchytail mutation results in reduced levels of dag1 mRNA 
transcripts as shown by RT-PCR, and a complete loss of both α- and β-dystroglycan 
proteins according to western blot analysis. A mild dystrophic phenotype is exhibited 
in patchytail mutants at 3dpf, with loss of birefringence in posterior somites. The 
muscle degeneration progresses rapidly after 4dpf, with most somites exhibiting loss 
of birefringence by 7dpf. There is also impaired locomotion at 7dpf, with slower 
swimming speeds and a reduced touch-evoked escape response. 
 
3.1.2.2.2 dag1hu3072 
dag1 was obtained from the Sanger Institute Zebrafish Mutation resource (Wienholds 
et al., 2003, Stemple, 2004). It is a TILLING mutant harbouring a C1568T change, which 
causes a premature termination of translation (R398> Stop) within the mucin domain 
of α-dystroglycan (see figure3.1). dag1 is a recessive allele and is maintained as a 
heterozygous stock. 
A schematic drawing indicating the position of the mutation (R398 > STOP) within the 
mucin domain of dystroglycan in the dag1hu3072 zebrafish (SP=signal peptide; TM= 
transmembrane domain). The protease site between α and β dystroglycan is at residue 
627.
Figure 3.1: Schematic of dag1hu3072 mutation
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3.1.3 Chapter aims and hypotheses 
This chapter describes the further characterisation of dag1hu3072 mutant fish in terms of 
muscle damage and motility. 
Hypotheses: 
 The dag1 mutation affects the stabilisation of the DGC and muscle integrity in 
zebrafish 
 The dag1 mutation affects zebrafish larval motility 
 
3.2 Results 
 
3.2.2 dag1hu3072 embryos have a muscular dystrophy phenotype 
A dystrophic phenotype can be observed in dag1 larvae from 3dpf, while the skeletal 
muscle of siblings remains unaffected. This is shown by the loss of birefringence of the 
somitic muscles in dag1 larvae (figure 3.2). Unlike the patchytail larvae, the muscle 
damage appears to be randomly distributed throughout the body, rather than only 
affecting posterior somites.  
 
The dystrophic phenotype in dag1 larvae progresses over time, with an increasing 
amount of muscle damage visible from 3 to 5dpf (figure 3.2). Birefringence intensity of 
sibling larvae was used as a benchmark to which all other values were normalised. At 
3dpf, the intensity of birefringence in dag1 fish is approximately 77% of sibling levels. 
The muscle birefringence decreases over time, and at 5dpf the intensity of the 
birefringence image is about 65% that of sibling larvae. 
 
Chapter 3 
58 
  
B
Birefringence of sibling and dag1 muscle at 3 and 5dpf.
(A) Representative birefringence images at 3 and 5dpf. dag1 mutants show a loss of 
birefringence compared to siblings (sib). The loss of birefringence progresses with age. (B) 
Quantification of sapje birefringence images. Each plot represents mean birefringence of 30 
sapje larvae normalised against average sibling value and error bars represent SEM. 
Figure 3.2: Loss of birefringence in dag1 at 3 and 5dpf
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Myogenesis and myofibrillogenesis appear to be unaffected in dag1 (Lin et al., 2011). 
Labelling the F-actin of dag1 larvae to visualise the muscle architecture suggests the 
cause of the dystrophic phenotype is due to detachment of muscle fibres from the 
vertical myosepta (figure 3.3). The severity of the phenotype increases with age, with 
more detachment and disorganisation of muscle fibres visible at 5dpf. 
 
  
Figure 3.3: Confocal images of 3 and 5dpf larvae stained with rhodamine 
phalloidin 
Rhodamine phalloidin staining shows the disrupted muscle structure in dag1 somites 
(white arrow heads), compared with the neatly organised array of muscle fibres in 
sibling (sib) larvae (scale bars 50μm). 
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3.2.1 Dystroglycan expression in zebrafish  
Excluding sarcospan, all DGC proteins are present in zebrafish and are concentrated at 
the myosepta (Parsons et al., 2002, Chambers et al., 2003, Guyon et al., 2003). 
Western blot analysis of whole embryo lysates shows full length β-dystroglycan is 
expressed in wildtype, but not dag1 embryos (figure 3.4). Whole mount 
immunohistochemistry was carried out on wildtype and dag1 embryos to visualise the 
localisation of dystroglycan. Figure 3.4 shows dystroglycan expression at the myosepta 
of wildtype embryos and also shows punctate staining within the somites. The strong 
staining at the myosepta is lost in dag1 embryos.  
 
Loss of dystroglycan immunoreactivity was to be expected in the dag1 embryos since 
the antibody used is targeted to the C-terminal tail of β-dystroglycan. The nonsense 
mutation in dag1 is upstream of this epitope, so if any truncated dystroglycan was 
present, it would not contain this recognition sequence. There is some residual 
dystroglycan staining in dag1 embryos; this could be explained by non-specific 
antibody binding to muscle detachments, skin and myosepta, which may be 
particularly sticky. 
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Figure 3.4: Loss of dystroglycan immunoreactivity in dag1 embryos
sib dag
B
(A) Western blot of embryo lysates probed with antibodies against β-dystroglycan (top 
panel) and α-tubulin (bottom panel). (B) confocal images of 4dpf sibling (sib) and dag1
larvae stained with MANDAG2 (antibody against β-dystroglycan ). β-dystroglycan is 
localised to the vertical myosepta in siblings, and to structures within the somites, thought 
to be NMJs. This staining is lost in dag1 larvae. Scale bar is 100μm.
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In sibling embryos, dystroglycan co-localises with staining for postsynaptic 
acetylcholine receptors using Alexa Fluor-488 conjugated α-bungarotoxin (figure 3.5), 
suggesting the staining seen within the somites is representative of neuromuscular 
junctions (NMJs). Dystroglycan staining at NMJs is lost in dag1 fish. The dystroglycan 
deficient muscles of chimeric mice display a neuromuscular junction defect, 
characterised by fewer and fragmented nerve synapses (Cote et al., 1999). 
Postsynaptic receptor clusters were present in dag1 mutants (figure 3.5), although 
extensive analysis of the number and size of clusters was not carried out. patchytail 
embryos show well developed postsynaptic receptor clusters, with no noticeable 
differences between those found in wildtype embryos. Together, these data suggest 
dystroglycan may not be required for zebrafish neuromuscular junction formation. 
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Figure 3.5: Localisation of dystroglycan to NMJs
Confocal images of 4dpf embryos stained with Alexa Fluor 488 conjugated α-bungarotoxin
(α-BTX) and MANDAG2 (antibody against β-dystroglycan). In sibling (sib) embryos there is 
colocalisation between α-BTX (A) and β-dystroglycan (β-DG) (B). In dag1 embryos there is a 
loss of β-dystroglycan staining (E), but there appears to be acetylcholine receptor clustering 
(D & F).
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3.2.3 dag1hu3072 embryos have a loss of dystrophin expression 
Members of the DGC are important for maintaining the stability of their interacting 
proteins. The effect of lack of dystroglycan on the stability of dystrophin was therefore 
investigated. Immunofluorescence staining for dystrophin showed expression at the 
myosepta of wildtype embryos. The expression of dystrophin in dag1 embryos was 
seen to be reduced at 3 and 5dpf (figure3.6). 
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Figure 3.6: Dystrophin staining in dag1 mutants
Confocal images of 3 and 5dpf larvae stained with MANDRA1 (antibody against 
dystrophin) and DAPI. In sibling embryos, dystrophin is localised to the vertical myosepta, 
to which muscle fibre attach. Dystrophin staining in muscle is not as strong in dag1 mutants, 
especially at 5dpf. Scale bars are 50μm.
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3.2.4 dag1hu3072 embryos show impaired motility 
 
 
3.2.4.1 Zebrafish locomotion behaviours 
Though locomotion and behaviour may be more commonly associated with juvenile 
and adult stages of zebrafish development, simple patterns of motility and behaviour 
can be observed during embryonic and early larval stages (Granato et al., 1996). 
Zebrafish embryos are well suited to movement analysis as they perform well 
characterised behaviours from an early stage. The first spontaneous muscle 
contractions occur at 17hpf (Saint-Amant and Drapeau, 1998). These movements 
become stronger, more coordinated and occur more regularly as the embryo develops. 
As the embryo becomes close to hatching, it starts to change position within the 
chorion and displays slow, rhythmic movement of the pectoral fins. Hatching occurs 
between 48 and 60hpf, after which larvae move less often, but respond to tactile 
stimuli with an escape response (Granato et al., 1996). At 4-5dpf, the swim bladder 
inflates, and larvae are able to display more robust swimming behaviours. 
 
3.2.4.2 dag1hu3072 embryo hatching is delayed compared with siblings 
In the developing zebrafish, hatching from the chorion results from a combination of 
processes. The release of enzymes from the hatching gland digests the chorion, 
weakening the membrane, and allowing the embryos to use muscular movement to 
release themselves from the chorion (Yamamoto et al., 1979). This hatching process 
normally occurs at around 48-60hpf (Granato et al., 1996).  
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Immotile zebrafish mutant embryos such as frozen and sloth are completely paralyzed 
and fail to hatch from their chorions (Granato et al., 1996). At 48hpf, 12±2.39% of 
dag1hu3072 larvae have hatched, compared with 26±3.05% of sibling larvae (figure 
3.7A). However, at later stages there is no significant difference between the 
percentage of dag1 and sibling embryos that have hatched. There also seems to be a 
hatching delay in patchytail mutants, with only 85±4% of patchytail embryos hatched 
at 60hpf, compared with 95±3% of wildtype embryos (Gupta et al., 2011). 
 
The delay in hatching observed in dag1 mutant may suggest a mild muscle weakness 
during early development. However, this may also be explained by a disruption in 
hatching gland function. To establish whether defects in the hatching gland are 
responsible for the delay in hatching in dag1 embryos, the morphology of the gland, 
and the levels of hatching enzymes could be examined in the mutant fish (Trikic et al., 
2011). 
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Figure 3.7 dag1hu3072 embryos show impaired motility
dag1 zebrafish show defects in motility. (A) The percentage of sibling  (sib) and dag1
embryos hatched from their chorions at 48, 50, 52 and 54hpf was calculated. Bars 
represent the mean data of 4 independent repeats, and error bars represent SEM. Each 
experiment included a total  of at least 80 embryos. An unpaired t-test indicated a 
significant difference between the percentage of dag1 embryos hatched at 48hpf 
compared with sibling embryos (t=3.619, df=6, p=0.011). Unpaired t-tests indicated no 
significant differences between the percentage of sibling and dag1 embryos hatched at 
subsequent time points. (B) An embryo swirl assay was carried out on sibling (sib) and dag1 
larvae at 3, 4 and 5dpf. A petri dish containing 20 larvae was swirled until larvae collected 
in the centre of the dish. The percentage of larvae that swam out of the centre (3cm 
diameter) of the petri dish was calculated. The bars represent the mean data of 3 
independent repeats, and error bars represent SEM. Unpaired t-tests indicated significant 
differences between the percentage of sibling and dag1 embryos that swam away from the 
middle of the dish at 3dpf (t=9.062, df=4, p=0.0008), 4dpf (t=9.599, df=4, p=0.0007) and 
5dpf (t=8.179, df=4, p=0.0002).
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3.2.4.3 dag1hu3072 larvae show defects in motility 
dag1hu3072 larvae show reduced motility in a swirl assay. When a petri dish of embryos 
is swirled around, the larvae collect in the middle of the dish. As this motion stops, 
wildtype larvae exhibit a swimming response away from the centre of the dish 
(Granato et al., 1996, Gupta et al., 2012). Significantly fewer dag1hu3072 larvae escaped 
from the centre of the dish compared with sibling larvae at 3, 4 and 5dpf (figure 3.7B). 
 
3.4.4.4 Measuring zebrafish locomotion using automated methods 
Automated observation may be a more robust way of measuring zebrafish motility. 
Behaviours can be recorded more precisely, and a wide variety of parameters, 
including distance, speed and turning, can be measured with medium throughput. 
Zebrafish larval movement was analysed using the Viewpoint Zebrabox system and 
video tracking software (Emran et al., 2008). 
 
When carrying out automated measurement of zebrafish movement, it is important to 
control conditions in order to get consistent results. Time of day can have an impact on 
zebrafish larval movement; they tend to be more active in the morning than later in 
the day (MacPhail et al., 2009). In addition, 5dpf larvae display a diurnal rhythm in 
locomotor activity, showing higher levels of activity during the day compared with at 
night (Prober et al., 2006). Density of raising may also influence motility; larvae raised 
in groups showed higher levels of activity compared with those raised individually 
(Zellner et al., 2011). Overcrowding of larvae may increase stress levels, which may in 
turn affect levels of motility. The size of the testing arena used in the assay is another 
factor affecting  levels of motility; larvae in a 24-well plate showed elevated 
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locomotion compared with those in 48- and 96-well plates (Padilla et al., 2011). 
Temperature can also affect locomotor activity (Burgess and Granato, 2008). Therefore 
it is important to keep these variables consistent between experiments in order to 
produce reproducible outcomes. 
 
Larvae show characteristic locomotor responses to sudden changes in illumination. 
(Burgess and Granato, 2007, Emran et al., 2008, MacPhail et al., 2009, Ali et al., 2012). 
A startle response is elicited when lights are turned on, followed by a return to low 
baseline locomotion levels.  The startle response is an unconditioned behaviour 
demonstrated by zebrafish from 4-5dpf, and is characterised by rapid acceleration in 
response to visual, touch or acoustic stimuli (Kimmel et al., 1974). When lights are 
turned off, there is an increase in locomotor activity, thought to facilitate navigation 
back to areas of illumination (Burgess and Granato, 2007). This behaviour, known as 
the visual-motor response, can be utilised to induce movement of zebrafish larvae in 
an automated assay format, in order to track and measure levels of motility in 
dystrophic mutants. 
 
Before measuring the motility of dag1 fish, wildtype larvae were used to validate the 
approach, in order to ensure consistent and reproducible results. 5dpf larvae were 
placed into individual wells of 48- or 24-well plates. After transfer to the wells, larvae 
were allowed to acclimatise for 10 minutes in the Zebrabox apparatus. This period of 
time has been shown to ensure low and stable levels of basal swimming activity (Ali et 
al., 2012). The locomotion of each larva was then recorded and analysed in the 
Zebrabox recording apparatus equipped with Videotrack software.  A light cycle 
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program of 30 seconds light, 2 minutes dark was used in order to induce movement of 
the larvae. This program was repeated 4 times for a total of 10 minutes recording time.  
 
Carrying out the assay with a 24-well plate was found to give larger and less variable 
amounts of movement than with a 48-well plate. There was a significant effect of plate 
type on distance travelled in the 10 minute period, with larvae in the 24-well plate 
moving longer distances (figure 3.8). The smaller size of the wells in the 48-well plate 
could be limiting the locomotion of the larvae.  The 24-well plate format was chosen 
for subsequent assays to promote consistent levels of motility between assays, and to 
ensure the movement of the larvae was not limited by the size of the well.  
 
Figure 3.8: Effect of plate size on Viewpoint Zebrabox movement 
analysis
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horizontal line represents the 
mean distance travelled by 
larvae in each repeat, and error 
bars represent SEM. One-way 
ANOVA followed by the Tukey
post-hoc test indicated 
significant differences between 
the mean distance travelled in 
24- vs. 48-well plates (F=24.73, 
df=5,210, p<0.0001) Means 
with the same letter do not 
differ significantly from each 
other.
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The motility assay was also carried out using 3 and 4dpf larvae. At 3dpf, spontaneous 
swimming is not very frequent but larvae elicit a response when given an external 
stimulus e.g. touch. When the viewpoint assay was carried out with 3dpf larvae, 
motility was very low, with most larvae not responding to the light flashes (see figure 
3.9 for representative traces). At 4dpf, distances moved varied considerably, with 
some larvae moving large distances, but some not responding at all within the 10 
minute period (figure 3.9). At 4dpf, the swim bladder inflates, but the timing of this 
varies, which could explain the variable responses; the larvae that didn’t respond may 
not have fully inflated swim bladders. To ensure maximum response levels, future 
assays were carried out at 5dpf, although motility could potentially be quantified at 
earlier stages if the larvae were stimulated to move. This could be carried out using 
PTZ (pentylenetetrazole), a convulsant agent that induces intense locomotor activity. 
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Figure 3.9: Viewpoint Zebrabox movement analysis of 3, 4 and 5dpf 
larvae
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Viewpoint tracking analysis of 3, 4 and 5dpf wildtype zebrafish. (A) shows 
representative traces for 3dpf larvae. At this age, larvae do not swim spontaneously 
very often, and most did not move during the 10 minute tracking period. At 4dpf, 
responses are variable, with some larvae moving large distances, and others not 
moving at all during the tracking period. (B) shows representative traces of 4dpf larvae; 
(red lines = movement >10mm/sec, green lines = movement <10mm/sec) and (D) 
shows quantification of distance moved during the tracking period for 3 separate 
plates of larvae. At 5dpf, responses are more robust; (C) shows representative traces of 
5dpf larvae, and (E) shows quantification of distance moved during the tracking period 
of 3 separate 24 well plates of larvae. Error bars represent ±SEM.
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In order to quantify the motility of dag1 and sibling larvae, individuals were placed into 
wells of a 24-well plate at 5dpf, and the activity of each was tracked as described 
above. dag1 larvae showed significant differences in the different parameters analysed 
(figure 3.10). Mutants moved shorter distances within the 10 minute period compared 
with siblings, spent less time moving, and less time moving at speeds greater than 
10mm/sec. 
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Figure 3.10: Viewpoint tracking analysis of dag1hu3072
and sibling larvae
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3.5 Discussion 
 
 
 
3.5.1 Dystroglycan mutant zebrafish display a muscular dystrophy phenotpye 
The zebrafish provides a useful model for investigating the role of dystroglycan in 
muscle. This is difficult to study in mammals due to early embryonic lethality.  
dag1 mutant muscles can be properly specified and differentiated, but by 3dpf there is 
disruption in muscle integrity. The muscle damage appears to be randomly distributed 
throughout the trunk. This stochastic fibre damage is a hallmark of human muscular 
dystrophy and animal models, including the dystrophin-deficient zebrafish sapje. The 
muscle damage was shown to become more severe over time, suggesting the 
phenotype is progressive.  
 
The muscle damage in dag1 mutants appear more severe than in the other 
dystroglycan mutant patchytail, where muscle damage is initially restricted to 
posterior somites. It is unclear why there is an earlier onset of more severe muscle 
damage in dag1 mutants compared with patchytail. The patchytail missense mutation 
may be a hypomorphic allele, but western blotting of embryo lysates did not detect α- 
or β-dystroglycan. The different severities of these two mutants may reflect the broad 
variation in symptoms presented by dystroglycanopathy patients. 
 
The zebrafish also provides useful models for examining the pathophysiological 
aspects of dystroglycanopathies. Dystroglycanopathies result from defective 
glycosylation of α-dystroglycan, which reduces laminin-2 binding. Many genes 
encoding known or putative glycosyltransferases for dystroglycan have been reported, 
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including LARGE, FKRP, FKTN, POMT1, POMT2 and POMGNT1. Orthologues of these 
glycosyltransferases are present in zebrafish (Moore et al., 2008). Excluding POMGNT2, 
morpholino knockdown analyses have confirmed that the orthologues function 
similarly in zebrafish, with morphants displaying muscle pathology (Thornhill et al., 
2008, Avsar-Ban et al., 2010, Kawahara et al., 2010, Lin et al., 2011). This further 
validates the zebrafish as a model of muscular dystrophies. 
 
When comparing the dag1 mutant to mammalian models of muscular dystrophy, there 
are key differences in the timing of the onset of the dystrophic phenotype. The early 
onset may be due to an early developmental role of dystroglycan in basement 
membrane organisation. This may also be true in mammalian muscle, but cannot be 
investigated due to the peri-implantation lethality of Dag1 knockout mice. Instead, the 
late onset in humans and mice may be due to regeneration that doesn’t occur in the 
zebrafish. The mild phenotype of mdx mice, a model of Duchenne muscular dystrophy 
(DMD), is thought to result from, in part, a higher regenerative capacity of mouse 
muscle. Other zebrafish models of muscular dystrophy, such as the dystrophin mutant 
sapje, display an early onset of the dystrophic phenotype. This early phenotype in 
dag1 and sapje may be a result of precocious locomotion. Zebrafish generate muscle 
load within the first 24 hours of development, and become free swimming larvae by 
3dpf. Therefore weak muscle attachments resulting from mutations in DGC proteins 
may become damaged earlier in development. 
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3.5.2 Loss of dystrophin localisation in dag1 mutants 
Components of the DGC are important in maintaining the stability of other complex 
proteins. Dystroglycan is a key component of the DGC, providing the essential link 
between laminin in the ECM and the actin cytoskeleton, via the cytoskeletal linker 
dystrophin. There is a disruption in dystrophin localisation in the dag1 mutants. 
Dystrophin expression is also reduced in dag1 morphants (Parsons et al., 2002), 
patchytail embryos (Gupta et al., 2011) and in the dystroglycan deficient muscles of 
chimeric mice (Cote et al., 1999). Some muscles in MCK-DG null mice also showed 
decreased expression of dystrophin (Cohn et al., 2002). This highlights the importance 
of dystroglycan in the stabilisation of the DGC. 
 
Conversely, dystroglycan localisation is perturbed in dystrophin deficient 
environments, as is the case in DMD. Loss of dystroglycan function at the sarcolemmal 
membrane is thought to be an important pathway in the aetiology of DMD. This idea 
will be explored further in subsequent chapters. 
 
3.5.3 Zebrafish locomotion analysis 
dag1 mutants were found to exhibit impaired locomotion in the motility assays carried 
out. The automated tracking analysis of larval movement using the Zebrabox provides 
a simple method for quantifying movement. This could also be carried out in other 
models of muscular dystrophies and could be used as a read out of muscle function in 
drug screens for potential therapeutics, as a zebrafish equivalent of the 6 minute walk 
test in human trials (McDonald et al., 2010) and mobility tests used in mouse studies, 
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such as exercise resistance tests (Burdi et al., 2009, Tinsley et al., 2011, Kobayashi et 
al., 2012) 
 
Further work investigating the motility of dag1 mutants could include characterising 
the startle response. If muscle is weaker in dag1 zebrafish, the latency of the response 
may be increased. This could be measured using a high speed camera, in conjunction 
with the Zebrabox system and Viewpoint tracking software. 
 
3.6 Concluding remarks 
Dystroglycan is a core component of the DGC and is important for maintaining muscle 
integrity, and for stabilising dystrophin expression at the zebrafish myosepta. 
Dystroglycan function is lost in a number of muscular dystrophies including the 
dystroglycanopathies and Duchenne muscular dystrophy. The loss of dystroglycan and 
the DGC is an important mechanism in the manifestation of DMD. Preventing the loss 
of dystroglycan from the sarcolemma may be able to stabilise muscle attachments and 
ameliorate dystrophy, and this hypothesis will be investigated in chapters 4 and 5. 
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Chapter 4: Regulation of dystroglycan in a zebrafish model of Duchenne 
Muscular Dystrophy (sapje) 
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4.1 Introduction 
 
4.1.1 Loss of dystroglycan in Duchenne muscular dystrophy 
Duchenne muscular dystrophy (DMD) is caused by mutations in the gene encoding 
dystrophin (Hoffman et al., 1987, Koenig et al., 1987), an important structural protein 
in muscle cells. Dystrophin was found to form part of a large complex at the 
sarcolemmal membrane (Ervasti et al., 1990). This complex, termed the dystrophin-
associated glycoprotein complex (DGC), provides a link between the actin cytoskeleton 
and the extracellular matrix (Ervasti and Campbell, 1993). This link is thought to 
protect the sarcolemma from damage during continued cycles of contraction and 
relaxation.  
 
The adhesion receptor dystroglycan is a major component of the DGC, forming the 
essential link between dystrophin and the rest of the DGC. Loss of dystroglycan 
function at the sarcolemma is common to many muscular dystrophies, including DMD. 
 
There is a significant reduction in dystroglycan and other proteins in the DGC at the 
sarcolemma of skeletal muscles where dystrophin is lost, such as in mdx mice 
(Ohlendieck and Campbell, 1991) and DMD patients (Ohlendieck et al., 1993). In the 
absence of dystrophin, the DGC lacks stable connections to the actin cytoskeleton, 
which may destabilise complex components and render the proteins more vulnerable 
to degradation. This destabilisation and loss of the DGC is thought to weaken the 
sarcolemma, making it more susceptible to contraction-induced damage.  
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The molecular mechanisms by which dystroglycan and other complex components are 
lost from the sarcolemma in the absence of dystrophin are not completely understood. 
However, tyrosine phosphorylation of dystroglycan is thought to play an important 
role in controlling the integrity of the DGC (Moore and Winder, 2010, Miller et al., 
2012). 
 
4.1.2 Dystroglycan phosphorylation 
Tyrosine phosphorylation of β-dystroglycan is an important mechanism for modulating 
the interaction between dystroglycan and its binding partners (James et al., 2000, Ilsley 
et al., 2001, Sotgia et al., 2001, Ilsley et al., 2002). The WW domain of dystrophin binds 
a PPxY motif at the C-terminal tail of β-dystroglycan. Phosphorylation of the tyrosine 
residue in this interaction site (Y892 in the human protein, Y890 in mouse) disrupts 
dystrophin binding (Ilsley et al., 2001). 
 
Phosphorylation of Y892 is proposed to be mediated by Src family kinases (Sotgia et 
al., 2001). Co-transfection of cells with c-src and β-dystroglycan induces the 
phosphorylation of β-dystroglycan, but co-transfection with other tyrosine kinases 
resulted in little or no phosphorylation.  
 
Tyrosine phosphorylation is thought to promote β-dystroglycan internalisation. Y892 
phosphorylated β-dystroglycan becomes localised to an intracellular compartment in 
Cos-7 cells co-expressing c-Src and an alkaline phosphatase tagged β-dystroglycan 
construct (Sotgia et al., 2003). Mouse muscle tissue probed with an antibody specific 
for phosphorylated dystroglycan shows intracellular punctate staining as opposed to 
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the sarcolemmal staining seen with non-phosphorylated dystroglycan (Sotgia et al., 
2003). In addition, cell surface biotinylation assays in H2K mouse myoblasts provide 
further evidence for the internalisation of phosphorylated β-dystroglycan (Miller et al., 
2012). Non-phosphorylated β-dystroglycan remains on the cell surface, whereas 
tyrosine phosphorylated β-dystroglycan can be detected on the cell surface and in the 
cytosol. Over time, levels of phosphorylated β-dystroglycan decreased at the cell 
surface and increased in the cytosol. These data support the hypothesis that 
phosphorylation of β-dystroglycan may be a signal for its internalisation. 
 
One potential fate of internalised β-dystroglycan is degradation. Elevating the levels of 
phosphorylated β-dystroglycan, by transforming NIH 3TC cells with v-Src, results in a 3-
4 fold reduction in the total levels of β-dystroglycan, suggesting phosphorylation may 
promote dystroglycan degradation (Sotgia et al., 2001).  
 
4.1.3 Degradation of dystroglycan in the absence of dystrophin 
The ubquitin-dependent proteasomal pathway has been implicated in the degradation 
of DGC components in the absence of dystrophin. Proteasomes are strongly expressed 
in necrotic muscle fibres of DMD patients compared with control muscles (Kumamoto 
et al., 2000). Moreover, proteasomal inhibitor treatment of mdx mice and DMD muscle 
explants restores dystroglycan and other DGC components to the membrane and 
improves muscle pathophysiology (Bonuccelli et al., 2003, Assereto et al., 2006, 
Bonuccelli et al., 2007, Gazzerro et al., 2010). 
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4.2 Aims and hypotheses 
Dystrophin binding to dystroglycan obstructs the phosphorylation of the tyrosine in 
the PPxY motif, allowing the DGC to be maintained at the sarcolemma. It was 
hypothesised that in the absence of dystrophin in the mutant zebrafish sapje, the 
tyrosine in the PPxY motif of dystroglycan would be more exposed to tyrosine kinases 
and thus more readily phosphorylated. This in turn could lead to decreased stability of 
dystroglycan at the sarcolemma and an increase in the turnover of dystroglycan. In 
addition, there may be an increase in the degradation of dystroglycan. This would be 
an important pathway by which the integrity of the DGC is lost in the absence of 
dystrophin, and could potentially be manipulated in order to stabilise dystroglycan at 
the sarcolemma. 
 
This chapter describes investigations in to the regulation of dystroglycan function in 
the zebrafish model of Duchenne muscular dystrophy. The potential of using 
pharmacological inhibitors to manipulate the phosphorylation and degradation of 
dystroglycan will also be assessed. 
 
Hypotheses: 
 Levels of dystroglycan will be lower in sapje compared with wildtype siblings 
due to an increase in phosphorylation and degradation. 
 Inhibitors of Src kinase and the proteasome are able to increase levels of 
dystroglycan. 
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4.3 Results 
 
4.3.1 sapje zebrafish have a dystrophic phenotype 
 
 
4.3.1.1 sapje show loss of birefringence 
The sapje zebrafish was identified as a member of a group of dystrophic mutants in a 
large forward genetic screen (Granato et al., 1996). This class of zebrafish mutants 
showed disorganisation and detachment of normally differentiated skeletal muscle 
fibres. The muscle pathology can be detected by loss of birefringence of somitic muscle 
(figure 4.1), as with the dag1 mutant zebrafish described in chapter 3. 
 
4.3.1.2 sapje show loss of dystrophin expression at somite borders 
sapje results from a nonsense mutation within exon 4 of the zebrafish orthologue of 
the human DMD gene (Bassett et al., 2003). Dystrophin is localised at the peripheral 
ends of somitic myofibres, where they attach to the vertical myosepta (figure 4.1). 
Immunohistochemistry with an antibody directed against a C-terminal epitope 
common to all isoforms of dystrophin, shows a loss of dystrophin at the somite 
borders in sapje (figure 4.1). Shorter isoforms of dystrophin are still expressed in sapje 
(Bassett et al., 2003). 
 
Loss of dystrophin staining was to be expected in sapje embryos, since the nonsense 
mutation in dystrophin is upstream of the antibody epitope. If any truncated 
dystrophin was present, it would not be detected by this antibody, since it would not 
contain the recognition sequence. 
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4.3.1.3 sapje show fibre detachment and disorganisation 
The dystrophic phenotype of sapje mutants is caused by the mechanical failure of 
muscle attachments at the embryonic MTJ (myotendinous junction) (Bassett et al., 
2003). Fibre detachment can be detected as early as 3dpf, demonstrating the 
importance of dystrophin in the maintenance of stable muscle attachments and 
integrity. 
 
Muscle disorganisation and detachment can be observed in the zebrafish larvae by 
staining the F-actin in the muscle fibres with rhodamine phalliodin (figure 4.1). The 
myotome of sibling larvae is neatly organised, with muscle fibres spanning each somite 
block and attaching to the myosepta. However, the muscle architecture is disrupted in 
sapje mutants, and muscle fibres are detached from the myosepta. 
Chapter 4 
87 
  
A B
sibling sapje
C D
d
ys
tr
o
p
h
in
Figure 4.1: Characterisation of sapje zebrafish
(A) and (B): Birefringence images of sibling and sapje embryos at 4dpf. When viewed 
through a polarising filter, sapje display loss of muscle birefringence, as shown by dark 
patches on the trunk (B). Sibling larvae show no loss of birefringence (A). (C) and (D): 
confocal images of 4dpf larvae stained with an antibody against dystrophin. In sibling 
larvae dystrophin is localised to the vertical myosepta, at muscle fibres attachment 
sites (C). There is a loss of dystrophin staining at the somite borders in sapje (D). (E) 
and (F): confocal images of 4dpf larvae labelled with rhodamine phalliodin. sapje show 
disrupted muscle structure (F – white arrow heads) compared with sibling larvae (E). 
scale bars are 100μM
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4.3.1.4 The dystrophic phenotype worsens over time 
Quantification of birefringence levels at 3 and 5dpf shows the progressive nature of 
the dystrophic phenotype. Birefringence intensity of sibling larvae was used as a 
benchmark to which all other values were normalised. Figure 4.2 shows the 
birefringence levels of sapje larvae decrease over time from 3dpf to 5dpf. At 3dpf the 
intensity of sapje birefringence is approximately 35% lower than sibling birefringence. 
This loss of birefringence progresses and at 5dpf the intensity is about 50% lower in 
sapje, compared with siblings. 
 
Treatment from 2.5dpf to 5dpf with a 0.005% concentration of the anaesthetic tricaine 
(MS222) was able to reduce this decline in muscle integrity (figure 4.2). At 3dpf there is 
no significant difference between the birefringence intensity of MS222 and control 
treated sapje. However, at 5dpf, the birefringence intensity is significantly lower for 
control larvae. This suggests that inhibiting embryo movement prevents or slows down 
the rate of muscle damage and preserves muscle integrity to some extent. 
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B
(A) Representative birefringence images at 3 and 5dpf. (B) Quantification of control 
and tricaine treated sapje birefringence images at 3 and 5dpf. Each plot represents 
mean birefringence of 15 larvae normalised against average sibling intensity and error 
bars represent SEM. There is a significant difference between the intensity of control 
and tricaine treated larvae at 5dpf (unpaired t-test, t=4.313, df=28, p=0.0002), but not 
at 3dpf (unpaired t-test: t=0.9660, df=28, p=0.3423).
Figure 4.2: Loss of birefringence in sapje at 3 and 5dpf
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4.3.1.5 sapje show defects in motility 
Unlike dag1 embryos, hatching rate appears to be unaffected by the sapje mutation. 
However, later in development, movement appears to be affected in the sapje 
mutants.  
 
sapje show reduced motility in the swirl assay used in chapter 3 (Granato et al., 1996, 
Gupta et al., 2012). When a petri dish containing larvae is swirled around, larvae 
collect in the middle of the dish. Upon cessation of the swirling motion, larvae exhibit a 
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swimming response away from the centre. The percentage of sapje that escaped from 
the centre of the petri dish was significantly lower compared with siblings at 3, 4 and 
5dpf (figure 4.3). This suggests the mutants have a defect in locomotion. 
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Figure 4.3: sapje show defects in motility
An embryo swirl assay was carried out on sibling (sib) and sapje (sap) 
larvae at 3, 4 and 5dpf. A petri dish containing 20 larvae from a  
heterozygous sap/+ cross was swirled until larvae collected in the centre 
of the dish. The percentage of larvae that swam out of the centre (3cm 
diameter) of the petri dish upon cessation of the swirling motion was 
calculated. The bars represent the mean data of 3 independent repeats, 
and error bars represent SEM. Unpaired t-tests indicated  significant 
differences between the percentage of sibling and sap embryos that 
swam away from the middle of the dish at 3dpf (t=3.068, df=4, p=0.0374), 
4dpf (t=18.24, df=4, p<0.0001) and 5dpf (t=20.20, df=4, p<0.0001).
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The motility defect is further demonstrated by analysing the larval movement using 
the Viewpoint Zebrabox system and video tracking software used in chapter 3. 5dpf 
sibling and sapje larvae were placed into individual wells of a 24-well plate, and 
locomotion was tracked and quantified over a ten minute period. Alternating light and 
dark periods were used to stimulate larval movement.  
 
Analysis of viewpoint tracking data revealed significant differences in the movement of 
sapje larvae, when compared with siblings (figure 4.4). sapje move significantly shorter 
distances than siblings over the ten minute period, with a mean distance travelled of 
359 ± 35mm compared with 1208 ± 82mm. sapje larvae spend less time moving during 
the tracking period than siblings, with a mean time of 78.4 ± 7.7 seconds compared 
with 184.9 ± 8.6 seconds. Time moving at fast speeds (greater than 10mm/sec) was 
also significantly lower in sapje compared with siblings; sapje spent an average of 6.7 ± 
2.1 seconds swimming at high speeds, whilst siblings spent 30.5 ± 2.9 seconds. 
Together, these results indicate the sapje mutation has effects on larval motility. 
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Figure 4.4: Viewpoint tracking analysis of sapje and 
sibling larvae
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4.3.2 Loss of dystroglycan in sapje mutants 
The DGC localises to the sarcolemmal membrane in zebrafish, existing as a membrane-
associated complex (Guyon et al., 2003). In zebrafish embryos, DGC components are 
concentrated at the myosepta (Parsons et al., 2002, Chambers et al., 2003, Guyon et 
al., 2003).  
 
Whole-mount immunohistochemistry shows dystroglycan localisation at the myosepta 
of sibling embryos, and also some punctate staining within the somites, which may 
represent NMJs (figure 4.5).  
 
Since dystroglycan levels are reduced when dystrophin is absent in mammals, the 
levels of dystroglycan in sibling and sapje larvae were investigated. Compared with 
sibling larvae, there appears to be weaker dystroglycan staining in sapje. This is 
especially evident at 4 and 5dpf (figure 4.5). 
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Figure 4.5: Confocal images of 3,4 and 5dpf larvae stained with DAPI, 
MANDAG2  (antibody against β-DG) and rhodamine phalloidin
Dystroglycan is localised to the vertical myosepta in sibling larvae and this staining appears to be 
weaker in sapje, especially at 4 and 5dpf. Rhodamine phalloidin staining shows the disrupted 
muscle structure in sapje somites (white arrow heads), compared with the neatly organised array 
of muscle fibres in sibling larvae (scale bars 50μm).
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Western blotting of whole larvae lysates confirms lower dystroglycan protein levels in 
sapje compared with siblings (figure 4.6). Quantification of dystroglycan levels by 
densitometry showed a significant decrease in sapje, which became more pronounced 
from 3dpf to 5dpf. Compared with sibling larvae of the same age, the level of 
dystroglycan was reduced in sapje by approximately 34% at 3dpf, 47% at 4dpf and 75% 
at 5dpf. 
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Lysates of individual 3, 4 and 5dpf 
sibling and sapje larvae were made. 
(A) shows representative blots of 
lysates probed with antibodies against 
β-dystroglycan (top panel) and α-
tubulin (bottom panel). (B) The 
density of the blot probed against β -
dystroglycan was quantified relative 
to α-tubulin levels in each sample, 
and represented as a ratio of average 
sibling signal. Graph shows mean + 
SEM of 12 samples from 3 
independent experiments. There is a 
significant decrease in the level of β-
dystroglycan in larvae with the sapje
mutation at 3, 4 and 5dpf (unpaired t-
tests, 3dpf: t=3.595, df=22, p=0.0016; 
4dpf: t=4.946, df=22, p<0.0001; 5dpf: 
t=15.49, df=22, p<0.0001).
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Figure 4.6: β-dystroglycan levels in sibling and sapje larvae
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4.3.3 Levels of phosphorylated dystroglycan are elevated in sapje 
It was hypothesised that in the absence of dystrophin binding, the C-terminal tail of β-
dystroglycan may be more readily phosphorylated. Therefore, levels of phosphorylated 
β-dystroglycan in sapje and sibling larvae were examined.  
 
Whereas MANDAG2 is sensitive to phosphorylation and does not recognise 
phosphorylated dystroglycan (Miller et al., 2012), the antibody 1709 specifically 
recognises dystroglycan with a phosphorylated tyrosine residue (Y892 in humans, Y863 
in zebrafish).  
 
Immunofluorescence staining for phosphorylated β-dystroglycan showed localisation 
at the myosepta (figure 4.7), but the staining did not appear as defined as that seen 
with non-phosphorylated β-dystroglycan (figure 4.5). Immunofluorescence staining of 
sapje larvae showed localisation to puncta within the somitic muscle blocks (figure 
4.7). This can also be seen in some sibling larvae, but to a lesser extent. 
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Figure 4.7: Confocal images of 3dpf larvae stained with 
1709 (antibody against phosphorylated dystroglycan)
sibling sapje
Phosphorylated β-dystrolgycan shows staining at the myosepta, with 
some staining within the somites. Scale bars are 100μm.  
Western blotting with 1709 revealed a slight increase in phosphorylated β-
dystroglycan levels in lysates of 3 and 4dpf sapje mutants, compared with siblings, but 
this was not statistically significant. Levels of phosphorylated β-dystroglycan are 
significantly lower in sapje at 5dpf (figure 4.8). 
 
 
Levels of non-phosphorylated dystroglycan decrease over time in sapje (figure 4.6). 
Since the antibody MANDAG2 is sensitive to phosphorylation, and 1709 is specific for 
tyrosine phosphorylation (Miller et al., 2012), the ratio of phosphorylated to non-
phosphorylated β-dystroglycan in sapje larvae can be assessed. 
 
Quantification of MANDAG2 and 1709 western blots revealed a significant increase in 
the ratio of phosphorylated to non-phosphorylated dystroglycan at 3 and 4dpf in sapje 
compared with sibling larvae (figure 4.9). There was no significant difference between 
the ratios of phosphorylated to non-phosphorylated β-dystroglycan in 5dpf sibling and 
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sapje samples. These results suggest the levels of phosphorylated β-dystroglycan are 
elevated relative to total dystroglycan in sapje, when compared with sibling larvae. 
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(A) Representative western blots of embryo lysates at 3,4 and 5dpf, probed with an 
antibody raised against phosphorylated β-dystroglycan  (top panel) and anti-α-tubulin 
(bottom panel). (B) The density of the blot probed against phosphorylated dystroglycan was 
quantified relative to α-tubulin levels in each sample, and represented as a ratio of average 
sibling signal. Graph shows mean + SEM of 9 samples from 3 independent experiments. 
Levels of phosphorylated dystroglycan are slightly increased in sapje at 3 and 4dpf, but this 
increase is not statistically significant (3dpf - Unpaired t-test: t=1.950, d.f.=16, p=0.0690; 
4dpf – Unpaired t-test: t=0.7851, d.f.=16, p=0.4439). When compared with sibling lysates, 
levels of phosphorylated dystroglycan at 5dpf are significantly lower in sapje (Unpaired t-
test: t=4.169, d.f.=16, p=0.0007).
Figure 4.8: Levels of phosphorylated β-dystroglycan in sapje and 
sibling larvae
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sibling and sapje whole embryo 
lysates probed with antibodies for 
phosphorylated βDG (top panel), 
βDG (middle panel) and α-tubulin 
(bottom panel). α-tubulin signal 
indicates approximately equal 
loading of protein in each sample.  
B) The density of the blot probed 
against p-βDG has been quantified 
relative to βDG levels in each 
sample and normalised to the 
average sibling signal. Graph 
shows mean + SEM of 8 samples 
from 3 independent experiments. 
There is a significant increase in 
the ratio of p-βDG:βDG in sapje
compared with siblings  at 3 and 4 
dpf. (3dpf – Unpaired t-test with 
Welch’s correction: t=3.771, d.f.=9, 
p=0.0044; 4dpf- Unpaired t-test: 
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Figure 4.9: Ratio of phosphorylated to non-phosphorylated 
dystroglycan in sapje and sibling zebrafish
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4.3.4 Manipulation of dystroglycan phosphorylation 
Since earlier work has shown tyrosine reside 892 of dystroglycan to be a substrate for 
Src family kinases, the ability of Src inhibitors to alter the phosphorylation levels of 
dystroglycan was investigated. 
 
4.3.4.1 Src inhibitor treatment of H2k myoblasts 
H2K myoblast cells were treated for 6 hours with either PP2 or Dasatinib, or with 
DMSO only. Western blot analysis of cell lysates was used to examine the effect of 
these inhibitors on the level of phosphorylated dystroglycan. 
 
PP2, a well-established inhibitor of Src family tyrosine kinases, was able to significantly 
reduce levels of phosphorylated dystroglycan at a concentration of 10μM, compared 
with DMSO only treated cells (figure 4.10). 
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Figure 4.10: Phosphorylated dystroglycan in PP2 treated myoblasts
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Myoblasts were treated with PP2 (or DMSO only) for 6 hours, before lysates were collected. 
(A) Representative western blot of myoblast lysates, probed with an antibody raised against 
phosphorylated β-dystroglycan (top panel) and anti-α-tubulin (bottom panel). (B) The 
density of the blot probed against phosphorylated dystroglycan was quantified relative to α-
tubulin levels in each sample, and represented as a ratio of average DMSO only control 
signal. Graph shows mean + SEM of 6 samples from 3 independent experiments. There is a 
significant effect of PP2 treatment on the levels of phosphorylated β-dystroglycan in 
myoblasts. The level of phosphorylated β-dystroglycan is significantly lower in myoblasts 
treated with 10μM PP2, compared with myoblasts treated with DMSO only.  One way 
ANOVA was carried out (F=8.051, d.f.=3,20, p=0.0010) followed by Dunnett’s Multiple 
Comparison Test (ns=not significant, **p<0.005).
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Dasatinib (Luo et al., 2006) is a potent Abl and Src family inhibitor, used in the 
treatment of several types of leukaemia. It is able to decrease phosphorylated 
dystroglycan levels in H2K myoblasts at lower concentrations than PP2. Compared with 
DMSO only treated cells, there is a significant decrease in phosphorylated dystroglycan 
at concentrations of 0.1, 0.5 and 1μM (figure 4.11). 
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Myoblasts were treated with Dasatinib (or DMSO only) for 6 hours, before lysates were 
collected. (A) Representative western blot of myoblast lysates, probed with an antibody 
raised against phosphorylated β-dystroglycan (top panel) and anti-α-tubulin (bottom 
panel). (B) The density of the blot probed against phosphorylated dystroglycan was 
quantified relative to α-tubulin levels in each sample, and represented as a ratio of 
average DMSO only control signal. Graph shows mean + SEM of 6 samples from 3 
independent experiments. There is a significant decrease in the levels of phosphorylated 
β-dystroglycan in Dasatinib treated myoblasts, compared with DMSO treated controls. 
One way ANOVA was carried out (F=27.94, d.f.=3,20, p<0.0001) followed by Dunnett’s
Multiple Comparison Test (***p<0.001).
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Figure 4.11: Phosphorylated dystroglycan in Dasatinib treated myoblasts
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Src inhibitor treatment worked in the expected way in H2k myoblasts, reducing levels 
of phosphorylated dystroglycan. The ability of Src inhibitors to alter the 
phosphorylation of dystroglycan in vivo in zebrafish embryos was therefore assessed. 
 
4.3.4.2 Src inhibitor treatment of LWT embryos 
Dechorionated London Wild Type (LWT) embryos were treated with PP2 or Dasatinib, 
or DMSO only from 24hpf. This time point was chosen in order to minimise levels of 
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developmentally related embryo death and to prevent interfering with early 
embryogenesis. Embryo lysates were made after 24 and 48 hours of drug treatment.  
 
Dasatinib treatment of zebrafish embryos was able to decrease levels of 
phosphorylated dystroglycan in LWT embryos, and also decrease the ratio of 
phosphorylated to non-phosphorylated dystroglycan. PP2 treatment, however, was 
toxic at concentrations exceeding 1μM, with embryos displaying pericardial and yolk 
sac oedema.  
 
Embryos that had been treated with 1 or 5μM Dasatinib for 24 hours, had significantly 
lower levels of phosphorylated dystroglycan than DMSO only treated controls (figure 
4.12). Levels of phosphorylated dystroglycan were reduced by approximately 15% in 
embryos treated with 1μM Dasatinib, and by approximately 76% in embryos treated 
with 5μM Dasatinib. 
 
Compared with treatment for 24 hours, treatment for 48 hours was found to be more 
effective in decreasing levels of phosphorylated dystroglycan. Western blots of embryo 
lysates and subsequent densitometric analysis indicated a significant decrease in the 
amount of phosphorylated dystroglycan in embryos treated with 1 or 5μM Dasatinib 
compared with DMSO only treated controls (figure 4.13). Phosphorylated dystroglycan 
levels were reduced by approximately 59 and 80% in embryos treated with 1 and 5μM 
Dasatinib respectively. In addition, there was a significant decrease in the ratio of 
phosphorylated to non-phosphorylated dystroglycan in embryos treated with 
Dasatinib (figure 4.13). The effect on the level of phosphorylated β-dystroglycan, 
compared with the level of the non-phosphorylated protein is more striking than the 
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global decrease in phosphorylated β-dystroglycan, and can be observed in embryos 
treated with 0.5μM of Dasatinib. 
 
pβ-DG
α-tub
58
46
58
46
A
Lysates were prepared from LWT embryos treated with Dasatinib (or DMSO only) for 
24 hours from 24hpf. (A) Representative western blot of embryo lysates, probed with 
an antibody raised against phosphorylated β-dystroglycan (top panel) and anti-α-
tubulin (bottom panel). (B) The density of the blot probed against phosphorylated 
dystroglycan was quantified relative to α-tubulin levels in each sample, and 
represented as a ratio of average DMSO only control signal. Graph shows mean + SEM 
of at least 8 samples from 3 independent experiments. Dasatinib treatment 
significantly affects the level of phosphorylated β-dystroglycan in LWT embryos. One-
way ANOVA was carried out (F=56.34, d.f.=3,30, p<0.0001) followed by Dunnett’s
Multiple Comparison Test (ns= not significant, *p<0.05,***p<0.001).
B
Figure 4.12: Phosphorylated dystroglycan in WT embryos treated 
with dasatinib for 24 hours
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B
C
A
LWT zebrafish were treated with Dasatinib, or DMSO 
only, from 24hpf until 96hpf, when lysates were made 
from pools of 10 embryos. (A) shows a western blot of 
lysates probed with antibodies against phosphorylated 
β-dystroglycan (top panel), β-dystroglycan (middle 
panel) and α-tubulin (bottom panel). (B) The density of 
the blot probed against phosphorylated dystroglycan 
was quantified relative to α-tubulin levels in each 
sample, and represented as a ratio of average DMSO 
only control signal. Graph shows mean + SEM of at least 
8 samples for each treatment, from 3 independent 
experiments. There is a significant decrease in the levels 
of phosphorylated β-dystroglycan in dasatinib treated 
embryos, compared with DMSO treated controls. One 
way ANOVA was carried out (F=54.16, d.f.=3,30, 
p<0.0001) followed by Dunnett’s Multiple Comparison 
Test (ns = not significant, ***p<0.001). (C) The density 
of the blot probed against phosphorylated dystroglycan 
was quantified relative to non-phosphorylated 
dystroglycan levels in each sample, and normalised to 
the average DMSO only control signal. Graph shows 
mean + SEM of at least 8 samples for each treatment, 
from 3 independent experiments. There is a significant 
decrease in the ratio of phosphorylated to non-
phosphorylated dystroglycan in dasatinib treated 
embryos, compared with DMSO treated controls. One-
way ANOVA was carried out (F=234.1, d.f.=3,30, 
p<0.0001) followed by Dunnett’s Multiple Comparison 
Test (***p<0.001)
Figure 4.13: Phosphorylated dystroglycan in dasatinib treated wildtype 
embryos
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4.3.5 Manipulation of proteasomal degradation 
Data indicating a decrease in β-dystroglycan in sapje, when compared with sibling 
larvae is presented in section 4.3.2. This is also seen in DMD patients and mammalian 
models of the disease. It is thought that in the absence of dystrophin, dystroglycan and 
other DGC components are destabilised from the membrane and are subject to 
proteasome dependent degradation. Therefore, inhibitors of this pathway were used 
to investigate whether dystroglycan levels in zebrafish embryos could be manipulated. 
 
Dechorionated LWT embryos were treated with the proteasome inhibitor MG132 or 
DMSO only from 24hpf. Embryo lysates were made after 48 hours of drug treatment 
and western blots carried out to analyse the levels of dystroglycan in the different 
treatment groups. 
 
Western blots of embryo lysates and subsequent densitometric analysis indicated that 
the proteasome inhibitor MG132 had no significant effect on the levels of non-
phosphorylated β-dystroglycan (figure 4.14). However, there was a significant increase 
in the levels of phosphorylated β-dystroglycan in embryos treated with 5μM MG132, 
compared with DMSO only treated controls (figure 4.14). 
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Figure 4.14: Dystroglycan in MG132 treated LWT embryos
Lysates were prepared from LWT embryos treated with 
MG132 (or DMSO only) for 48 hours from 24hpf. (A) & (C) 
show representative western blots of lysates probed with 
antibodies against β-dystroglycan  (A-top panel), 
phosphorylated β-dystroglycan (C-top panel) and α-tubulin 
(bottom panels). (B) The density of the blot probed against 
dystroglycan was quantified relative to α-tubulin levels in 
each sample, and represented as a ratio of average DMSO 
only control signal. Graph shows mean + SEM of 6 samples 
from 3 independent experiments.  There is no significant 
difference between the levels of β-dystroglycan in the 
different treatment groups (One-way ANOVA followed by 
Dunnett’s Multiple Comparison test: F=2.500, df=2,5, 
p=0.1156). (D) The density of the blot probed against 
phosphorylated β-dystroglycan was quantified relative to α-
tubulin levels in each sample, and represented as a ratio of 
average DMSO only control signal. Graph shows mean + SEM 
of 6 samples from 3 independent experiments. There is a 
significant difference between the levels of phosphorylated 
dystroglycan in the different treatment groups. One-way 
ANOVA was carried out (F=15.76, df=2,15, p=0.0002) 
followed by Dunnett’s Multiple comparison test (ns=not 
significant, ***p<0.0005).
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4.4 Discussion 
 
4.4.1 The muscular dystrophy phenotype of sapje progresses over time 
sapje zebrafish are characterised by a dystrophic phenotype, observable by loss of 
birefringence of somitic muscle. Muscle damage and disorganisation can be seen more 
clearly by staining embryos with rhodamine phalloidin. Larval motility is also reduced 
in sapje mutants, as indicated by results from embryo swirl assays and the Viewpoint 
tracking data. 
 
Quantifying the intensity of birefringence images revealed a progressive loss of muscle 
birefringency over time from 3 to 5dpf. Anesthetising embryos prevented this decline 
in muscle birefringence. This suggests that muscle damage may be related to motor 
activity. A similar effect is observed in candyfloss mutants, which result from mutations 
in the laminin α2 gene; treating candyfloss embryos with tricaine resulted in a 
complete suppression of the dystrophic phenotype at 3dpf (Hall et al., 2007). Removal 
of tricaine was used to induce muscle contraction in sapje mutants, and using time 
lapse photomicroscopy, allowed the observation of myofibre detachment in real time 
(Berger et al., 2010). Together, these results provide evidence to suggest the 
generation of muscle force plays a key role in promoting the detachment of muscle 
fibres from the myosepta in zebrafish. As zebrafish motility increases with age, more 
myofibres become detached, resulting in a decrease in muscle integrity and worsening 
of the dystrophic phenotype. 
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4.4.2 Age-dependent decrease in dystroglycan levels in sapje 
The stability of the mammalian DGC is dependent on dystrophin expression and its 
localisation at the cell membrane. When dystrophin is absent, as in the mdx mouse 
and DMD patients, levels of dystroglycan and other DGC components are reduced 
(Ohlendieck and Campbell, 1991, Ohlendieck et al., 1993).  
 
Loss of DGC components has previously been shown in dystrophin morphant zebrafish 
using western blot analysis (Guyon et al., 2003). However, whilst there was a clear 
reduction in levels of β-, γ- and δ-sarcoglycan in morphant embryos, dystroglycan 
levels were variable; some experiments showed no change in β-dystroglycan 
expression, whilst others showed a clear decrease. Morphant embryos also displayed a 
spectrum of phenotypes, with some appearing normal. The authors estimated a 70% 
reduction in dystrophin expression in the anti-sense morpholino injected embryos. 
Residual dystrophin expression may account for the preservation of dystroglycan 
expression in some embryos. The morpholino was targeted against exon 1 of the 
muscle specific Dp427 isoform. Therefore other isoforms of dystrophin, which do not 
share this exon, could be present, and these may be able to bind and stabilise 
dystroglycan expression. In addition, blots were carried out at 4dpf when the effects of 
the morpholino may have worn off. The localisation of dystroglycan in morphant 
embryos was also not investigated; even though dystroglycan expression is not 
reduced in some embryos, it may not be localised to the membrane correctly. 
 
Here, an age-dependent decrease in dystroglycan protein levels in dystrophin mutant 
zebrafish has been demonstrated. There is a marked reduction in β-dystroglycan levels 
in sapje compared with siblings of the same age. This can be observed using both 
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whole-mount immunohistochemistry and western blotting techniques. Quantification 
of western blot analysis clearly shows this loss becomes more pronounced over time.  
This suggests that, as in mammals, the stability of dystroglycan at the membrane is 
dependent on dystrophin expression. 
 
As loss of dystroglycan expression is also seen in mammals with dystrophin mutations, 
these data provide further evidence that the biochemistry of the DGC is conserved 
between mammals and zebrafish.  The downstream mechanism of dystroglycan loss as 
a consequence of dystrophin deficiency may be similar in mammals and zebrafish, and 
sapje provides a useful model for understanding this process in more detail.  
 
The proposed mechanisms for the loss of dystroglycan at the membrane in dystrophin 
deficient environments are internalisation and degradation. Tyrosine phosphorylation 
is known to regulate the assembly and disassembly of many adhesion complexes 
(Burridge and Chrzanowska-Wodnicka, 1996). Phosphorylation of tyrosine residue 890 
prevents dystroglycan from binding dystrophin and is thought to lead to its 
internalisation, thus promoting complex disassembly. It was hypothesised that loss of 
dystrophin would promote the phosphorylation and subsequent internalisation of 
dystroglycan. 
 
4.4.3 Increased phosphorylation of dystroglycan in sapje 
It was hypothesised that the levels of phosphorylated dystroglycan would be increased 
in sapje. Using western blot analysis, the levels of phosphorylated dystroglycan in sapje 
larvae were examined, compared with siblings of the same age. Phosphorylated 
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dystroglycan levels are slightly increased in sapje at 3 and 4dpf, but these increases 
were not statistically significant. The fate of phosphorylated β-dystroglycan may be 
degradation, and this may explain why levels of phosphorylated species are not much 
higher in the sapje mutants at 3 and 4dpf. If the phosphorylated dystroglycan is being 
rapidly degraded, a large increase in dystroglycan phosphorylation may not be 
detectable without preventing degradation. At 5dpf, the level of phosphorylated 
dystroglycan is lower in sapje mutants. This may be due to elevated degradation. 
 
Since the overall level of dystroglycan in the absence of dystrophin is lower, the 
amount of substrate to phosphorylate will also be lower. Therefore, the ratios of 
phosphorylated to non-phosphorylated dystroglycan in sapje and sibling larvae were 
investigated. Compared with the amount of non-phosphorylated β-dystroglycan, the 
level of phosphorylated β-dystroglycan was elevated in sapje at 3 and 4dpf. These data 
are in support of the hypothesis that the absence of dystrophin may lead to an 
elevation in the tyrosine phosphorylation of β-dystroglycan. 
 
Since tyrosine phosphorylation is believed to lead to the internalisation of β-
dystroglycan (Sotgia et al., 2003, Miller et al., 2012), there may be a shift in 
dystroglycan localisation from the sarcolemma to the cytosol.  Non-phosphorylated 
dystroglycan shows strong staining at the myosepta, whereas phosphorylated 
dystroglycan staining is less defined.  However, this could be due to high background 
staining of the 1709 antibody. Immunofluorescence staining of sapje larvae showed 
phosphorylated dystroglycan localised to punctate structures within the somitic 
muscle blocks.  Although this may be non-specific binding of the antibody, it could 
represent internalised phosphorylated dystroglycan. However, the exact localisation of 
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this staining cannot be concluded. This could be further investigated by co-localisation 
experiments with markers of the endocytic, or other trafficking pathways. Sectioning 
of the zebrafish may provide better means for examining the cellular localisation of 
phosphorylated dystroglycan than whole-mount immunohistochemistry.  
 
If the fate of phosphorylated dystroglycan is internalisation, the elevation of 
phosphorylation in sapje may be an important signalling pathway in the manifestation 
of the disease phenotype. Tyrosine phosphorylation of dystroglycan has previously 
been identified as an important mechanism for controlling the integrity of the DGC 
(Miller et al., 2012). Preventing this phosphorylation event may be able to promote the 
formation of stable dystroglycan complexes at the membrane and improve the 
dystrophic phenotype displayed in sapje zebrafish. Inhibitors of Src, the kinase thought 
to be involved in this process, were used to investigate whether the phosphorylation 
of dystroglycan could be manipulated. 
 
4.4.4 Manipulation of dystroglycan phosphorylation 
Src inhibitors were able to significantly lower the levels of phosphorylated 
dystroglycan in H2K myoblasts and LWT zebrafish embryos. Dasatinib was able to 
decrease phosphorylated dystroglycan levels in H2K myoblasts at lower concentrations 
than PP2. In contrast to PP2, Dasatinib was non-toxic to zebrafish embryos, where it 
was also able to reduce levels of phosphorylated dystroglycan. 
 
Dasatinib and other Src inhibitors could be used in sapje to prevent the loss of 
dystroglycan and improve the muscular dystrophy phenotype. A similar approach has 
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been used in the mdx mouse; preventing the phosphorylation of dystroglycan Y890 by 
substituting the tyrosine for phenylalanine was able to restore expression of DGC 
proteins to the membrane and ameliorated the dystrophic phenotype (Miller et al., 
2012).  
 
Src phosphorylation provides a druggable target in the proposed pathway leading to 
the loss of dystroglycan in Duchenne muscular dystrophy. Many Src inhibitors, such as 
Dasatinib, have been developed in other therapeutic settings. Since Dasatinib is able to 
reduce the levels of phosphorylated dystroglycan in both myoblasts and zebrafish 
embryos, and is well-tolerated in vivo, it may be a promising candidate to improve the 
dystrophic phenotype in sapje. This idea will be explored further in chapter 5. 
 
Although dystroglycan phosphorylation is thought to promote its internalisation, the 
fate of internalised dystroglycan is not fully understood. A cell surface biotinylation 
assay revealed a time-dependent decrease in the amount of phosphorylated 
dystroglycan at the cell surface and an increase in cytosolic phosphorylated 
dystroglycan. This suggests that tyrosine phosphorylation of dystroglycan may be a 
signal for its internalisation. However, the subsequent trafficking pathway is not 
known, as phosphorylated dystroglycan did not colocalise with transferrin receptors, 
EEA1 or lysotracker (Miller et al., 2012). 
 
The phosphorylation of dystroglycan may be a signal for a subsequent downstream 
process, such as degradation. Phosphorylated β-dystroglycan has been shown to be 
ubquitinated, whereas non-phosphorylated β-dystroglycan is not (Rob Piggott, 
unpublished results). There is evidence to support the hypothesis that phosphorylated 
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dystroglycan is degraded. Elevating the phosphorylation of β-dystroglycan, by 
transforming NIH 3TC cells with v-Src, resulted in a 3-4 fold reduction in the total levels 
of β-dystroglycan (Sotgia et al., 2001). Once internalised, phosphorylated dystroglycan 
may then be degraded in downstream pathways. 
 
The decrease in dystroglycan levels over time in sapje suggests it may be being 
degraded. The proteasome-dependent degradation pathway is elevated in DMD 
(Kumamoto et al., 2000), and inhibiting this pathway has been shown to be beneficial 
to mdx mice (Bonuccelli et al., 2003, Bonuccelli et al., 2007). Therefore, the 
proteasome inhibitor MG132 was used to investigate whether the degradation of 
dystroglycan can be manipulated in zebrafish. 
 
4.4.5 Manipulation of proteasomal degradation 
Treatment of zebrafish embryos with MG132 slightly increased levels of β-
dystroglycan, but this was not statistically significant. However, there was a significant 
increase in phosphorylated β-dystroglycan in treated embryos, compared with DMSO 
only treated controls. It is thought that phosphorylation of dystroglycan is a signal for 
its internalisation and possibly its degradation. If phosphorylated dystroglycan is 
indeed the species that is degraded, this may explain why there is a significant increase 
in phosphorylated dystroglycan in treated embryos, but not a significant increase in 
non-phosphorylated dystroglycan.  
 
Proteasomal inhibitors may be able to increase dystroglycan levels more significantly in 
a system where the proteasomal degradation pathway is elevated. This may be the 
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case in sapje, where levels of dystroglycan are decreased. The mdx mouse also has 
decreased dystroglycan levels, which are thought to result from an elevation in protein 
degradation pathways. Proteasomal inhibitors may be able to ameliorate the 
dystrophic phenotype in sapje, as has been shown in mdx mice previously. If 
proteasomal inhibitors are beneficial to sapje muscle, this may provide evidence of the 
same pathophysiological pathway occurring in the dystrophin-deficient muscle of both 
fish and mammals, and would highlight the zebrafish as a useful tool in the DMD drug 
discovery pipeline. 
 
4.5 Concluding remarks 
Loss of dystrophin in mammals and zebrafish leads to the loss of dystroglycan, and 
other DGC proteins. Phosphorylated dystroglycan is elevated in the zebrafish 
dystrophin mutant sapje. This change in the balance between phosphorylated and 
non-phosphorylated species may prevent dystroglycan from forming stable complexes 
at the membrane. Phosphorylation of dystroglycan has previously been identified as a 
possible signal for internalisation and is also important in controlling the integrity of 
the DGC. The fate of internalised dystroglycan is thought to be degradation. 
Understanding the internalisation and degradation processes of dystroglycan may 
have therapeutic implications, as the loss of the DGC is a central part of the aetiology 
of Duchenne muscular dystrophy. 
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Chapter 5: Chemical treatment of a zebrafish model of Duchenne 
Muscular Dystrophy (sapje) 
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5.1 Introduction 
 
5.1.1 Altered dystroglycan expression in sapje 
As in mammals, dystroglycan stability in zebrafish appears to be dependent on 
dystrophin. The absence of dystrophin in the muscle of sapje mutants results in a time-
dependent loss of dystroglycan expression. This could be explained by an elevation in 
dystroglycan degradation, as in the mdx mouse and DMD patients, where levels of 
dystroglycan and other DGC proteins are also reduced.  
 
It is unknown what targets dystroglycan and other complex components for 
degradation in DMD. It has been suggested that in the absence of dystrophin, the DGC 
lacks stable connections to the actin cytoskeleton, and this loss of stability of the 
complex proteins may render them more susceptible to degradation. 
 
As discussed in chapter 4, tyrosine phosphorylation of dystroglycan has been identified 
as a signal for internalisation, and this is believed to play an important role in 
controlling the integrity of the DGC. 
 
In sapje mutants, there is a shift in the balance of phosphorylated and non-
phosphorylated β-dystroglycan. The elevated phosphorylation levels may lead to an 
increased internalisation of dystroglycan and disassembly of the DGC. Once 
dystroglycan is internalised, it may then be degraded. 
 
Inhibiting proteasomal degradation, the final step in the proposed pathway leading to 
the loss of dystroglycan in the absence of dystrophin, was able to restore dystroglycan 
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and other DGC proteins to the sarcolemma and improve muscle pathophysiology in 
mdx mice and explants from DMD patients (Bonuccelli et al., 2003, Assereto et al., 
2006, Bonuccelli et al., 2007, Gazzerro et al., 2010). Since dystroglycan levels are 
decreased in sapje, these inhibitors may also be beneficial in the zebrafish. Inhibitors 
of dystroglycan phosphorylation may also be able to improve dystrophy by preventing 
loss of dystroglycan function at the membrane. Preventing tyrosine phosphorylation of 
dystroglycan in the mdx mouse has also been shown to improve the dystrophic 
phenotype (Miller et al., 2012). 
 
5.1.2 Usefulness of zebrafish in drug discovery 
Zebrafish are rapidly emerging as a powerful tool in various stages of the drug 
discovery pipeline (Zon and Peterson, 2005). They are especially valuable in early 
stages of research, providing an in vivo system in which to demonstrate drug efficacy 
before more costly mammalian models are used.  
 
Zebrafish are particularly amenable to muscular dystrophy drug discovery as disruption 
in muscle integrity and function can be readily observed in early stages of 
development. In addition, zebrafish express orthologues of most genes known to be 
mutated in human muscular dystrophies (Steffen et al., 2007). Mutations in these 
genes result in dystrophic phenotypes in zebrafish (Bassett et al., 2003, Guyon et al., 
2005, Nixon et al., 2005, Hall et al., 2007). 
 
Preventing dystroglycan phosphorylation, and its subsequent internalisation and 
degradation, has been identified as a potential target for DMD therapeutics. The 
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zebrafish provides a useful platform for assessing the effectiveness of preventing 
dystroglycan loss in ameliorating the dystrophic phenotype. 
 
5.2 Aims and hypotheses 
Increased phosphorylation of dystroglycan in sapje may be an important signalling 
pathway in the manifestation of the disease phenotype, resulting in increased 
internalisation and disassembly of the DGC. Once lost from the membrane, 
dystroglycan and other DGC proteins may then be degraded. The work described 
within this chapter aims to investigate whether inhibiting steps in the proposed 
pathway leading to the loss of dystroglycan in DMD is able to stabilise dystroglycan 
expression and ameliorate dystrophy in sapje. 
 
Hypothesis: 
 Inhibiting the phosphorylation and degradation of dystroglycan is able to 
ameliorate the dystrophic phenotype in sapje.  
 
5.3 Results 
 
5.3.1 Development of the assay 
Muscle pathology can be readily observed in the zebrafish larva, by examining the 
birefringence under polarising light. Loss of birefringence can therefore be used as a 
simple visual readout of muscle damage. 
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In order to identify drugs that may delay or prevent the onset of the dystrophic 
phenotype, compounds were added before mutants can be identified. Therefore, the 
assay was carried out on a mixed population of offspring from heterozygous sapje fish, 
comprising approximately 25% homozygous mutant embryos. If inhibitors of Src kinase 
or proteasomal degradation are able to prevent or slow the progression of dystrophy, 
they may be able to decrease the percentage of embryos displaying loss of 
birefringence. 
 
Carrying out the assay on a mixed population meant large numbers of embryos were 
needed in each treatment group. This is to prevent false positive results, where low 
numbers of mutant fish are aliquotted into drug treatment groups by chance. 50 
embryos were used per treatment group, so that sufficient numbers of homozygous 
mutants were treated with each concentration of drug. Assays were also repeated 5 
times to improve the reliability of results. 
 
Embryos were treated from 24hpf in order to prevent compounds affecting early 
development and to reduce the loss of embryos through developmentally related 
death. Treatment was carried out for at least 48 hours, when muscle birefringence can 
then be assessed. This duration of drug exposure was found to be effective in reducing 
levels of phosphorylated β-dystroglycan and increasing levels of non-phosphorylated 
β-dystroglycan when treating embryos with inhibitors of Src kinase and proteasomal 
degradation (chapter 4). 
 
A schematic of the assay is shown in figure 5.1 
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24 hpf
72 hpf
♀ ♂sap/+  X  sap/+ 
96 hpf
• sort, dechorionate and divide into 
wells with dilution of drug in E3 media 
(final concentration DMSO 1%)
• incubate at 28⁰C
• anaesthetise larvae and carry out 
birefringence assay, counting the 
numbers of fish with each phenotype
• embryos from a heterozygous sapje
cross – collected, sorted and placed 
into petri dishes with E3 media
• incubate at 28⁰C
48 hpf
Figure 5.1: Schematic of assay
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5.3.2 Positive control compound 
A recent drug screen by the Kunkel group identified aminophylline, a non-selective 
phosphodiesterase (PDE) inhibitor, as effective in reducing the proportion of sapje and 
sapje-like fish displaying the muscle pathology detected by birefringence (Kawahara et 
al., 2011).  
 
Aminophylline treatment of embryos from heterozygous sapje pairs resulted in a 
reduction of larvae displaying a dystrophic phenotype, compared with those treated 
with DMSO only (figure 5.2). There was a significant increase in the percentage of 
larvae showing an unaffected muscle phenotype in the groups treated with 5μM 
aminophylline compared with those treated with DMSO only. This validates the assay 
design in terms of its ability to detect compounds capable of correcting the dystrophic 
phenotype. 
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Figure 5.2: Treatment of embryos with Aminophylline
Embryos were treated with 5μM Aminophylline or DMSO only for 48 
hours before a birefringence assay was carried out. The number of 
larvae showing normal or disrupted muscle birefringence were counted. 
There is a significant increase in the percentage of embryos showing an 
unaffected muscle birefringence phenotype in the treated group 
compared with DMSO only controls (Unpaired t-test: t=4.7, df=4, 
p=0.0093). Data points represent mean values from 3 independent 
experiments, with a total of approximately 150 embryos per treatment 
group. Error bars represent SEM.
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5.3.3 Src kinase inhibitors 
 
5.3.3.1 Dasatinib treatment is able to decrease the percentage of embryos showing a 
dystrophic phenotype 
Dasatinib (figure 5.3), an inhibitor of Abl and Src family kinases, was shown to decrease 
levels of phosphorylated dystroglycan in H2K myoblasts and LWT embryos (chapter 4). 
sapje larvae have elevated levels of phosphorylated dystroglycan, and it is 
hypothesised that this may promote the disassembly of the DGC in the absence of 
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dystrophin. Embryos were therefore treated with Dasatinib to investigate whether 
inhibiting Src is beneficial to dystrophic muscle. 
 
Dasatinib 2-aminothiazole group
Figure 5.3: Chemical structure of Dasatinib
The chemical structure of Dasatinib is shown on the left. A screen of a compound collection identified 
2-aminothiazole (right-hand panel) as a novel Src family kinase inhibitor template (Das et al., 2006). 
Dasatinib was developed through the optimisation of this template, using structure-activity 
relationship analysis. Dasatinib is a ATP-competitive kinase inhibitor; the aminothiazole moiety 
occupies the site normally bound by ATP. Aminothiazole derivatives generally have favourable in vivo 
properties and good bioavailability (Ghaemmaghami et al., 2010). Several kinase inhibitors with this 
scaffold have been described, including VEGF-2 kinase inhibitors (Borzilleri et al., 2006).
 
 
Treatment of sapje zebrafish with Dasatinib from 24 to 72hpf was able to reduce the 
proportion of embryos with a dystrophic phenotype (figure 5.4). For concentrations 
greater than 1μM Dasatinib, there is a significant increase in the percentage of 
embryos with an unaffected muscle birefringence phenotype (figure 5.4B). 
There is a concentration-dependent restoration of muscle integrity (figure 5.4C). 
Taking the proportion of dystrophic fish in DMSO only treated groups as 0% rescue, 
percentage rescue of the dystrophic phenotype was calculated. The effect of Dasatinib 
plateaued at about 2μM, with a maximum of approximately 35% of the dystrophic 
population displaying normal muscle birefringence. 
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Figure 5.4: Effect of 48 hour Dasatinib treatment on sapje muscle 
phenotype
A
B
C
Embryos were treated with Dasatinib or DMSO 
only for 48 hours before a birefringence assay was 
carried out. The number of larvae showing normal 
or disrupted muscle birefringence were counted. 
Those showing disrupted birefringence were 
further subdivided into mild (disrupted 
birefringence affecting 1-5 somitic muscle blocks), 
moderate (6-10 somites) and severe (10+ 
somites) phenotypes. (A) shows the proportion of 
embryos displaying each phenotype. (B) shows 
the there is a significant increase in the 
percentage of embryos showing an unaffected 
muscle birefringence phenotype in the groups 
treated with Dasatinib compared with the DMSO 
only control group (One-way ANOVA: F=15.66, 
df=4,20, p<0.0001, followed by Dunnett’s
Multiple Comparison Test: ns= not significant, 
*p<0.05, ***p<0.001). (C) shows the percentage 
rescue of the dystrophic phenotype, taking the 
proportion of dystrophic fish in DMSO only 
treated groups as 0% rescue. Data points 
represent mean values of 5 independent 
experiments, with a total of approximately 250 
embryos per treatment group. Error bars 
represent SEM.
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The severity of the muscle damage was also examined (figure 5.5). Damage was 
classed as either mild (fewer than 5 somite blocks showing disrupted birefringence), 
moderate (5-10) or severe (10 or more). There is a significant decrease in the 
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percentage of larvae showing a severe phenotype in the groups treated with 5 and 
10μM Dasatinib compared with DMSO alone. 
 
Figure 5.5: Effect of  48 hour Dasatinib treatment on the 
severity of the sapje muscle phenotype
A B
Embryos were treated with Dasatinib or DMSO only for 48 hours before a 
birefringence assay was carried out. The number of larvae showing normal or 
disrupted muscle birefringence were counted. Those showing disrupted 
birefringence were further subdivided into mild (disrupted birefringence 
affecting 1-5 somitic muscle blocks), moderate (6-10 somites) and severe (10+ 
somites) phenotypes. (A) shows the proportion of larvae showing mild, 
moderate and severe muscle damage. (B) shows there is a significant decrease 
in the percentage of larvae showing a severe phenotype in the groups treated 
with 5 and 10 μM Dasatinib compared with DMSO alone (One-way ANOVA: 
F=7.332, df=4,20, p=0.0008, followed by Dunnett’s Multiple Comparison Test: 
*p<0.05, ***p<0.001). Data points represent mean values of 5 independent 
experiments, with a total of approximately 250 embryos per treatment group. 
Error bars represent SEM.
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Similar results were obtained when embryos were treated with Dasatinib from 24 to 
96hpf (figure 5.6 & 7), with treatment appearing slightly more effective in slowing or 
preventing the progression of the muscle pathology. There is a significant increase in 
the percentage of embryos with an unaffected muscle birefringence phenotype for all 
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concentrations used, compared to embryos treated with DMSO only (figure 5.6B). 3 
day Dasatinib treatment reduced the percentage of embryos showing disrupted 
muscle birefringence from ~25% to ~15%, a rescue of approximately 40% (figure 5.6C). 
There is also a significant decrease in the percentage of larvae showing a severe 
phenotype (figure 5.7). 
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Figure 5.6: Effect of 72 hour Dasatinib treatment on sapje muscle 
phenotype
A
B
C
Embryos were treated with Dasatinib or DMSO 
only for 72 hours before a birefringence assay 
was carried out. The number of larvae showing 
normal or disrupted muscle birefringence were 
counted. Those showing disrupted 
birefringence were further subdivided into mild 
(disrupted birefringence affecting 1-5 somitic 
muscle blocks), moderate (6-10 somites) and 
severe (10+ somites) phenotypes. (A) shows the 
proportion of embryos displaying each 
phenotype. (B) shows the there is a significant 
increase in the percentage of embryos showing 
an unaffected muscle birefringence phenotype 
in the groups treated with Dasatinib compared 
with the DMSO only control group (One-way 
ANOVA: F=15.69, df=3,16, p<0.0001, followed 
by Dunnett’s Multiple Comparison Test: 
**p<0.01, ***p<0.001). (C) shows the 
percentage rescue of the dystrophic phenotype, 
taking the proportion of dystrophic fish in 
DMSO only treated groups as 0% rescue. Data 
points represent mean values of 5 independent 
experiments, with a total of approximately 250 
embryos per treatment group. Error bars 
represent SEM.
Percentage of larvae with
unaffected phenotype
Concentration Dasatinib (M)
%
 e
m
b
ry
o
s
0 1 5 10
0
20
40
60
80
100
**
*** ***
 
Chapter 5 
129 
  
Figure 5.7: Effect of  72 hour Dasatinib treatment on the 
severity of the sapje muscle phenotype
A
B
Embryos were treated with dasatinib or DMSO only for 72 hours before a 
birefringence assay was carried out. The number of larvae showing normal or 
disrupted muscle birefringence were counted. Those showing disrupted 
birefringence were further subdivided into mild (disrupted birefringence 
affecting 1-5 somitic muscle blocks), moderate (6-10 somites) and severe (10+ 
somites) phenotypes. (A) shows the proportion of larvae showing mild, 
moderate and severe muscle damage. (B) shows there is a significant decrease 
in the percentage of larvae showing a severe phenotype in the groups treated 
with dasatinib compared with DMSO alone (One-way ANOVA: F=8.016, df=3,16, 
p=0.0017, followed by Dunnett’s Multiple Comparison Test: *p<0.05, **p<0.01, 
***p<0.001). Data points represent mean values of 5 independent experiments, 
with a total of approximately 250 embryos per treatment group. Error bars 
represent SEM.
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5.3.3.2 Dasatinib is able to decrease levels of phosphorylated β-dystroglycan in sapje 
It was hypothesised that Src kinase inhibitors may be able to improve the muscular 
dystrophy phenotype by preventing the phosphorylation, and subsequent loss of 
dystroglycan from the muscle membrane. Therefore, the levels of phosphorylated β-
dystroglycan in treated sapje would be reduced compared to non-treated fish.  
 
Western blot analysis of sapje larvae treated with Dasatinib indicated there were 
significantly lower levels of phosphorylated β-dystroglycan in these samples compared 
with sapje embryos treated with DMSO only (figure 5.8). Levels of non-phosphorylated 
dystroglycan were also examined, and these were found to be significantly higher in 
fish treated with 5μM Dasatinib, compared with DMSO treated controls. 
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Figure 5.8: Effect of Dasatinib treatment on levels of 
phosphorylated and non-phosphorylated β-dystroglycan
p β-DG
α-tub
55
35
55
A
Lysates were made from embryos treated with Dasatinib or DMSO only. (A) shows western 
blots  probed against antibodies for p β-DG (phosphorylated β-dystroglycan) and α-tubulin. 
(B) The density of the blot probed against p β-DG was quantified relative to α-tubulin levels 
in each sample, and normalised to average control signal. There is a significant decrease in 
the level of phosphorylated β-dystroglycan in larvae treated with Dasatinib, compared with 
controls (One-way ANOVA: F=27.23, df=2,15, p<0.0001, followed by Dunnett’s Multiple 
Comparison test, ***p<0.001). (C) shows western blots probed against antibodies for β-DG 
(β-dystroglycan) and α-tubulin. (D) The density of the blot probed against β-DG was 
quantified relative to α-tubulin levels in each sample, and normalised to average control 
signal. There was a significant difference in the levels of β-DG in larvae between different 
treatment groups (One-way ANOVA: F=12.86, df=2,15, p=0.0006, followed by Dunnett’s
Multiple Comparison test, ns=not significant, ***p<0.001). Graphs represent the mean of 6 
samples from 3 independent experiments, error bars are SEM.
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5.3.3.3 Saracatinib treatment 
Saracatinib (figure 5.9) is another Abl and Src family kinase inhibitor used in the 
treatment of leukaemia. Treatment of sapje embryos with Saracatinib was able to 
reduce the proportion of embryos displaying a dystrophic phenotype (figure 5.10). 
However, it was not as effective as Dasatinib, and required higher concentrations to 
significantly increase the proportion of embryos showing unaffected muscle 
birefringence (figure 5.10B), and significantly decrease the proportion displaying a 
severe phenotype (figure 5.11). This may relate to the higher IC50 of Saracatinib in 
comparison with Dasatinib. 
 
Saracatinib 4-anilinoquinazoline
The chemical structure of Saracatinib is shown on the left. A 4-anilinoquinazoline scaffold 
(right-hand panel) forms the basis for several Src kinase inhibitors (Kluhs et al., 2007). The 
modification of this 4-anilinoquinazoline skeleton is important for kinase selectivity (Fang 
et al.,2013). Several structure-activity relationship analyses have demonstrated the 
significance of these modifications; the presence of nitrogen at position 1 and 3 of the 
anilinoquinazoline ring is important for the binding affinity of Saracatinib to the kinase 
domain of c-Src (Fang et al. 2013).
Figure 5.9 Chemical structure of Saracatinib
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Figure 5.10: Effect of 48 hour Saracatinib treatment on sapje
muscle phenotype
A
C
Embryos were treated with Saracatinib or DMSO 
only for 48 hours before a birefringence assay 
was carried out. The number of larvae showing 
normal or disrupted muscle birefringence were 
counted. Those showing disrupted birefringence 
were further subdivided into mild (disrupted 
birefringence affecting 1-5 somitic muscle 
blocks), moderate (6-10) and severe (10+) 
phenotypes. (A) shows the proportion of 
embryos displaying each phenotype. (B) shows 
the there is a significant increase in the 
percentage of embryos showing an unaffected 
muscle birefringence phenotype in the groups 
treated with 5 and 10μM Saracatinib compared 
with the DMSO only control group (One-way 
ANOVA: F=10.21, df=3,16, p=0.0005, followed 
by Dunnett’s Multiple Comparison Test: ns= not 
significant ,**p<0.01, ***p<0.001). (C) shows 
the percentage rescue of the dystrophic 
phenotype, taking the proportion of dystrophic 
fish in DMSO only treated groups as 0% rescue. 
Data points represent mean values of 5 
independent experiments, with a total of 
approximately 250 embryos per treatment 
group. Error bars represent SEM.
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Figure 5.11: Effect of  48 hour Saracatinib treatment on 
the severity of the sapje muscle phenotype
A B
Embryos were treated with Saracatinib or DMSO only for 48 hours before a 
birefringence assay was carried out. The number of larvae showing normal 
or disrupted muscle birefringence were counted. Those showing disrupted 
birefringence were further subdivided into mild (disrupted birefringence 
affecting 1-5 somitic muscle blocks), moderate (6-10) and severe (10+) 
phenotypes. (A) shows the proportion of larvae showing mild, moderate 
and severe muscle damage. (B) shows a significant decrease in the 
percentage of larvae showing a severe phenotype in the group treated with 
10μM Saracatinib compared with DMSO alone (One-way ANOVA: F=3.893, 
df=3,16, p=0.0290, followed by Dunnett’s Multiple Comparison Test: ns=not 
significant,*p<0.05). Data points represent mean values of 5 independent 
experiments, with a total of approximately 250 embryos per treatment 
group. Error bars represent SEM.
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5.3.4 Inhibiting ubiquitination and proteasomal degradation 
It is thought that in the absence of dystrophin, there are increased levels of DGC 
protein degradation. One of the main degradation pathways in muscle is the ubiquitin-
dependent proteasomal pathway. There are increased levels of proteasome expression 
in DMD patient muscle biopsies compared with control muscle and muscle biopsies 
from other neuromuscular diseases (Kumamoto et al., 2000). In addition, treatment 
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with proteasomal inhbitors has been shown to improve muscle pathophysiology in 
mdx mice and DMD muscle explants (Bonuccelli et al., 2003, Assereto et al., 2006, 
Bonuccelli et al., 2007, Gazzerro et al., 2010). 
 
Phosphorylation of β-dystroglycan has been identified as a signal for internalisation 
and possibly degradation (Sotgia et al., 2001, Sotgia et al., 2003, Miller et al., 2012). 
Evidence from our lab suggests phosphorylated β-dystroglycan, but not the non-
phosphorylated protein, is ubiquitinated (Rob Piggott, unpublished results). Thus, it 
was hypothesised that phosphorylated β-dystroglycan is internalised, where it may be 
subject to ubiquitination and further downstream processes, such as degradation or 
translocation to the nucleus (Lara-Chacon et al., 2010). 
 
5.3.4.1 PYR-41 is able to decrease the proportion of fish showing a dystrophic 
phenotype 
PYR-41 is an inhibitor of ubiquitin-activating enzyme (E1) (figure 5.12; Yang et al., 
2007). Treatment of embryos from a heterozygous sapje cross, from 24 to 72hpf, was 
able to decrease the percentage of embryos with disrupted muscle birefringence 
(figure 5.13). When fish were treated with 0.5 or 1μM PYR-41, there was a significant 
increase in the percentage displaying a normal muscle birefringence pattern compared 
with control groups (figure 5.13B). An optimal concentration of 1μM PYR-41 was able 
to reduce the population of embryos with a dystrophic phenotype by approximately 
45% (figure 5.13C). The effect of PYR-41 in preserving muscle integrity produced a bell-
shaped dose-response curve; concentrations higher than 1μM were less effective at 
decreasing the proportion of embryos with a dystrophic phenotype (figure 5.13B & C). 
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When examining the severity of the muscle damage, there were significantly lower 
percentages of larvae displaying a severe phenotype in groups treated with PYR-41, 
compared with control groups (figure 5.14). 
 
PYR-41
Figure 5.12: Structure of PYR-41
The chemical structure of PYR-41 is shown above. PYR-41 is a pyrazone derivative that 
identified from a high-throughput screen for inhibitors of ubiquitination (Yang et al. 2007). It 
is thought that this compound functions by covalently modifying the active site cysteine of 
ubiquitin-activating enzyme (E1) via either the N-aryl bond (1), or the exocyclic double bond 
(2). Related pyrazones were also evaluated for inhibitory activity against E1. Those 
compounds with the nitro substitute on the furan ring (3) inhibited E1, whereas those 
without did not, thus demonstrating the importance of this nitrogen for activity.
(1) (2)
(3)
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Figure 5.13: Effect of 48 hour PYR-41 treatment on sapje muscle 
phenotype
A
B
C
Embryos were treated with PYR-41 or DMSO only for 48 
hours before a birefringence assay was carried out. The 
number of larvae showing normal or disrupted muscle 
birefringence were counted. Those showing disrupted 
birefringence were further subdivided into mild 
(disrupted birefringence affecting 1-5 somitic muscle 
blocks), moderate (6-10) and severe (10+) phenotypes. 
(A) shows the proportion of embryos displaying each 
phenotype. (B) shows there is a significant increase in 
the percentage of embryos showing an unaffected 
muscle birefringence phenotype in the groups treated 
with 0.5 and 1μM PYR-41 compared with DMSO only 
control groups (One-way ANOVA: F=9.165, df=3,16, 
p=0.0009, followed by Dunnett’s Multiple Comparison 
Test: *p<0.05, ***p<0.001). (C) shows the percentage 
rescue of the dystrophic phenotype, taking the 
proportion of dystrophic fish in DMSO only treated 
groups as 0% rescue. Data points represent mean 
values of 5 independent experiments, with a total of 
approximately 300 embryos per treatment group. Error 
bars represent SEM.
Proportion of embryos in each treatment
group displaying each phenotype
Concentration PYR-41 (µM)
%
 e
m
b
ry
o
s
0 0.5 1 2
0
50
100
unaffected
mild
moderate
severe
 
Chapter 5 
138 
  
Percentage of larvae with
severe phenotype
Concentration PYR-41 (M)
%
 e
m
b
ry
o
s
0
0.
5 1 2
0
5
10
15
20
25
*
**
*
Figure 5.14: Effect of  48 hour PYR-41 treatment on the severity of the 
sapje muscle phenotype
A
B
Embryos were treated with PYR-41 or 
DMSO only for 48 hours before a 
birefringence assay was carried out. 
The number of larvae showing normal 
or disrupted muscle birefringence were 
counted. Those showing disrupted 
birefringence were further subdivided 
into mild (disrupted birefringence 
affecting 1-5 somitic muscle blocks), 
moderate (6-10) and severe (10+) 
phenotypes. (A) shows the proportion 
of larvae showing mild, moderate and 
severe muscle damage. (B) shows a 
significant decrease in the percentage 
of larvae showing a severe phenotype 
in the groups treated with PYR-41 
compared with DMSO alone (One-way 
ANOVA: F=5.316, df=3,16, p=0.0098, 
followed by Dunnett’s Multiple 
Comparison Test: *p<0.05, **p<0.01). 
Data points represent mean values of 5 
independent experiments, with a total 
of approximately 300 embryos per 
treatment group. Error bars represent 
SEM.
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Similar results were obtained when fish were treated with PYR-41 from 24 to 96hpf 
(figure 5.15 & 16), with lower concentrations being most effective at reducing the 
percentage of larvae displaying a dystrophic phenotype. Here, a concentration of 
0.5μM PYR-41 showed the most significant increase in the proportion of larvae 
showing an unaffected muscle phenotype (figure 5.15B), and the largest decrease in 
larvae showing a severe dystrophic phenotype (figure 5.16).  
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Figure 5.15: Effect of 72 hour PYR-41 treatment on sapje muscle 
phenotype
A B
C Embryos were treated with PYR-41 or DMSO only for 72 hours before a birefringence assay was carried 
out. The number of larvae showing normal or 
disrupted muscle birefringence were counted. Those 
showing disrupted birefringence were further 
subdivided into mild (disrupted birefringence 
affecting 1-5 somitic muscle blocks), moderate (6-10 
somites) and severe (10+ somites) phenotypes. (A) 
shows the proportion of embryos displaying each 
phenotype. (B) shows there is a significant increase in 
the percentage of embryos showing an unaffected 
muscle birefringence phenotype in the groups 
treated with PYR-41 compared with DMSO only 
control groups (One-way ANOVA: F=16.74, df=3,16, 
p<0.0001, followed by Dunnett’s Multiple 
Comparison Test: ns = not significant, ***p<0.001). 
(C) shows the percentage rescue of the dystrophic 
phenotype, taking the proportion of dystrophic fish in 
DMSO only treated groups as 0% rescue. Data points 
represent mean values of 5 independent 
experiments, with a total of approximately 300 
embryos per treatment group. Error bars represent 
SEM.
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Figure 5.16: Effect of  72 hour PYR-41 treatment on the 
severity of the sapje muscle phenotype
A
B
Embryos were treated with PYR-41 or DMSO only for 48 hours before a 
birefringence assay was carried out. The number of larvae showing normal or 
disrupted muscle birefringence were counted. Those showing disrupted 
birefringence were further subdivided into mild (disrupted birefringence 
affecting 1-5 somitic muscle blocks), moderate (6-10) and severe (10+) 
phenotypes. (A) shows the proportion of larvae showing mild, moderate and 
severe muscle damage. (B) shows a significant decrease in the percentage of 
larvae showing a severe phenotype in the groups treated with PYR-41 compared 
with DMSO alone (One-way ANOVA: F=5.875, df=3,16, p=0.0067, followed by 
Dunnett’s Multiple Comparison Test: *p<0.05, **p<0.01). Data points represent 
mean values of 5 independent experiments, with a total of approximately 300 
embryos per treatment group. Error bars represent SEM.
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5.3.4.2 PYR-41 is able to increase levels of dystroglycan in sapje 
Western blotting was carried out to examine the levels of β-dystroglycan in treated 
and control fish, to investigate whether the effect of PYR-41 in maintaining muscle 
integrity in sapje fish is associated with an increase in dystroglycan protein levels. 
Densitometric analysis of western blots indicated there were significantly higher levels 
of non-phosphorylated and phosphorylated β-dystroglycan in lysates from sapje larvae 
treated with PYR-41 compared with sapje larvae treated with DMSO only (figure 5.17). 
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Figure 5.17: Effect of PYR41 treatment on levels of phosphorylated 
and non-phosphorylated β-dystroglycan
β-DG
α-tub
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A
Lysates were made from embryos treated with 1μM PYR-41 or DMSO only. (A) shows 
western blots  probed against antibodies for β-dystroglycan (β-DG) and α-tubulin (α-tub). 
(B) The density of the blot probed against β-DG was quantified relative to α-tubulin levels in 
each sample, and normalised to average control signal. There was a significant increase in 
the level of β-dystroglycan in larvae treated with PYR-41, compared with controls (Unpaired 
t-test: t=4.479, df=10, p=0.0012). (C) shows western blots probed against antibodies for 
phosphorylated β-dystroglycan (pβ-DG) and α-tubulin (α-tub). (D) The density of the blot 
probed against p β-DG was quantified relative to α-tubulin levels in each sample, and 
normalised to average control signal. There was a significant increase in the levels of pβ-DG 
in larvae treated with PYR-41, compared with DMSO only treated controls (unpaired t-test: 
t=5.063, df=12, p=0.0003). Graphs represent the mean of 6 samples from 3 independent 
experiments, error bars are SEM.
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5.3.4.3 MG132 is able to reduce the percentage of sapje larvae with a dystrophic 
phenotype 
MG132 (figure 5.18) is a proteasomal inhibitor, which was shown to increase levels of 
dystroglycan in zebrafish embryos (chapter 4). 
 
Velcade Boronic acid
MG132
(A) Shows the chemical structure of MG132, one of the first proteasome inhibitors to be synthesised (Tsubuki
et al., 1993). This compound inhibits the chymotrypsin-like activity of the proteasome. However, MG132 
exhibits several properties that make it unsuitable as a drug molecule. These include lack of specificity and 
poor bioavailability (Adams et al., 1996). Replacing the aldehyde group of MG132 with boronic acid increased 
the potency of the compound 100-fold (Adams et al., 1998). This compound was modified further to create 
Velcade (shown in B). Compared with MG132, Velcade dissociates from the proteasome more slowly, 
conferring stable inhibition.
A
B
Figure 5.18: Chemical structure of 2 proteasomal inhibitors: 
MG132 and Velcade
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Treatment of embryos with MG132 from 24 to 72hpf was able to decrease the 
proportion of fish displaying a dystrophic phenotype (figure 5.19). There was a 
statistically significant increase in the percentage of embryos with an unaffected 
muscle phenotype in groups treated with 5 and 10μM MG132, compared to the DMSO 
only group (figure 5.19B). 
 
The effect of MG132 in decreasing the ratio of affected fish was concentration 
dependent (figure 5.19C). The percentage rescue of the dystrophic population was 
calculated, taking the percentage of dystrophic fish in DMSO only control groups as 0% 
rescue. The effect of MG132 plateaus at a concentration of about 2μM, with a 
maximum of approximately 35% of the dystrophic population displaying normal 
muscle birefringence.  
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Figure 5.19: Effect of 48 hour MG132 treatment on sapje muscle 
phenotype
A
B
C
Embryos were treated with MG132 or DMSO only 
for 48 hours before a birefringence assay was 
carried out. The number of larvae showing normal 
or disrupted muscle birefringence were counted. 
Those showing disrupted birefringence were further 
subdivided into mild (disrupted birefringence 
affecting 1-5 somitic muscle blocks), moderate (6-
10) and severe (10+) phenotypes. (A) shows the 
proportion of embryos displaying each phenotype. 
(B) shows that there is a significant difference in the 
percentage of embryos showing an unaffected 
muscle birefringence phenotype between the 
different treatment groups (One-way ANOVA: 
F=3.833, df=5,24, p=0.0108),  with significant 
increases  between the DMSO only control group 
and  those treated with 5 and 10μM MG132 
(Dunnett’s Multiple Comparison Test: *p<0.05, 
**p<0.01). (C) shows the percentage rescue of the 
dystrophic phenotype, taking the proportion of 
dystrophic fish in DMSO only treated groups as 0% 
rescue. Data points represent mean values of 5 
independent experiments, with a total of 
approximately 250 embryos per treatment group. 
Error bars represent SEM.
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When examining the severity of the muscle phenotypes in treated and non-treated 
groups, there was no significant difference between the percentages of embryos 
displaying a severe phenotype (figure 5.20). 
 
Figure 5.20: Effect of  48 hour MG132 treatment on the severity of the 
sapje muscle phenotype
A
B
Embryos were treated with MG132 or DMSO only for 48 hours before a birefringence assay 
was carried out. The number of larvae showing normal or disrupted muscle birefringence 
were counted. Those showing disrupted birefringence were further subdivided into mild 
(disrupted birefringence affecting 1-5 somitic muscle blocks), moderate (6-10) and severe 
(10+) phenotypes. (A) shows the proportion of larvae showing mild, moderate and severe 
muscle damage. (B) shows there is no significant difference in the percentage of larvae 
showing a severe phenotype in the groups treated with MG132 compared with DMSO 
alone (One-way ANOVA followed by Dunnett’s Multiple Comparison Test: F=1.197, df=5,24, 
p=0.3403). Data points represent mean values of 5 independent experiments, with a total 
of approximately 250 embryos per treatment group. Error bars represent SEM.
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5.3.4.4 MG132 is able to increase levels of dystroglycan in sapje 
If MG132 is able to delay the onset of the dystrophic phenotype and maintain muscle 
integrity, it may be acting by preventing the degradation of dystroglycan and other 
DGC proteins. Therefore, the levels of β-dystroglycan in treated and control fish were 
analysed using western blotting. 
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Densitometric analysis of western blotting data from treated and control treated fish 
indicated that there was significantly higher levels of β-dystroglycan in those exposed 
to MG132 (figure 5.21). In addition, the levels of phosphorylated β-dystroglycan were 
also higher.  
 
Figure 5.21: Effect of MG132 treatment on levels of phosphorylated 
and non-phosphorylated β-dystroglycan
β-DG
α-tub
55
35
55
A
Lysates were made from embryos treated with 5μM MG132 or DMSO only. (A) shows 
western blots  probed against antibodies for β-dystroglycan (β-DG ) and α-tubulin (α-tub). 
(B) The density of the blot probed against β-DG was quantified relative to α-tubulin levels in 
each sample, and normalised to average control signal. There is a significant increase in the 
level of β-dystroglycan in larvae treated with MG132, compared with controls (Unpaired t-
test: t=4.048, df=10, p=0.0023). (C) shows western blots probed against antibodies for 
phosphorylated β-dystroglycan (p β-DG) and α-tubulin. (D) The density of the blot probed 
against p β-DG was quantified relative to α-tubulin levels in each sample, and normalised to 
average control signal. There was a significant increase in the levels of β-DG in larvae 
between different treatment groups (Unpaired t-test: t=11.47, df=10, p<0.0001). Graphs 
represent the mean of 6 samples from 3 independent experiments, error bars are SEM.
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5.3.4.5 Longer treatment with MG132 is not beneficial to sapje fish 
Longer treatment with MG132, from 24 to 96hpf, did not decrease the proportion of 
fish with affected muscle birefringence, or affect the severity of the muscle phenotype 
(figure 5.22).  
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Figure 5.22: Effect of 72 hour MG132 treatment on sapje muscle 
phenotype
A
B Embryos were treated with MG132 or DMSO only for 72 hours before a birefringence assay was carried out. The 
number of larvae showing normal or disrupted muscle 
birefringence were counted. Those showing disrupted 
birefringence were further subdivided into mild (disrupted 
birefringence affecting 1-5 somitic muscle blocks), 
moderate (6-10) and severe (10+) phenotypes. (A) shows 
the proportion of embryos displaying each phenotype. (B) 
shows no significant difference in the percentage of 
embryos showing an unaffected muscle birefringence 
phenotype between the different treatment groups (One-
way ANOVA: F=0.6216, df=5,24, p=0.6847). (C) shows the 
proportion of larvae showing mild, moderate and severe 
muscle damage. There are no significant differences 
between the percentages of each phenotype in each 
treatment group. (One-way ANOVAs, mild: F=1.389, 
df=5,24, p=0.2636, moderate: F=0.6875, df=5,24, 
p=0.6376, severe: F=0.3302, df=5,24, p=0.8897). Data 
points represent mean values of 5 independent 
experiments, with a total of approximately 250 embryos 
per treatment group. Error bars represent SEM.
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5.3.4.6 Velcade is able to decrease the proportion of larvae with a dystrophic 
phenotype 
Velcade (figure 5.18) is a potent inhibitor of the proteasome, approved by the FDA for 
the treatment of multiple myeloma (Adams, 2004). 
 
Treatment of embryos with Velcade was able to decrease the percentage of fish 
displaying aberrant muscle birefringence (figure 5.23). There was a statistically 
significant increase in the percentage of embryos with unaffected muscle birefringence 
in groups treated with 0.125, 0.25 and 0.5μM Velcade, compared to the DMSO only 
group (figure 5.23B). However, this was not significant at a concentration of 1μM. 
  
At the concentrations used, there was not a concentration-dependent effect of 
Velcade on decreasing the percentage of dystrophic fish (figure 5.23C). However, this 
may have been observed if lower concentrations were used as the dose-response 
effect of Velcade may have plateaued.  
 
As Velcade is a more potent proteasomal inhibitor than MG132, it was expected to 
elicit a greater effect in preserving muscle integrity. However, Velcade decreased the 
percentage of dystrophic fish to a lesser extent than MG132, with an optimal rescue of 
approximately 28% of the dystrophic population (figure 5.23C). 
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Figure 5.23: Effect of 48 hour Velcade treatment on sapje muscle 
phenotype
A
B
C
Embryos were treated with Velcade or DMSO only 
for 48 hours before a birefringence assay was carried 
out. The number of larvae showing normal or 
disrupted muscle birefringence were counted. Those 
showing disrupted birefringence were further 
subdivided into mild (disrupted birefringence 
affecting 1-5 somitic muscle blocks), moderate (6-10) 
and severe (10+) phenotypes. (A) shows the 
proportion of embryos displaying each phenotype. 
(B) shows that there is a significant difference in the 
percentage of embryos showing an unaffected 
muscle birefringence phenotype between the 
different treatment groups (One-way ANOVA: 
F=4.487, df=4,20, p=0.0095, followed by Dunnett’s
Multiple Comparison Test: ns= not significant, 
*p<0.05, **p<0.005). (C) shows the percentage 
rescue of the dystrophic phenotype, taking the 
proportion of dystrophic fish in DMSO only treated 
groups as 0% rescue. Data points represent mean 
values of 5 independent experiments, with a total of 
approximately 250 embryos per treatment group. 
Error bars represent SEM.
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As with MG132, upon examining the severity of the muscle phenotypes in treated and 
control treated groups, there was no significant difference between the percentages of 
embryos displaying a severe phenotype (figure 5.24). 
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Figure 5.24: Effect of  48 hour Velcade treatment on the severity of 
the sapje muscle phenotype
A
B
Embryos were treated with Velcade or DMSO only for 48 hours before a birefringence 
assay was carried out. The number of larvae showing normal or disrupted muscle 
birefringence were counted. Those showing disrupted birefringence were further 
subdivided into mild (disrupted birefringence affecting 1-5 somitic muscle blocks), 
moderate (6-10 somites) and severe (10+ somites) phenotypes. (A) shows the 
proportion of larvae showing mild, moderate and severe muscle damage. (B) shows 
there is no significant difference in the percentage of larvae showing a severe 
phenotype in the groups treated with Velcade compared with DMSO alone (One-way 
ANOVA followed by Dunnett’s Multiple Comparison Test: F=0.3547, df=4,20, p=0.8377). 
Data points represent mean values of 5 independent experiments, with a total of 
approximately 250 embryos per treatment group. Error bars represent SEM.
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5.3.5 Compound treatment of dag1 embryos does not prevent development of the 
dystrophic phenotype 
Although biochemical data suggest otherwise, it is possible that the drugs are 
improving muscle integrity in sapje fish through another mechanism, rather than by 
preventing β-dystroglycan phosphorylation and degradation. The ability of these 
inhibitors to delay or prevent the onset of the dystrophic phenotype in dag1 fish was 
therefore investigated.  
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The pathophysiological mechanism leading to the dystrophic phenotype seen in sapje 
and dag1 involves the loss of connection between the actin cytoskeleton and 
extracellular matrix, with both mutations causing defects in the DGC complex. 
Therefore if these compounds are improving muscle integrity in sapje by a mechanism 
that is independent of dystroglycan and the DGC, treatment may also be beneficial to 
dag1 fish. 
 
Treatment of embryos from heterozygous dag1 fish with Dasatinib, PYR-41 and MG132 
was unable to decrease the proportion of embryos with a dystrophic phenotype, or 
alter the ratios of larvae displaying mild, moderate or severe phenotypes (figures 5.25, 
5.26 and 5.27). This suggests that the effect of these drugs on the dystrophic 
phenotype may be dependent on dystroglycan expression. 
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Figure 5.25: Effect of 48 hour Dasatinib treatment on dag1 muscle 
phenotype
B
Embryos were treated with Dasatinib or DMSO only for 
48 hours before a birefringence assay was carried out. 
The number of larvae showing normal or disrupted 
muscle birefringence were counted. Those showing 
disrupted birefringence were further subdivided into 
mild (disrupted birefringence affecting 1-5 somitic 
muscle blocks), moderate (6-10) and severe (10+) 
phenotypes. (A) shows the proportion of embryos 
displaying each phenotype. (B) shows no significant 
difference in the percentage of embryos showing an 
unaffected muscle birefringence phenotype between 
the different treatment groups (One-way ANOVA: 
F=0.2905, df=2,12, p=0.7530). (C) shows the proportion 
of larvae showing mild, moderate and severe muscle 
damage. There are no significant differences between 
the percentages of each phenotype in each treatment 
group. (One-way ANOVAs, mild: F=1.649, df=2,12, 
p=0.3454, moderate: F=0.1486, df=2,12, p=0.8635, 
severe: F=0.1277, df=2,12, p=0.8813). Data points 
represent mean values of 5 independent experiments, 
with a total of approximately 250 embryos per 
treatment group. Error bars represent SEM.
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Figure 5.26: Effect of 48 hour PYR-41 treatment on dag1 muscle 
phenotype
B
Embryos were treated with PYR-41 or DMSO only for 
48 hours before a birefringence assay was carried 
out. The number of larvae showing normal or 
disrupted muscle birefringence were counted. Those 
showing disrupted birefringence were further 
subdivided into mild (disrupted birefringence 
affecting 1-5 somitic muscle blocks), moderate (6-10) 
and severe (10+) phenotypes. (A) shows the 
proportion of embryos displaying each phenotype. 
(B) shows no significant difference in the percentage 
of embryos showing an unaffected muscle 
birefringence phenotype between the different 
treatment groups (One-way ANOVA: F=0.1875, 
df=2,12, p=0.8314). (C) shows the proportion of 
larvae showing mild, moderate and severe muscle 
damage. There are no significant differences 
between the percentages of each phenotype in each 
treatment group. (One-way ANOVAs, mild: 
F=0.06795, df=2,12, p=0.9347, moderate: F=0.3782, 
df=2,12, p=0.6930, severe: F=1.062, df=2,12, 
p=0.3762). Data points represent mean values of 5 
independent experiments, with a total of 
approximately 250 embryos per treatment group. 
Error bars represent SEM.
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Figure 5.27: Effect of 48 hour MG132 treatment on dag1 muscle 
phenotype
B
Embryos were treated with MG132 or DMSO 
only for 48 hours before a birefringence assay 
was carried out. The number of larvae showing 
normal or disrupted muscle birefringence were 
counted. Those showing disrupted birefringence 
were further subdivided into mild (disrupted 
birefringence affecting 1-5 somitic muscle 
blocks), moderate (6-10) and severe (10+) 
phenotypes. (A) shows the proportion of 
embryos displaying each phenotype. (B) shows 
no significant difference in the percentage of 
embryos showing an unaffected muscle 
birefringence phenotype between the different 
treatment groups (One-way ANOVA: F=0.4779, 
df=2,12, p=0.6314). (C) shows the proportion of 
larvae showing mild, moderate and severe 
muscle damage. There are no significant 
differences between the percentages of each 
phenotype in each treatment group. (One-way 
ANOVAs, mild: F=0.1143, df=2,12, p=0.8929, 
moderate: F=0.6246, df=2,12, p=0.5520, severe: 
F=0.3705, df=2,12, p=0.6980). Data points 
represent mean values of 5 independent 
experiments, with a total of approximately 250 
embryos per treatment group. Error bars 
represent SEM.
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5.3.6 Chemical treatment does not affect larval motility 
As shown in chapter 4, it is possible to decrease the severity of the dystrophic 
phenotype by anesthetising larvae. Tricaine (MS222) has also been shown to suppress 
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the phenotype of the laminin α2 mutant candyfloss (Hall et al., 2007). To exclude the 
possibility that the drugs are acting to delay or prevent the onset of the dystrophic 
phenotype by paralysing the fish, or by decreasing the amount of movement, the 
motility of treated and control treated wildtype larvae was examined.  
 
Treated larvae did not appear to show any visible motility defects, and exhibited a 
touch evoked escape response. However, to quantify the amount of movement carried 
out by treated and control treated fish more accurately, a Viewpoint tracking assay 
was performed. As a positive control for larval sedation, MS222 treated fish were also 
tested.  At all concentrations of MS222 used, larvae travelled shorter distances, spent 
less time moving, and less time moving at fast speeds (figure 5.28). At low 
concentrations of MS222, larvae were still able to swim, but showed significantly lower 
levels of motility in the parameters analysed. This suggested that this tracking assay 
could be used to evaluate the effects of drugs on locomotor activity, and results from 
MS222 treated fish could be used as comparisons against compounds thought to have 
sedative effects. 
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Figure 5.28: Effect of tricaine on WT zebrafish larvae motility
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WT larvae were  immersed in various concentrations 
of tricaine in E3 media, or E3 only (controls) for 30 
minutes before the Viewpoint tracking assay was 
carried out. (A) Shows representative traces for each 
treatment group; red lines= movement > 10mm/sec, 
green lines= movement <10mm/sec. Distance 
moved (B), time spent moving (C) and time spent 
moving at speeds greater than 10mm/sec (D) are all 
significantly affected by the addition of tricaine. 
One-way ANOVAs were carried out (B: F=68.38, 
df=4,35, p<0.0001; C: F=152, df=4,35, p<0.0001; D: 
F=99.76, df=4,35, p<0.0001), followed by Dunnett’s
multiple comparison tests (*** p<0.001). Each bar 
represents mean tracking data from 8 larvae from 2 
separate multi-well plates and error bars represent 
SEM.
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Wildtype larvae were continually treated with Dasatinib, PYR-41, MG132, or DMSO 
only from 1 to 5dpf. Figure 5.29 indicates that these drugs had no effect on the total 
distance larvae travelled, or the time spent moving during the ten minute tracking 
period. 
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Figure 5.29 Effect of drug treatment on motility of WT larvae
LWT larvae were treated with indicated concentrations of drug, or DMSO only, from 1 to 5dpf. 
One-way ANOVA analysis of Viewpoint tracking data indicated no significant differences 
between drug treated and control groups for the distance moved (A,C & E), or time spent 
moving (B,D & F) in the ten minute tracking period. Bars represent mean tracking data of 16 
larvae from 2 separate 24-well plates; SEM represents SEM.
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5.3.7 Treatment of larvae after the onset of muscle damage 
When patients are diagnosed with DMD, significant muscle damage has usually already 
occurred. Therefore, when evaluating the potential value of new therapeutic 
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interventions, it is crucial to elucidate whether the disease progression can be 
stopped, or slowed down, after the onset of muscle damage. 
 
Muscle damage in sapje fish is progressive, with the phenotype worsening from 3 to 
5dpf (chapter 4). The ability of drug treatment to alter the decline in muscle 
birefringence over time was examined.  
 
Simple quantification of birefringence image intensity, as carried out in chapter 4, was 
found not to be a reliable method for quantifying muscle damage across different 
experiments. This was because the intensity of the image is sensitive to small changes 
in the orientation of the polarising lenses and the larva. When images are taken at the 
same time, these factors influencing the brightness of the birefringence can be easily 
controlled. However, this system is not robust enough to measure small changes in the 
level of muscle damage accurately over different experiments. An alternative method 
for quantifying muscle damage was therefore needed. 
 
5.3.7.1 A novel method of quantifying muscle damage 
Plotting a graph of birefringence image intensity along the length of a wildtype fish 
gives a regular and even pattern of peaks and troughs, representing bright somites and 
darker somite boundaries (figure 5.30). In contrast, sapje fish show a very irregular 
pattern of peaks and troughs due to the disruption of the birefringence pattern. 
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Figure 5.30: Intensity profile plots of  wildtype and sapje birefringence 
images at 3dpf
(A) and (C) show birefringence images of 
wildtype and sapje larvae. Yellow lines shows 
the position used to generate the intensity 
profiles shown in (B) and (D) for wildtype and 
sapje fish respectively.
 
Carrying out Fourier transforms of the line scan data breaks down the graph into its 
individual frequencies. Wildtype fish show a single frequency of about 10 cycles per 
mm, corresponding to the number of peaks and troughs per mm. sapje fish show an 
underlying frequency of about 10 cycles per mm, but show a more disordered 
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frequency distribution due to the disruption in the periodicity of the line scan caused 
by loss of birefringence (figure 5.31). At a spatial frequency of 5 cycles/mm, the pixel 
intensity power of sapje is significantly higher than that of the wildtype at both 3 and 
5dpf (figure 5.32). 
 
Analysis of fish with greater levels of muscle birefringence disruption gives a higher 
value for pixel intensity power at 5 cycles per mm (red graph in figure 5.31 C & D). As 
the dystrophic phenotype worsens over time, the birefringence pattern becomes more 
disrupted, resulting in a quantitative difference using Fourier analysis (figure 5.32). 
Between 3 and 5dpf, Fourier transforms of line scanning data show a significant 
increase in the pixel intensity power at 5 cycles per mm. 
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Figure 5.31: Line scans and Fourier transforms of 3dpf larvae
Left-hand panels show line scans of sibling (A) and sapje (C) muscle birefringence images. 
Right-hand graphs (B) and (D) show the Fourier transforms of the data. Fourier transforms 
of sibling fish  (B) show a single frequency of just over 10 cycles/mm, representing the 
number of somites per mm. Fourier transforms of sapje fish line scans (D), show an 
underlying frequency at about 10 cycles/mm, but also exhibit other smaller frequency 
modes, due to the disruption in birefringence. (E) shows the images used to create  the line 
scans in (C, D).
B
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Figure 5.32 Fourier analysis of 3 and 5dpf sibling and sapje fish
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Birefringence images were used to generate line 
scans of the ventral and dorsal myotomes of each 
fish. (A-D) show representative Fourier 
transforms of line scan data from sibling (sib) and 
sapje (sap) fish at 3 and 5dpf. The pixel intensity 
power at a spatial frequency of 5 cycles/mm is 
plotted in E. 2 values were generated from each 
image (dorsal and ventral) and averaged to give a 
single value for each fish. Bars plotted represent 
the mean+ SEM of 12 fish. At a spatial frequency 
of 5 cycles/mm, the pixel intensity power is 
significantly higher for sapje fish, compared with 
sibling fish at both 3 and 5 dpf (3dpf - Unpaired t-
test with Welch’s correction: t=4.577, df=18, 
p=0.0002; 5dpf: Unpaired t-test with Welch’s 
correction: t=7.923, df=18, p<0.0001). There is 
also a clear statistical difference between sapje
fish at 3 and 5dpf (Unpaired t-test: t=6.046, 
df=22, p<0.0001).
(A) sib 3dpf
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5.3.7.2 Effect of Dasatinib on muscle damage 
The ability of Dasatinib to slow the progression of muscle damage was assessed, as this 
drug was most effective at reducing the percentage of fish with a dystrophic 
phenotype. Fourier transforms of line scanning data from sapje larvae treated with 
Dasatinib from 3 to 5dpf were carried out.  At a concentration of 1μM, there is a slight 
decrease in the pixel intensity power at 5 cycles per mm, compared with DMSO only 
treated controls, but this was not statistically significant (figure 5.33). At higher 
concentrations of Dasatinib, there was also no significant difference in the values. 
 
Birefringence images were used to 
generate line scans of the ventral and 
dorsal myotomes of each fish. Fourier 
transforms of line scan data from 
control treated and Dasatinib treated 
sapje fish were then carried out. The 
pixel intensity power at a spatial 
frequency of 5 cycles/mm was plotted 
in the adjacent graph. Bars represent 
the mean+ SEM of 30 fish for 3 
independent experiments. At a spatial 
frequency of 5 cycles/mm, there is no 
statistical difference in the pixel 
intensity power between the different 
treatment groups (One-way ANOVA 
followed by Tukey’s Multiple 
Comparison test: F=1.273, df= 3,116, 
p=0.2869)
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Figure 5.33: Fourier analysis of Dasatinib treated embryos
 
5.3.7.3 Effect of Dasatinib on larval movement 
Although the quantification of muscle damage indicated no detectable difference 
between treated and non-treated fish, there may be an improvement in muscle 
function. Therefore, the movement of larvae treated with Dasatinib between 3 and 
5dpf was also analysed, using the Viewpoint tracking system. 
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There is a slight increase in the distance travelled by Dasatinib treated larvae within 
the tracking period, compared with DMSO treated controls (figure 5.34), and this 
increase is statistically significant at a concentration of 5μM. There was no significant 
difference between treated larvae and controls when comparing the time spent 
moving during the tracking period, although there is an upward trend. 
 
Figure 5.34: Viewpoint tracking analysis of Dasatinib treated embryos
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sapje larvae were treated with indicated concentrations of Dasatinib, or DMSO 
only, from 3 to 5dpf. One-way ANOVA analysis of Viewpoint tracking data 
indicated a significant increase between Dasatinib treated and control groups for 
the distance moved (A – One way ANOVA: F=3.188, df=2,69, p=0.0474, followed 
by Dunnett’s multiple comparison test: *p<0.05, ns= not significant), but not time 
spent moving (B – One way ANOVA: F=1.995, df=2,69, p=0.1438, followed by 
Dunnett’s multiple comparison test: ns= not significant)) in the ten minute 
tracking period. Bars represent mean data from 24 individual larvae from 3 
separate 24-well plates; error bars are SEM.
 
5.4 Discussion 
Inhibitors of Src kinase and the ubiquitin-dependent proteasomal pathway have been 
shown to be effective in reducing the proportion of larvae from a heterozygous sapje 
cross with a dystrophic phenotype. A summary of the results from the compound 
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treatment assay is shown in table 5.1. Inhibition of tyrosine kinase and E1 ubiquitin-
ligase activity for 48 or 72 hours resulted in a decrease in the proportion of larvae with 
a dystrophic phenotype, and the proportion displaying a severe muscle phenotype. 48-
hour proteasome inhibition was able to decrease the percentage of larvae with a 
dystrophic phenotype, but had no effect on percentage of embryos with a severe 
dystrophic phenotype. In addition, 72-hour treatment had no effect on the proportion 
of embryos with a dystrophic phenotype, or the severity of the phenotypes displayed. 
 
The maximum rescue of the dystrophic population achieved in the compound 
treatment assay was approximately 30-45%, which is slightly lower than results from a 
recent screen by the Kunkel group (Kawahara et al., 2011). This could be explained by 
differences in the assay system used. The screen used fewer embryos per treatment, 
so would be more sensitive to fluctuations in the percentage of embryos with an 
affected muscle birefringence in each group. In addition, the screen was much higher 
throughput than the assay described in this study, which could mean numbers of 
affected fish were miscounted, especially if the phenotype was mild or the larvae was 
oriented incorrectly in relation to the polarising lenses. When aminophylline, a 
chemical pulled out from the screen carried out by Kawahara and collegues, was used 
as a positive control, levels of rescue achieved were comparable to that achieved with 
the compounds used in this study. 
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Compound 48 hour treatment 72 hour treatment
Effect on % 
larvae with 
dystrophic 
phenotype
Effect on % 
larvae with 
severe 
phenotype
Effect on % 
larvae with 
dystrophic 
phenotype
Effect on % 
larvae with 
severe 
phenotype
Tyrosine kinase inhibitors
Dasatinib ↓ ↓ ↓ ↓
Saracatinib ↓ ↓ n/a n/a
E1 ubiquitin-activating enzyme inhibitor
PYR-41 ↓ ↓ ↓ ↓
Proteasomal inhibitors
MG132 ↓ ↔ ↔ ↔
Velcade ↓ ↔ n/a n/a
Table 5.1: Summary table showing the effects of compound treatment 
on sapje phenotype
Key:
↓ significant decrease in the proportion of larvae with dystrophic/severe phenotype, 
compared with control treated embryos
↔ no significant difference in the proportion of larvae with dystrophic/severe phenotype, 
compared with control treated embryos
 
5.4.1 Inhibiting Src kinase 
Src kinase inhibitors Dasatinib and Saracatinib were able to decrease the percentage of 
fish with a dystrophic phenotype. There was also a significant decrease in the 
percentage of embryos with a severe muscle phenotype. In addition, Dasatinib was 
able to significantly decrease the level of phosphorylated β-dystroglycan in sapje fish. 
This was associated with a concomitant increase in non-phosphorylated β-
dystroglycan. This suggests that Dasatinib, by reducing levels of phosphorylated β-
dystroglycan, is having an inhibitory effect on the phosphorylation of dystroglycan, and 
is able to delay or prevent the onset of dystrophy in some fish. These results are in 
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support of work carried out in the mdx mouse, where muscle histology and function 
were improved by preventing the phosphorylation of dystroglycan (Miller et al., 2012). 
 
Dasatinib treatment of dag1 embryos did not affect the percentage of fish with a 
dystrophic phenotype, suggesting that dystroglycan is required for the drug to affect 
muscle integrity. Furthermore, drug treatment of wildtype embryos did not affect 
larval movement, suggesting Dasatinib is not preventing the onset of dystrophy by 
paralysing the fish. These results, together with the biochemical data, are in support of 
Dasatinib affecting the muscle phenotype of sapje by a dystroglycan-dependent 
mechanism. 
 
sapje larvae treated with Dasatinib after the onset of the dystrophic phenotype did not 
show a statistically significant improvement in the severity of muscle damage 
compared with non-treated controls. The vast variability in the amount of muscle 
damage in sapje larvae may have masked any beneficial effect of drug treatment, or 
the assay may not be sensitive enough to detect any effect. Alternatively, inhibiting Src 
kinase after the disease onset may not be able to slow the disease progression. There 
may have already been elevated phosphorylation and degradation of dystroglycan 
before 3dpf. Although there was no observable effect on muscle damage, there was a 
slight improvement in the motility of treated larvae. Longer treatment of larvae could 
be carried out to examine the effect of Dasatinib treatment on the life span of sapje 
mutants and their motility at later time points.  
 
It would be important to carry out experiments with other kinase inhibitors, to show 
that the phenotypic rescue observed with Dasatinib and Saracatinib treatment is 
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specific to the activities of these drugs, and not a more general effect of kinase 
inhibition. Performing the assay with inhibitors of other kinases would also provide 
more evidence that the phosphorylation of dystroglycan is carried out by Src kinases; if 
these inhibitors are unable to reduce dystroglycan phosphorylation and improve 
muscle integrity in sapje, it would suggest that the Src family of kinases are responsible 
for this modification of dystrolgycan. 
 
5.4.2 Inhibiting ubiquitination and proteasomal degradation  
PYR-41, an inhibitor of ubiquitin-activating enzyme (E1), was able to decrease the 
percentage of embryos with disrupted muscle birefringence and increase levels of β-
dystroglycan protein. This suggests that PYR-41, by causing an increase in dystroglycan 
levels, is able to affect the cell biochemistry in the expected way. These data are in 
support of the hypothesised pathway by which dystroglycan is lost in the absence of 
dystrophin. 
 
PYR-41 was more effective at lower concentrations (0.5 and 1μM) than at higher 
concentrations. This may be due to compensatory upregulation of other degradation 
pathways in response to an inhibition of the ubiquitin-dependent proteasomal 
pathway. PYR-41 has been shown to increase sumolyation in HEK293 cells (Yang et al., 
2007). Therefore increased concentrations of PYR-41 may result in elevated 
degradation of DGC components, or other proteins that may have a protective effect 
on muscle integrity, by an alternative pathway. 
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Proteasomal inhibitors were able to increase dystroglycan levels, and slow the onset of 
the dystrophic phenotype in sapje zebrafish. These compounds have been previously 
shown to ameliorate muscle damage in mdx mice and the GRMD dog. These data 
further validate the zebrafish as a valuable tool for investigating new therapies for 
muscular dystrophy. 
 
Both PYR-41 and MG132 increased levels of phosphorylated β-dystroglycan to a 
greater extent than non-phosphorylated β-dystroglycan. This may suggest it is the 
phosphorylated form of the protein which is primarily degraded in an ubiquitin- and 
proteasome-dependent manner. Combining these compounds with inhibitors of β-
dystroglycan phosphorylation may be able to increase levels of non-phosphorylated 
dystroglycan even further. This may have greater effects on dystrophic muscle 
improvement, or enable lower doses of drugs to be used. 
 
Several reports have highlighted the role of the ubiquitin-dependent proteasomal 
pathway in the pathogenesis of various muscle diseases. This pathway has been 
implicated in the atrophy of skeletal muscle in several conditions including sarcopenia 
and cachexia (Mitch and Goldberg, 1996, Altun et al., 2010), and proteasomal 
inhibitors are able to suppress the accelerated levels of protein breakdown and block 
atrophy in a number of animal models (Tawa et al., 1997, Fischer et al., 2000, Caron et 
al., 2011, Jamart et al., 2011, Zhang et al., 2013). In dystrophic muscle, proteasome 
activity is reported to be increased (Kumamoto et al., 2000, Selsby et al., 2010). 
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The data here further support the idea that the proteasomal pathway plays a role in 
protein degradation in dystrophin deficient muscle and suggests that increasing 
expression of dystroglycan is able to prevent muscle damage to some extent. 
 
Results presented in chapters 4 and 5 suggest the decrease in dystroglycan expression 
observed in sapje fish could be mediated by the proteasome, either directly or 
indirectly. Since β-dystroglycan is a membrane protein, and the proteasome is 
primarily involved in the degradation of cytosolic proteins, the proteasomal pathway 
may be indirectly implicated in its degradation. 
 
Ubquitination and the activity of the proteasome is needed for the efficient 
translocation of the EGFR (endothelial growth factor receptor) to MVBs (multivesicular 
bodies), and MG132 is able to inhibit the degradation and promote the recycling of 
EGFR (Longva et al., 2002). The proteasome is also thought to play a role in the 
degradation of sodium channel Nav1.5; MG132 was able to restore the protein 
expression of Nav1.5 in the cardiac muscle of mdx5cv mice(Rougier et al., 2013). 
Whether proteasomal degradation plays a direct or indirect role in the degradation of 
dystroglycan remains to be explored, but the fact that inhibitors of this pathway have 
been shown to be beneficial in several animal models of DMD suggests they may have 
potential in a therapeutic setting. 
 
Although MG132 was effective in reducing the percentage of dystrophic fish when 
embryos were treated from 1 to 3dpf, it was not effective over longer incubations. 
Inhibition of the proteasome may be able to increase levels of β-dystroglycan to some 
extent, but over longer periods, it may be subject to internalisation, or increased 
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degradation by compensatory mechanisms. In addition, there was also no decrease in 
the percentage of larvae with a severe muscle phenotype in the treated groups, 
compared with the DMSO treated groups. This suggests MG132 may only be able to 
delay the onset of dystrophy in the mild phenotype group.  
 
There has been conflicting evidence supporting a role for proteasomal inhibitors in 
rescuing the dystrophic phenotype in mdx mice. Continuous systemic treatment of 
mdx mice with MG-132 over 8 days resulted in the restoration of DGC proteins at the 
membrane and an improvement in muscle integrity (Bonuccelli et al., 2003). Similar 
improvement of the dystrophic phenotype has been observed using Velcade in mdx 
mice (Gazzerro et al., 2010) and the GRMD dog (Araujo et al., 2013). In another study, 
8 day MG132 treatment increased the tetanic force of mdx muscles, but longer 
treatment appeared to be ineffective at improving muscle function (Selsby et al., 
2012). In addition, muscles seemed to be more susceptible to contraction induced 
injury. Thus, inhibiting the proteasome may offer short term improvements to the 
pathophysiology of dystrophic muscle, but the continuous use of inhibitors may be 
ineffective, or even deleterious. 
 
Velcade did not decrease the percentage of dystrophic fish as effectively as MG132, 
which was unexpected since it is a more potent inhibitor of the proteasome. As well as 
inhibiting the proteasome, MG132 has also been shown to inhibit calpains (Lee and 
Goldberg, 1998). As such, it is possible that the inhibitory effect of MG132 on calpains 
may also play a role in maintaining muscle integrity in treated sapje fish. 
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5.4.2.1 Calpain 
Calpain activity is thought to be increased in dystrophic muscle (Spencer et al., 1995). 
Sarcolemmal damage allows increased calcium influx, which can lead to the 
overactivation of calpain (Alderton and Steinhardt, 2000).  
 
Studies investigating the usefulness of calpain inhbition in improving the dystrophic 
phenotype are conflicting. Treatment of mdx mice with the calpain inhibitor leupeptin 
ameliorated the muscle pathology (Badalamente and Stracher, 2000). Treatment with 
BN82270, a combined calpain inhibitor and antioxidant, improved grip strength in the 
mdx mouse, but histological improvements were not observed (Burdi et al., 2006). The 
improvement in muscle function could be attributed to the antioxidant function of 
BN82270. Treatment of the mdx mouse with green tea extract was able to protect 
against oxidative stress and decrease muscle necrosis (Buetler et al., 2002). The 
antioxidant idebenone was also able to improve exercise performance and reduced 
the cardiac pathology in the mdx mouse (Buyse et al., 2009). Transgenic 
overexpression of calpastatin, an endogenous inhibitor of calpains, ameliorated muscle 
damage in mdx mice in one study (Spencer and Mellgren, 2002), but failed to do so in 
another (Briguet et al., 2008). In addition, recent studies using leupeptin and C101, a 
leupeptin-based compound, have also been unsuccessful in decreasing muscle damage 
or improving muscle function in mdx mice (Selsby et al., 2010) and the GRMD dog 
(Childers et al., 2011). Upon further investigation, m-calpain activation was increased 
in treated mice and dogs, suggesting there may be a compensatory mechanism to 
elevate calapin activity in response to exogenous inhibitors. In addition, there was also 
increased proteasomal activity. Thus, despite initial evidence to the contrary, calpain 
inhibitors do not appear to ameliorate the pathology of dystrophin-deficient muscle. 
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 5.4.2.2 NF-κB 
Proteasomal inhibitors also modulate the nuclear factor-kappa B (NF-κB) pathway, 
which may also be important in the pathogenesis of DMD. NF-κB is involved in many 
cellular processes including the inflammatory response (Lawrence, 2009), and also in 
the muscle degeneration process in DMD (Acharyya et al., 2007, Peterson and 
Guttridge, 2008). In addition, PYR-41 has been shown to inhibit NF-κB activation (Yang 
et al., 2007). 
 
Blocking activation of NF-κB has been shown to ameliorate muscle damage and 
improve muscle function in mdx mice (Messina et al., 2006, Delfin et al., 2011, 
Peterson et al., 2011). Thus, inhibitors of the proteasomal pathway may be working via 
a dual mechanism, preventing the degradation of dystroglycan and other DGC 
proteins, and also by suppressing elevated NF-κB activation. However, treatment of 
dag1 embryos with MG132 and PYR-41 did not decrease the percentage of fish 
displaying a dystrophic phenotype, suggesting that the effect of proteasomal inhibitors 
on the NF-κB pathway alone may not enough to improve muscle integrity. 
 
5.5 Concluding remarks 
Inhibitors of Src kinase, ubquitination and proteasomal degradation, are able to delay 
the onset of the dystrophic phenotype in the sapje zebrafish model of muscular 
dystrophy. It is hypothesised that these compounds are working to maintain muscle 
integrity by preventing the phosphorylation and degradation of β-dystroglycan. 
Preventing proteasomal degradation and phosphorylation of dystroglycan has also 
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been shown to improve muscle pathophysiology in mdx mice. Together, these results 
suggest that restoring dystroglycan expression may be beneficial to dystrophic muscle. 
The mechanism leading to loss of dystroglycan function in DMD may present new 
therapeutic targets for the treatment of this disease. Several inhibitors of Src kinase 
and the proteasome have already been developed, some of which are FDA approved, 
which may be able to speed up the drug development process. 
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Chapter 6: Discussion  
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6.1 Summary  
Dystroglycan is central to the DGC and plays important roles in muscle structure and 
function. This is exemplified in the dystroglycan mutant zebrafish (dag1), which 
displays loss of muscle integrity, and motility defects. Dystroglycan is also lost in the 
zebrafish model of DMD (sapje) and this occurs in an age-dependent manner. This is 
similar to what has been observed in dystrophin deficient muscle in mice and humans. 
Levels of phosphorylated dystroglycan are increased in sapje, compared with siblings. 
The loss of dystroglycan and the increase in phosphorylated dystroglycan in sapje is in 
support of the hypothesis that dystroglycan is more readily phosphorylated and 
degraded in the absence of dystrophin. This may be a key pathway in the pathogenesis 
of DMD, and preventing the loss of dystroglycan function may provide therapeutic 
potential. 
 
6.2 Model of dystroglycan loss in dystrophic muscle 
By contrast to approaches aiming to replace or repair genetic defect in DMD, the work 
presented in this thesis aimed to understand some of the downstream mechanisms 
that occur as a consequence of dystrophin deficiency in more detail. These findings can 
be added to the knowledge gained from other work to propose a model for the 
mechanism controlling the loss of sarcolemmal dystroglycan in dystrophin deficient 
muscle (figure 6.1).  
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Figure 6.1 Model for loss of dystroglycan in DMD
(A) In healthy muscle, dystrophin 
forms part of the DGC, which 
protects the muscle from 
damage. (B) In the absence of 
dystrophin, the tyrosine in the 
PPPY motif of β-dystroglycan is 
more readily phosphorylated (1). 
This leads to the internalisation 
(2), ubquitination (3) and 
degradation (4) of β-
dystroglycan. The other DGC 
components are also lost from 
the membrane, but the 
mechanism is unknown.
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The phosphorylation of β-dystroglycan is associated with its internalisation from the 
plasma membrane (Sotgia et al., 2003, Miller et al., 2012). This is thought to be 
mediated by Src family kinases (Sotgia et al., 2001). In support of this hypothesis, 
inhibitors of Src were able to reduce levels of phosphorylated dystroglycan in H2K 
myoblasts and zebrafish embryos. Although Dasatinib is an inhibitor of multiple 
kinases including Src and Abl family kinases, it is a more potent inhibitor of Src 
(Lombardo et al., 2004). Dasatinib has greater efficacy against Src kinase activity than 
Saracatinib, and this may explain its ability to preserve muscle structure in sapje fish at 
lower concentrations than Saracatinib. 
 
The endocytic route of phosphorylated dystroglycan has not been elucidated. 
Phosphorylated β-dystroglycan was shown to co-localise with transferrin receptors in 
Cos-7 co-transfected with β-dystroglycan and c-Src, suggesting a clathrin-dependent 
mechanism (Sotgia et al., 2003). However, a later report showed a lack of co-
localisation between phosphorylated β-dystroglycan and the transferrin receptor in 
H2K myoblasts (Miller et al., 2012). The absence of co-localisation with lysotracker also 
suggests phosphorylated dystroglycan is not trafficked to the lysosomal compartment. 
 
It is also unknown whether β-dystroglycan is trafficked alone, or if it co-trafficks with 
α-dystroglycan or any other components of the DGC. The DGC proteins are held 
together by various intermolecular contacts, and are all destabilised from the 
membrane in the absence of dystrophin. The mechanism by which each component is 
lost may be independent, but preventing the phosphorylation of β-dystroglycan in mdx 
mice led to the restoration of other components of the DGC including sarcoglycans and 
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sarcospan (Miller et al., 2012). This suggests that stabilising β-dystroglycan to the 
membrane is able to restore other complex components. 
 
Once inside the cell, the fate of phosphorylated dystroglycan is unknown.  
Phosphorylated dystroglycan has been shown to be ubiquitinated, whereas non-
phosphorylated dystroglycan is not (Rob Piggott, unpublished results). This may drive 
the degradation of β-dystroglycan or target it for subsequent trafficking. 
 
The proteasome has been implicated in the degradation of DGC components in the 
absence of dystrophin, and proteasomal inhibitors are able to restore DGC 
components and improve muscle pathophysiology in mdx mice and explants from 
DMD patients (Bonuccelli et al., 2003, Assereto et al., 2006, Bonuccelli et al., 2007, 
Gazzerro et al., 2010). In addition, the proteasomal inhibitor Velcade was able to 
decrease inflammation and increase levels of DGC components in the GRMD dog 
(Araujo et al., 2013). The work presented here provides more evidence supporting a 
role for proteasomal inhibitors in DMD therapy. It also suggests that the pathway by 
which dystroglycan is lost in dystrophin deficient muscle is conserved in zebrafish, 
further highlighting sapje as a tool for DMD drug discovery. 
 
The phosphorylation and degradation of dystroglycan has been identified as a key 
signalling pathway in the aetiology of DMD and this pathway provides druggable 
therapeutic targets. Inhibitors of this pathway were able to prevent or slow the 
progression of dystrophy in the zebrafish. This was associated with a concomitant 
increase in β-dystroglycan and a decrease in phosphorylated β-dystroglycan. 
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Several kinase and proteasome inhibitors have already been developed in different 
clinical settings. The repurposing of existing drugs holds great promise for rapidly 
advancing new therapeutic options to patient care. This would be an attractive 
strategy for reducing the time and cost of the drug development process. 
 
6.3 Use of proteasomal inhibitors in vivo 
Given the important role of the proteasome in normal cellular function, adverse side 
effects would be expected from inhibiting its activity. The clinical approval of Velcade 
for the treatment of multiple myeloma has validated the proteasomal pathway as a 
viable therapeutic target. However, although Velcade is reasonably well-tolerated in 
animal models (LeBlanc et al., 2002) and clinical trials, significant side effects are seen 
in some patients. These include peripheral neuropathy, gastrointestinal problems and 
thrombocytopenia (Richardson et al., 2005). More recently, cardiac problems have 
been identified (Takamatsu et al., 2010). DMD patients often have underlying cardiac 
defects (Finsterer and Stollberger, 2003), which could potentially be exacerbated by 
proteasomal inhibitor treatment. Inhibiting this pathway may also lead to the 
accumulation of damaged proteins, which may be toxic to the muscle cell. 
Accumulations of damaged proteins are seen in many neurodegenerative diseases, in 
which proteasome function is impaired (Keller et al., 2000, McNaught et al., 2001, 
Zhou et al., 2003, Kabashi et al., 2004). In addition, there may be a compensatory 
upregulation of other degradation pathways. Thus, long term treatment with 
proteasomal inhibitors may not be effective, or may even be deleterious. This could be 
mitigated by intermittent dosing of the drug. It would also be important to ensure the 
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dose was high enough to gain a therapeutic effect, whilst keeping unwanted side 
effects to a minimum. 
 
A more specific approach could be used to reduce off-target effects. An inhibitor of the 
E3 ubiquitin ligase for β-dystroglycan could be used to prevent its ubquitination. 
Although the identity of this enzyme is not yet known, WW domains within the Nedd4 
family of ubiquitin ligases have been shown to bind the C-terminal domain of β-
dystroglycan in vitro (Pirozzi et al., 1997). This approach has been suggested as a 
therapy for other muscle wasting disorders in which the ubiquitin-dependent 
proteasomal degradation pathway has been implicated. The E3 ligase MuRF1 is 
upregulated in atrophic muscle, and has been implicated in the degradation of muscle 
components including myosin and creatine kinase (Witt et al., 2005, Clarke et al., 2007, 
Cohen et al., 2009). A specific inhibitor of MuRF1 has been identified (Eddins et al., 
2011), but these have not yet been used in models of muscle atrophy. 
 
6.4 Src kinase inhibitors in vivo 
Given their important role in the regulation of many cellular processes, such as growth, 
proliferation, migration and survival, toxic effects would be expected from inhibitors of 
Src family kinases. As with Velcade, Dasatinib has some significant side effects, 
including cytopenia and fluid retention, but these can often be managed by reducing 
doses or intermittent treatment (Breccia and Alimena, 2013). 
 
Despite initial concerns over toxicity, many kinase inhibitors have been developed, and 
13 are currently approved for clinical use (Levitzki, 2013). These drugs are used in the 
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treatment of various cancers, but an increasing number of compounds are being 
tested in clinical trials for other diseases such as rheumatoid arthritis, psoriasis, asthma 
and inflammatory bowel disease (Kontzias et al., 2012).  
 
Although both proteasome and Src kinase inhibition are associated with side effects, 
combining both drugs may provide a synergistic effect. Using lower doses of both 
drugs may provide the same clinical benefit to dystrophic muscle with fewer side 
effects. Combining doses of proteasome and Src inhibitors could be explored in sapje 
initially, and then refined in the mdx mouse. 
 
In addition, a medicinal chemistry approach could be utilised to refine the properties 
of the inhibitor compounds used in the assay, in order to increase potency and reduce 
side effects. Modification of the efficacy and toxicity profiles drugs can be achieved by 
making small changes to their chemical structure. The zebrafish provides an ideal 
platform on which to test the biological effects of large numbers of modified 
compounds in vivo. Zebrafish are also good model in which to investigate the toxicity 
of each of the compounds. Thus, optimisation of the kinase and proteasome inhibitors 
could be carried out using the zebrafish as a screening tool, with the refined 
compounds taken forward to mammalian models. 
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6.5 Towards new therapies for DMD 
 
6.5.1 Therapies tested in clinical trials 
Each potential therapy for DMD has limitations. Therapies that aim to replace or repair 
the genetic defect in DMD, by delivery of dystrophin mini genes or anti-sense 
oligonucleotides, are limited by the risk of immune rejection and the route of delivery. 
Intramuscular injections prohibit the treatment of inaccessible muscle groups, and 
delivery is limited to fibres near the site of injection. Systemic delivery may be 
possible, but is limited by poor cellular uptake and rapid clearance from the 
circulation. 
 
Upregulation of utrophin circumvents immunological problems and may be achieved 
by oral delivery of compounds. However, utrophin may not fully restore all the binding 
partners of dystrophin. Specifically, utrophin does not contain the nNOS binding site 
found in the rod domain of dystrophin. 
 
Stop codon read through may also be achieved via an orally bioavailable compound. 
However, both utrophin upregulation and stop codon read through have, so far, not 
translated well in patient trials and may require a lot of refinement to improve 
efficacy.  
 
Therapies that have been taken forward to clinical trials have shown variable results 
between different patients. This, in part, may be due to the heterogeneity of the 
disease. 
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In DMD, different muscle groups are affected to varying degrees, and patients lose the 
ability to walk at different ages. Similarly, the severity of BMD is very variable. The 
functionality and stability of the truncated protein product is somewhat related to the 
variation in clinical phenotype (Bushby et al., 1993, Angelini et al., 1996). However, 
patients with the same genetic lesion also show varying degrees of severity (Anthony 
et al., 2011). This suggests that other factors may modulate the disease course. 
 
Various factors are thought to play a role in the modification of the dystrophic 
pathology. For example, genetic modifiers that affect the translation efficiency or 
expression levels of dystrophin have been identified (Cacchiarelli et al., 2010, 
Cacchiarelli et al., 2011, Bello et al., 2012). Utrophin expression has also been 
correlated with disease severity (Kleopa et al., 2006). Additional unknown factors may 
also play a role. It is possible that levels of proteasome and kinase activity may also 
modulate disease severity; lower levels of degradation and phosphorylation may 
preserve complex components at the sarcolemma, promoting muscle integrity and the 
slowing of disease progression. It may be of interest to investigate this further, given 
the importance of understanding the processes involved in the dystrophic pathology. 
 
6.5.2 Alternative therapies for DMD  
Many therapies have not translated well in humans. This may be due to the 
heterogeneity of the disease and factors downstream of dystrophin loss, which are 
currently not well understood.  
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Certain therapies such as stop codon read through and exon skipping would only be 
applicable to patients with particular genetic changes. In addition, these therapies are 
aimed at converting DMD to a milder, BMD-like phenotype. Therefore, there is scope 
for alternative therapies that may further slow disease progression.  
 
Knowledge of the downstream pathways resulting from loss of dystrophin, such as the 
mechanism by which dystroglycan is lost from the sarcolemma, could be utilised to 
develop new therapies. These therapies may be less expensive and would not be 
mutation-specific. They could also be used as adjuncts to other therapies that do not 
elicit a complete cure. 
 
Preventing dystroglycan phosphorylation and degradation has shown promise in 
ameliorating the dystrophic phenotype. Proteasome inhibitors are able to restore 
dystroglycan and other DGC components to the membrane, and improve muscle 
pathophysiology in the mdx mouse. Preventing dystroglycan phosphorylation in this 
mouse model was also able to improve the dystrophic phenotype. The work presented 
in this thesis also suggests that inhibitors of Src kinase and the proteasome are 
beneficial to dystrophic muscle in the sapje zebrafish.  
 
Although this approach offers no correction of the underlying cause of the disease (i.e. 
dystrophin is not being repaired or replaced), other cytoskeletal linkers, such as 
utrophin or plectin, may be able to compensate for the loss of dystrophin. Both 
utrophin and plectin are naturally upregulated in dystrophin-deficient muscle, and this 
is thought to have a protective role (Karpati et al., 1993b, Rezniczek et al., 2007). 
Plectin expression at the sarcolemma is further increased in Y890F+/+:mdx mice (Miller 
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et al., 2012). Thus, stabilising dystroglycan expression at the membrane, by preventing 
its phosphorylation and internalisation, may allow the formation of alternative 
adhesion complexes.  
 
All potential DMD therapies have caveats, but could be used in combination to provide 
better treatment of patients. Given the heterogeneity of the disease, different 
combinations may be beneficial for different patients. Stabilising dystroglycan at the 
sarcolemma may be able to enhance the effectiveness of other approaches such as 
utrophin upregulation or exon skipping, and inhibitors of Src kinase and the 
proteasome may be powerful adjuncts to these other therapies that are being 
developed. 
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